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Introduction 
 1
1 Introduction 
1.1 Hyaluronic acid 
1.1.1 Structure and physicochemical properties  
Hyaluronic acid (hyaluronan, HA) is a high-molecular mass polysaccharide found in the 
extracellular matrix, especially of soft connective tissues. In 1934 it was first isolated from the 
vitreous humor of bovine eyes by Meyer and Palmer (1934). They showed that the substance 
contained uronic acid and hexosamine, and thus, coined the term hyaluronic acid from 
hyaloid (vitreous) + uronic acid. About 20 years later the precise chemical structure of HA 
was solved (Weissmann and Meyer, 1954). By chemical and enzymatic methods Meyer and 
co-workers could establish that hyaluronan is a linear polymer built from repeating 
disaccharide units with the structure …[D-glucuronic acid (1-β-3) N-acetyl-D-glucosamine 
(1-β-4)]n... (Fig. 1-1).  
 
O
OH
OH
COOH
O O
OH
O
CH2OH
NHCOCH3
HO
H
n
 
 
Fig. 1-1: The chemical structure of hyaluronan. The polymer is built from alternating units of 
glucuronic acid (GlcUA) and N-acetylglucosamine (NAG). n = 20-25 000. 
 
Depending on the tissue source, the polymer usually consists of 2000 to 25000 disaccharides, 
giving rise to molecular masses ranging from 106 to 107 Da with extended lengths of 2-25 µm. 
Under in vivo conditions hyaluronic acid exists as a polyanion as the carboxyl groups of the 
glucuronic acid residues (pKa = 3-4, depending on ionic conditions (Hascall and Laurent, 
1997)) are predominantly charged. 
Chemically, hyaluronan is a member of the familiy of glycosaminoglycans (GAG), including 
chondroitin-, dermatan- and keratan sulphate, heparin and heparan sulphate. The GAG are 
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linear polysaccharides made of repeating disaccharides, which consist of uronic acid (or 
galactose) and hexosamines. In contrast to the other glycosaminoglycans, HA is not 
sulphated. In addition, it is distinguished from the other GAG as it is not covalently attached 
to a polypeptide core, but exists as an independent polysaccharide that associates non-
covalently with proteoglycans in the extracellular matrix. 
The conformation of hyaluronan in aqueous solution is a gently undulating, tape-like, two-
fold helix which forms as a result of 180° rotations between alternating disaccharides and is 
stabilised via internal hydrogen bonds and interactions with the solvent (Scott et al., 1984; 
Heatley and Scott, 1988) (Fig. 1-2 (A/B)). 
 
 
 
 
 
 
 
 
 
 
Fig. 1-2: Models depicting the polymeric structure and interaction of HA molecules. (A/B): 
projections, at right angles to each other, showing the two-fold helix that a HA molecule adopts in 
aqueous solution. The dotted lines in (B) represent hydrogen bonds; the circle-square pairs joined by 
dotted lines represent water bridges between acetamido and carboxyl groups. (C): proposed mode of 
interaction between two antiparallel HA molecules in which hydrophobic patches are opposed and 
acetamido and carboxyl groups are within hydrogen bonding distance. Red shading: hydrophobic 
patches; circles: acetamido groups; squares: carboxyl groups. (From Scott (1998) and Toole (2000)). 
 
 
The two-fold helical conformation of the HA molecule is characterised by repeating 
hydrophobic patches (8 CH-groups, extended over approximately three carbohydrate units), 
which are arrayed along the two flat sides of the tape-like polymer, with sequential patches 
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alternating between the two sides. As indicated in Fig. 1-2 C, the described secondary 
structure of HA allows for a further organization of the macromolecule in an aqueous 
environment. Rotary shadowing-electron microscopy showed that HA did self-aggregate into 
strands of a honeycomb meshwork in aqueous solution already at very low HA concentrations 
(1 µg/ml), and that the thickness of the strands increased with HA concentration (Scott et al., 
1991). Nuclear magnetic resonance studies (Scott and Heatley, 1999) then revealed that 
aggregation of HA chains in solution is stabilised both by hydrophobic interactions between 
the hydrophobic patches and by H-bonding between acetamido and carboxylate groups of 
neighbouring HA chains, which are aligned in an antiparallel fashion (Fig. 1-2 C). As these 
hydrophobic and hydrophilic bonds can form on both sides of the hyaluronan polymer, higher 
order aggregates can assemble, giving rise to an increased thickness of the strands in a HA 
meshwork. 
In a recent publication Scott and Heatley (2002) demonstrated that the tertiary structures 
(aggregation of antiparallel HA chains) are specifically and reversibly disaggregated by mild 
physicochemical methods (raising temperature or pH, respectively). Under physiological 
conditions the supramolecular organization of HA was found to be on the edge of stability, 
suggesting that reversible formation and breakdown of tertiary structures control important 
biological properties. Interestingly, NMR studies showed that HA oligosaccharides do not 
form tertiary structures, since they cannot form sufficient intermolecular bonds to produce 
stable aggregates. This may account for the size dependent biological effects of hyaluronan 
fragments.  
When HA is present at a very dilute concentration in saline solution, a HA molecule assumes 
an expanded random coil structure, which occupies a large domain, wherein the mass of 
hyaluronan itself is very low (0.1% (w/v) or less) due to the high water binding capacity of 
the macromolecule. Within the occupied domain the HA chains are forming pores, which are 
continuously changing in size, as the HA chains are constantly moving in solution. Thus, in 
principle all molecules can pass through the HA network, however, with different degrees of 
retardation depending on their hydrodynamic volumes. As the concentration is increased, high 
molecular mass hyaluronan is organized in the aforementioned tertiary structure. At 
concentrations of 0.5 mg/ml or more, as found in many tissues such as synovial fluid, 
umbilical cord and skin, the organized structure of HA leads to highly viscous solutions with 
viscoelastic properties (Hascall and Laurent, 1997; Toole, 2000). 
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1.1.2 Occurrence and physiological importance 
Hyaluronan is present in tissues and body fluids of all vertebrates as well as in the capsule of 
some strains of streptococci. As a component of the extracellular matrix hyaluronan is a major 
constituent in some tissues. The concentration is particularly high in rooster comb (up to 7.5 
mg/ml), in umbilical cord (∼ 4 mg/ml), in the synovial joint fluid (3 - 4 mg/ml), in the 
vitreous body of the eye (0.1 – 0.4 mg/g wet weight), in the matrix produced by the cumulus 
cells around the oocyte prior to ovulation (∼ 0.5 mg/ml) or in the pathological matrix that 
occludes the artery in coronary restenosis. The largest amount of hyaluronan (7 - 8 g, ca. 50 % 
of the total in the body) resides in skin tissue where it is present in both the dermis (∼ 0.5 
mg/g wet tissue) and the epidermis (∼ 0.1 mg/g wet tissue). In cartilage hyaluronan serves as 
an essential structural component of the matrix, as it retains aggrecan (the large chondroitin 
sulphate proteoglycan) molecules in the matrix by specific protein-hyaluronan interactions. In 
proliferating cells hyaluronan has been detected also intracellularly (Hascall and Laurent, 
1997; Prehm, 2002).  
Hyaluronan fulfils several distinct physiological functions that contribute both to structural 
properties of tissues and to cell behaviour during formation or remodelling of tissues. One of 
these functions is the direct contribution of hyaluronan to tissue homeostasis and 
biomechanics due to its unique physicochemical properties. In synovial joint fluid and also 
between soft tissue surfaces that slide along each other (e.g. fibrils in skeletal muscle) 
hyaluronan serves as a lubricant due to its viscoelastic behaviour in solution. The rheological 
and network-forming properties of hyaluronan also contribute to water homeostasis, tissue 
hydration and transport of macromolecules within tissues. That hyaluronan forms a diffusion 
barrier for other molecules was first demonstrated by Duran-Reynals, who showed that 
spreading of intra- or subcutaneously injected substances was facilitated by a ‘spreading 
factor’ (Duran-Reynals, 1928), which was later found to be a hyaluronidase (Chain and 
Duthie, 1939). 
In addition to the functions arising directly from the physicochemical properties of the 
polymer, hyaluronan also exerts biological effects via specific interactions with hyaluronan 
binding proteins (hyaladherins). The great number of hyaladherins known so far can be 
grouped into (i) the structural hyaluronan-binding proteins of the extracellular matrix, such as 
link protein and the aggregating proteoglycans, (ii) cell surface hyaluronan receptors and (iii) 
intracellular hyaluronan binding proteins.  
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Interactions between hyaluronan, link protein and the proteoglycan aggrecan account for the 
structural integrity and distinctive biomechanical properties of the extracellular matrix of 
cartilages. Similar proteoglycans with the potential to form aggregates with hyaluronan have 
been identified in various connective tissues (versican) and the brain (neurocan and brevican). 
By the interaction with cell surface receptors hyaluronan affects cell behaviour during 
morphogenesis, tissue remodelling, inflammation and diseases such as cancer and 
atherosclerosis. The most studied hyaluronan receptor to date is CD44 (lymphocyte homing 
receptor), which is known to participate in a wide variety of cellular functions, e.g. receptor 
mediated internalization/degradation of hyaluronan, cell migration and cell proliferation. 
Motility and proliferation of cells are also stimulated by the interaction of hyaluronan with 
RHAMM (receptor for hyaluronic acid mediated motility). Several other cellular receptors for 
hyaluronan have been identified including, ICAM-1 (intercellular adhesion molecule-1), the 
LEC receptor (Liver Endothelial Cell clearance receptor) and LYVE-1 (Lymphatic 
endothelial hyaluronan receptor) (Knudson and Knudson, 1999; Toole, 2000; Jackson, 2004). 
1.1.3 The role of hyaluronan during morphogenesis, tissue regeneration and 
tumorigenesis 
Migrating and proliferating cells, during morphogenesis of embryonic organs, during tissue 
regeneration and also during tumorigenesis are surrounded by pericellular matrices, which are 
enriched in hyaluronan. Hyaluronan can be tethered to the cells by binding to specific cell 
surface hyaluronan receptors (e.g. CD44), or the layer can be built from newly synthesized 
hyaluronan, which is formed on the inside of the plasma membrane and is translocated to the 
pericellular space. In the latter case the pericellular hyaluronan appears to be tethered to the 
cells by sustained attachment to hyaluronan synthase or associated proteins on the 
cytoplasmatic face of the plasma membrane (Laurent et al., 1996; Toole, 2000). 
The hyaluronan enriched pericellular matrix can affect cell proliferation and migration. One 
important way in which the pericellular “coat” may promote cell proliferation is by provision 
of a hydrated pericellular zone that facilitates cell rounding during mitosis. Migration and 
invasion of cells are facilitated by the hyaluronan enriched matrices, as they create hydrated 
pathways that separate cellular or fibrous barriers to penetration by the invading cells (Toole, 
2000). In addition, this pericellular “coat” is a structural component that isolates cells from 
contact with other cells and matrix compounds and protects cells against cytotoxic 
lymphocytes and viruses (Laurent and Fraser, 1992). 
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On the other hand hyaluronan can mediate aggregation of cells depending on the 
concentration and the molecular mass of the hyaluronan molecules. If present at low 
concentration, cell surface hyaluronan of high molecular mass can interact multivalently with 
receptors on adjacent cells, thus leading to cross-bridges between the cells. However, excess 
of high molecular mass hyaluronan inhibits cell aggregation due to saturation of the 
hyaluronan receptors. Hyaluronan fragments of low molecular mass, as they may be 
generated by degradation of hyaluronan with hyaluronidase, show the same effect, since they 
are too small for multivalent binding at receptors on adjacent cells. 
In addition to providing a suitable hydrated milieu or to cross-bridging cells, interaction of 
hyaluronan with its cell surface receptors initiates signaling pathways that promote cell 
movement, proliferation or differentiation. The function of hyaluronan varies depending on 
the size of the hyaluronan fragments also with respect to the receptor mediated effects on cell 
behaviour (Turley et al., 2002). For example it was shown in several in vitro and in vivo 
models that small hyaluronan fragments stimulate angiogenesis, whereas high molecular mass 
hyaluronan exerts inhibitory effects (West and Chen, 2000; Slevin et al., 2002).  
Hyaluronan and its degradation products of low molecular mass thus play a crucial role in 
tumor growth and metastasis. Elevated levels of hyaluronan are found in most malignant solid 
tumors (Knudson et al., 1989) and experimental evidence has been obtained which 
demonstrates that hyaluronan promotes tumor progression (Toole, 2002). For example it was 
shown that perturbation of the endogenous hyaluronan-protein interactions by overexpression 
of soluble hyaladherins, which competitively displace hyaluronan from its cell surface 
receptors (Peterson et al., 2000; Ahrens et al., 2001), or by treatment with antibodies that 
block hyaluronan-CD44 binding (Guo et al., 1994) leads to inhibition of tumor growth and 
invasion. Likewise, treatment with hyaluronan oligosaccharides was found to inhibit growth 
of several tumor types in vivo, presumably due to competitive inhibition of high molecular 
mass hyaluronan-CD44 binding (Zeng et al., 1998; Ghatak et al., 2002). However, the 
involvement of hyaluronan and its degradation products in tumor progression appears to be 
quite complex, considering that hyaluronan oligosaccharides may directly induce biological 
effects, which promote tumor growth and invasion, e.g. increased angiogenesis (Slevin et al., 
2002) or enhanced tumor cell motility (Sugahara et al., 2003).  
Tumor cells often exhibit not only elevated levels of hyaluronan but also increased 
hyaluronidase activity, and studies on transplantable tumors and cultured cell lines suggest 
that hyaluronidase-mediated hyaluronan degradation is related to increased angiogenesis and 
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metastasis (West and Chen, 2000). However, the finding that administration of hyaluronan 
oligosaccharides in vivo was found to inhibit tumor growth and that at least one of the several 
hyaluronidase genes corresponds to a previously mapped tumor suppressor (Csoka et al., 
1998), shows that both hyaluronan and hyaluronidases are involved in tumor promotion as 
well as in tumor suppression in a complex way, which is actively investigated at present. 
1.2 Hyaluronidases 
1.2.1 History and occurrence 
The term hyaluronidase was introduced by Karl Meyer in 1940 to denote enzymes that 
degrade HA (Meyer et al., 1940). The discovery of hyaluronidases resulted from two 
independent lines of investigation. In 1928 Duran-Reynals observed that extracts from 
mammalian testes and other tissues contained a “spreading factor”, a substance that facilitated 
the diffusion of antiviral vaccines, dyes and toxins injected subcutaneously (Duran-Reynals, 
1928). After the first isolation of HA from vitreous humor (Meyer and Palmer, 1934) a HA 
degrading enzyme was identified in autolysates of pneumococci by Meyer et al. (1937). In 
1939 it was shown that the spreading factor present in extracts from mammalian testes was 
also an enzyme, degrading HA (Chain and Duthie, 1939). 
In subsequent years hyaluronidases were identified from a large number of tissues and 
organisms, e.g. from some bacteria (bacteriophage-associated and bacterial hyaluronidase), 
pathogenic fungi (Candida, Streptomyces) and invertebrate animals (crustaceans, insects). In 
vertebrates hyaluronidases were found in the venom of snakes and lizards, in testes and in 
various somatic tissues, e.g. liver, kidney, lymphatic system and skin. The isolated enzymes 
differ in their molecular mass, substrate specificity, pH optimum and the mechanism of 
substrate degradation  (Meyer, 1971; Kreil, 1995; Frost et al., 1996; Csoka et al., 1997).  
1.2.2 Classification of hyaluronidases 
The first classification scheme for hyaluronidases was established in 1971 by Karl Meyer. 
According to their catalytic mechanism the different types of hyaluronidase are grouped into 
three main families (Fig. 1-3) (Meyer, 1971). 
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Fig. 1-3: Classification of hyaluronidases according to Meyer (1971). 
 
The first group of hyaluronidases are the hyaluronate 4-glycanohydrolases (EC 3.2.1.35) 
degrading HA by cleavage of the β-1,4-glycosidic bond to the tetrasaccharide as the main 
product. These enzymes are glycosidases with both hydrolytic and transglycosidase activity 
and degrade HA, chondroitin, chondroitin-4- and -6-sulphate and, to a small extent, dermatan 
sulphate. The best known enzymes are the testicular, the lysosomal and the bee venom 
hyaluronidase. 
The second type is represented by hyaluronidases occurring in the salivary glands of leeches 
and hookworms. These enzymes are hyaluronate 3-glycanohydrolases (EC 3.2.1.36) which 
degrade HA by cleavage of the β-1,3-glycosidic bond, thus, yielding sugar fragments having 
glucuronic acid at the reducing end. The main degradation product is the tetrasaccharide, too. 
The third group, the microbial hyaluronidases (4.2.2.1) are hyaluronate lyases. They degrade 
HA by a β-elimination reaction to yield the unsaturated disaccharide 2-acetamido-2-deoxy-3-
O-(β-D-gluco-4-enepyranosyluronic acid)-D-glucose as the main product. The hyaluronate 
lyases, isolated from various microorgansims, including e.g. strains of Clostridium, 
Micrococcus, Streptococcus and Streptomyces, differ in substrate specificity (Suzuki, 2000). 
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The classification of hyaluronidases established by Meyer was based on biochemical analysis 
of the enzymes and their reaction products. Molecular genetic analysis has shown that, as an 
alternative, hyaluronidases can be grouped into two main families - the hyaluronidases from 
eukaryotes and from prokaryotes - according to amino acid sequence homology (Csoka et al., 
1997; Csoka et al., 2001). 
1.2.3 Hyaluronidases from eukaryotes 
1.2.3.1 Mammalian hyaluronidases 
In the last years six hyaluronidase sequences with about 40 % identity to each other were 
identified in the human genome. Three genes (HYAL1, HYAL2 and HYAL3) are clustered on 
chromosome 3p21.3, coding for Hyal-1, Hyal-2 and Hyal-3. Another two genes (HYAL4 and 
PH20 (SPAM1)), coding for Hyal-4 and PH-20, and one expressed pseudogene (HYALP1) are 
similarly clustered on chromosome 7q31.3 (Csoka et al., 2001). 
Hyal-1:  
Hyal-1, first isolated from human plasma, is the predominant hyaluronidase in mammalian 
plasma and urine, and is also found at high levels in the liver, kidney, spleen and heart. It is 
localised in lysosomes and active at acidic pH (Frost et al., 1997). Mutations in the gene 
HYAL1 cause a newly described lysosomal disorder, mucopoysaccharidosis IX (Natowicz et 
al., 1996; Triggs-Raine et al., 1999). Furthermore, Hyal-1 appears to play a role in tumor 
formation. HYAL1 (also known as LUCA1) is a candidate tumor suppressor gene, which is 
inactivated in many tobacco-related tumors (Csoka et al., 1998; Frost et al., 2000). In 
addition, Hyal-1 was found to promote tumor cell cycling (Lin and Stern, 2001). 
Hyal-2: 
Also the Hyal-2 protein was found in many tissues, except the adult brain (Lepperdinger et 
al., 1998). It is localised either in lysosomes or anchored to the plasma membrane by a 
glycosylphosphatidylinositol (GPI) link. Like Hyal-1, the Hyal-2 enzyme has a pronounced 
activity optimum at pH 4, however, as shown for Hyal-2 from Xenopus laevis, low activity 
can be also detected under physiological conditions. Hyal-2 has an unusual substrate 
specificity cleaving high molecular mass HA to intermediate size fragments of approximately 
20 kDa (50-60 disaccharide units) (Lepperdinger et al., 2001). As the major hyaluronidases in 
mammalian somatic tissues Hyal-1 and Hyal-2 are believed to act in succession on degrading 
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HA: HA fragments of approx. 20 kDa are generated at the cell surface by GPI-anchored Hyal-
2, internalised and then further digested to tetrasaccharides by the lysosomal Hyal-1 (Csoka et 
al., 2001; Stern, 2004). Like Hyal-1, also the Hyal-2 protein is involved in tumor formation: it 
can function as either an oncogene or a tumor suppressor gene product. At the one hand, 
overexpression of Hyal-2 is reported to accelerate the formation of murine astrocytoma cells 
(Novak et al., 1999) and on the other hand, Hyal-2 was found to accelerate apoptosis (Chang, 
2002). 
Hyal-3: 
Very little is known about the Hyal-3 protein. It is widely expressed, e.g. in testes and bone 
marrow, but no activity can be identified using the available hyaluronidase assays (Stern, 
2003). 
Hyal-4: 
Hyal-4 appears to be a chondroitinase having absolute specificity for chondroitin and 
chondroitin sulphate with no ability to degrade HA. This substrate specificity is in marked 
contrast to the Hyal-1 and PH-20 enzymes, which can cleave both HA and - at a slower rate - 
chondroitin sulphate (Stern, 2003). 
PH-20: 
The PH-20 protein (also known as SPAM 1 (sperm adhesion molecule 1)) appears to be a 
multifunctional protein. The GPI-anchored protein is located on the surface of mammalian 
sperm and in the lysosome derived acrosome, where it is linked to the inner acrosomal 
membrane. The hyaluronidase activity of PH-20 is essential for penetration of the HA-rich 
cumulus ECM that surrounds the egg. In addition, plasma membrane PH-20 mediates HA-
induced cell signalling (increase in intracellular calcium) via a HA binding domain that is 
separate from the hyaluronidase domains. The inner acrosomal membrane PH-20 is a receptor 
for the zona pellucida surrounding the egg and plays a key role in sperm interaction with and 
penetration of the zona pellucida. 
While plasma membrane PH-20 shows hyaluronidase activity only at neutral pH, inner 
acrosomal membrane PH-20 was found to be active both at neutral and acidic pH. Recent 
results (Yudin et al., 2001) suggest that the enzyme activities at different pH involve two 
different domains in the protein: PH-20 may attain the capability of acid active hyaluronidase 
activity after the acrosome reaction, where the enzyme is endoproteolytically cleaved but held 
together by a disulfide bond. This endoproteolysis may alter the three-dimensional structure 
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of PH-20, enabling the domain, which is responsible for activity at acidic pH, to become 
active and thus imparting both neutral and acid-active activities to PH-20 (Cherr et al., 2001). 
PH-20 is relatively specific for testes, however, by sensitive techniques, it can also be 
detected in the epididymis, the female genital tract, breast, placenta and fetal tissues. Also in 
certain malignancies the expression of PH-20 is reported (Stern, 2003). 
Bovine testicular hyaluronidase (BTH) 
It has been known for a long time that extracts from mammalian testes contain hyaluronidase 
activity (Chain and Duthie, 1939), and preparations of bovine and ovine testicular 
hyaluronidase were therapeutically applied as a sprading factor in several medical fields for 
many years (Baumgartner and Moritz, 1988; Menzel and Farr, 1998). In 1997 it was shown 
that the major soluble hyaluronidase present in bull testes extracts is a fragment of the 
membrane bound PH-20 enzyme (Meyer et al., 1997).  
BTH is an endo-glycanohydrolase (EC 3.2.1.35) degrading HA by cleavage of the β-1,4-
glycosidic bond. In addition to HA, BTH also degrades chondroitin, chondroitin-4- and -6-
sulphate and, to a small extent, dermatan sulphate. By using ion-spray mass spectrometry, 
tetrasaccharide and saturated disaccharide fragments were identified as major and as smallest 
hydrolysis products, respectively (Takagaki et al., 1994).  
The mammalian PH-20 was found to be homologous to bee venom hyaluronidase (BVH) 
showing ca. 30 % sequence similarity and conservation of the active site residues (Gmachl 
and Kreil, 1993; Markovic-Housley et al., 2000). The hydrolysis of HA by BTH is thus 
supposed to occur according to the double-displacement substrate assisted mechanism 
described for BVH (cf. to 1.2.3.2, Fig. 1-5). Sequence alignment of BTH and BVH revealed 
that Glu149 of BTH corresponds to the acid-base catalyst Glu113 of BVH (Botzki et al., 
2004). 
Preparations of BTH typically show hyaluronidase activity at neutral and acidic pH. However, 
the pH activity profiles reported in the literature for various BTH preparations vary widely, 
depending on the mostly heterogeneous composition of the BTH preparations (Oettl, 2000), 
the source of the substrate (HA), the hyaluronidase assay (Hoechstetter et al., 2001) and the 
incubation conditions (Gorham et al., 1975; Gacesa et al., 1981; Oettl, 2000). Optimum 
activity of BTH was found at acidic pH (pH 3.5 - 4.0) (Bonner and Cantey, 1966; 
Muckenschnabel et al., 1998a; Seaton et al., 2000) as well as at weakly acidic pH (pH 5.0 – 
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6.0) (Dorfman and Ott, 1948; Allalouf et al., 1975; Highsmith et al., 1975) and at neutral pH 
(Tung et al., 1994; Csoka et al., 1998).  
In addition to hydrolysis, BTH also catalyses the reverse reaction, the transglycosylation 
reaction (Fig. 1-4). The transglycosylase activity of BTH is dependent on the pH value and 
the salt content of the incubation buffer. Investigations of Saitoh et al. (1995) revealed that the 
optimal pH for the transglycosylation reaction is about pH 7.0, whereas hydrolysis is favoured 
at pH < 5.0. The highest transglycosylase activity was found in the absence of NaCl, whereas 
transglycosylation was nearly completely inhibited at concentrations of NaCl higher than    
0.5 M (Saitoh et al., 1995).  
 
 
 
 
 
 
 
 
 
 
Fig. 1-4: Mechanism of hyaluronan degradation by bovine testicular hyaluronidase (BTH). 
 
1.2.3.2 Hyaluronidase from bee venom 
Bee venom hyaluronidase (BVH), a major allergen of bee venom, is a hyaluronate  
4-glycanohydrolase (E.C. 3.2.1.35) sharing ca. 30 % sequence similarity with the mammalian 
hyaluronidases. On the basis of sequence similarity mammalian hyaluronidases and BVH are 
assigned to family 56 of glycosyl hydrolases (Henrissat and Bairoch, 1996). Compared to the 
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human and bovine enzymes BVH lacks a C-terminal domain of ca. 120-150 amino acids 
(Gmachl and Kreil, 1993). Like BTH, in addition to HA the hyaluronidase from bee venom 
also degrades chondroitin sulphate. The pH activity profile of BVH reported by Allalouf et al. 
(1975) shows maximum activity at pH 4.5 and remarkable activity at neutral pH. 
In 2000, the crystal structure of BVH in complex with a HA-based tetrasaccharide was 
determined by Markovic-Housley et al. (2000). Due to the co-crystallised HA tetrasaccharide 
fragment, the catalytic mechanism of HA degradation could be elucidated. In general, 
glycosidases act via a double or a single nucleophilic displacement mechanism, which results 
in either retention or inversion of the configuration at the anomeric carbon atom. In both 
cases, the glycosidic bond to be cleaved is positioned between the carboxylates of two 
catalytic acids, one acting as acid/base and the other as nucleophile (Withers and Aebersold, 
1995; Markovic-Housley and Schirmer, 2002). In the crystal structure of BVH Glu113 
appears to be the acid/base catalyst, since it forms a hydrogen bond with the glycosidic 
oxygen of N-acetylglucosamine in subsite -1*. However, a catalytic residue being in the right 
position to act as a nucleophile is missing. Therefore a substrate-assisted mechanism is 
proposed with Glu113 acting as the proton donor and the N-acetyl carbonyl group of the 
substrate acting as the nucleophile (Fig. 1-5). This double displacement mechanism involves 
the binding of the saccharide in subsite -1* in a boat conformation and the formation and 
subsequent hydrolysis of a covalent oxazolinium ion intermediate.  
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Fig. 1-5: Double-displacement substrate assisted mechanism of bee venom hyaluronidase. The 
saccharide in subsite -1* (1) binds in boat conformation, and catalysis is proposed to occur via a 
formation of a covalent oxazolinium ion intermediate 2 to the product 3. Adapted from Marcovic-
Housley and Schirmer (2002). 
                                                 
* By convention, the sugar residue subsites are labelled from –n to +n, with –n at the non-reducing end and +n at   
the reducing end of the substrate. Cleavage occurs between the -1 and +1 subsites (Davies et al., 1997). 
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A similar mechanism has been postulated for chitinolytic enzymes of the glycosyl hydrolase 
families 18 and 20 (Terwisscha van Scheltinga et al., 1995; Drouillard et al., 1997).  
1.2.4 Hyaluronidases from prokaryotes 
A wide variety of microorganisms produce enzymes capable of degrading hyaluronate. 
Detailed overviews over the microbial hyaluronidases are given by Suzuki (2000) and Hynes 
and Walton (2000). 
To date, the amino acid sequences of a variety of hyaluronidases from prokaryotes have been 
decoded (Coutinho and Henrissat, 1999). The best known and characterised bacterial 
hyaluronidases are the hyaluronate lyases from Streptococcus pneumoniae and Streptococcus 
agalactiae (group B streptococcus, GBS), respectively (Jedrzejas and Chantalat, 2000; 
Pritchard et al., 2000; Jedrzejas, 2002). Both enzymes degrade HA by a β-elimination  
reaction to yield the unsaturated disaccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-ene-
pyranosyluronic acid)-D-glucose (?DiHA) as the main product (Pritchard et al., 1994; Li et 
al., 2000). 
Recently, the 3D structures of the hyaluronate lyases from S. pneumoniae and from S. 
agalactiae strain 3502 were elucidated by X-ray analyses (Li et al., 2000; Li and Jedrzejas, 
2001). The active site of the hyaluronate lyase from S. agalactiae is composed of two main 
parts, a catalytic triad responsible for the substrate degradation and an aromatic patch 
responsible for the selection and the positioning of cleavage sites on the polymeric substrate. 
The residues that form the aromatic patch of the enzyme are Trp371, Trp372 and Phe423, 
those of the catalytic triad are His479, Tyr488 and Asn429 (Li and Jedrzejas, 2001).  
The catalytic mechanism of S. agalactiae hyaluronate lyase, termed proton acceptance and 
donation (see Fig. 1-6), was revealed, based on the crystal structure of the native enzyme, the 
structures of the enzyme in complex with the disaccharide product of degradation (?DiHA) 
(Li and Jedrzejas, 2001) and in complex with hyaluronate hexasaccharide (Mello et al., 2002), 
the modelled complex with hyaluronate tetrasaccharide, site-directed mutagenesis studies 
(Pritchard et al., 2000) and comparison to the hyaluronate lyase from S. pneumoniae (Li et al., 
2000; Jedrzejas et al., 2002). In the first step, the positively charged cleft of the enzyme 
attracts and binds the negatively charged substrate chain. Three disaccharide units can be 
accommodated into the cleft (see Fig 1-6, only two, HA1 and HA2, of the three units are 
shown). In the second step, the aromatic patch of the active site interacts with the substrate 
Introduction 
 15
chain and anchors it in optimal position. In the third step, the glucuronic acid of HA1 is 
deprotonated at C5 by His479. At the same time, Tyr488 donates a proton to the glycosidic 
oxygen connecting D-glucuronic acid of HA1 and N-acetyl-D-glucosamine of HA2. The 
glycosidic bond is cleaved by 1,2-elimination forming the double bond of the unsaturated 
final product (fourth step). Finally (fifth step), the catalytic triad is regenerated: His479 is 
deprotonated and Tyr488 is protonated by a water molecule. 
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Fig. 1-6: Mechanism of hyaluronan degradation by hyaluronate lyase from S. agalactiae according to 
Li and Jedrzejas (2001). Schematic representation of hyaluronic acid with HA1 and HA2 as 
disaccharide units and the position of the side chains of Tyr488, His 479 and Asn429 relative to the 
substrate.   
 
The hyaluronate lyases from S. pneumoniae and S. agalactiae, respectively, are supposed to 
degrade the polymeric substrate via a processive mode of action (Li et al., 2000; Li and 
Jedrzejas, 2001). In this processive mechanism of action the enzyme probably binds randomly 
to a HA molecule and cleaves it into two pieces by the aforementioned β-elimination process 
(initial endolytic cleavage). The resulting unsaturated fragment, containing the reducing end 
of the primary HA molecule, leaves the catalytic cleft of the enzyme, whereas the other 
fragment remains in the cleft, where it is translocated by one disaccharide unit toward the 
reducing end. By this translocation process the truncated HA chain is positioned in the active 
site of the enzyme, so that an unsaturated disaccharide product (?DiHA) is generated by the 
following catalytic cleavage. The produced ?DiHA is released from the enzyme, and the 
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remaining HA chain is again translocated in the cleft by one disaccharide unit for the next 
round of catalysis (exolytic processive degradation).  
The processive degradation mechanism was initially suggested, based on the analysis of the 
products of HA degradation (Baker and Pritchard, 2000), and could be supported by 
elucidation of the 3D structures of the enzymes in complex with hyaluronan fragments of 
varying length (Jedrzejas et al., 2002; Mello et al., 2002). With respect to the direction of 
hyaluronan degradation the data reported in the literature are contradictory. Analysis of the 
structural data of the enzyme in complex with substrate suggests that the degradation takes 
place from the reducing to the nonreducing end of a HA chain, as described above (Jedrzejas 
et al., 2002). However, based on the analysis of the degradation products Baker and Pritchard 
(2000) proposed that the processive degradation proceeds from the nonreducing to the 
reducing end of the substrate chain. Therefore the mechanism proposed by Baker and 
Pritchard (2000) differs from that suggested by Jedrzejas et al. (2002) insofar as - after the 
initial endolytic cleavage - not the saturated fragment but the unsaturated fragment remains at 
the enzyme to be further degraded to disaccharides.  
1.3 Methods for the determination of hyaluronidase activity 
1.3.1 Classical methods 
A variety of assays has been devised for the determination of hyaluronidase activity over the 
years. The classical methods can be grouped into biological, physicochemical and chemical 
methods according to Meyer and Rapport (1952). Since in this thesis hyaluronidase 
preparations were investigated by several of the classical physicochemical and chemical 
methods, a short introduction into the classical assays for hyaluronidase is given in the 
following. 
1.3.1.1 Biological methods 
Spreading effect 
Biological assays measuring the effect of hyaluronidase co-administration on the spreading of 
an indicator dye injected into the skin of animals were described by a number of authors (for 
complete listing of references see Gibian (1959)). Although the spreading assay cannot be 
used as an accurate quantitative assay of hyaluronidase (Meyer and Rapport, 1952), it is the 
Introduction 
 17
most direct method for the determination of the therapeutical efficacy of hyaluronidase 
preparations, which are intended to be applied as spreading factors to improve the absorption 
of drugs. In this context it is noteworthy that a spreading assay developed by Jaques (1953) 
showed results comparable to those obtained by viscosimetric and turbidimetric in vitro 
methods (Humphrey and Jaques, 1953). 
Decapsulation of mucoid strains of streptococci 
Another biological method is based on the ability of hyaluronidase to degrade the mucoid 
capsule of group A and group C streptococci (Fulton et al., 1950; Meyer and Rapport, 1952).  
1.3.1.2 Physicochemical methods 
Mucin clot prevention method  
This method is based on the observation that native hyaluronate in acid solution precipitates 
with protein in a fibrous clot. After incubation of hyaluronate with hyaluronidase the 
character of the precipitate changes from fibrous to flocculent, finally no precipitate is 
obtained (Robertson et al., 1940; McClean, 1943). One unit of hyaluronidase was defined as 
the amount of enzyme, which prevents the clotting of 0.4 mg of crude hyaluronate (Harris and 
Harris, 1950). 
Spinnability method 
The spinnability of dialised bovine synovial fluid is destroyed by hyaluronidases. The 
spinnability is determined by a special apparatus which measures the length to which a 
filament of the substrate solution can be drawn at a standard velocity. One unit of enzyme was 
defined as the amount of enzyme, which reduced the spinnability to 50% of the initial value in 
20 min under standard conditions (Gunter, 1949).  
Viscosity reduction method 
In this method the reduction in viscosity of a solution of hyaluronic acid, induced by the 
action of hyaluronidase, is measured. The viscosimetric method, originally elaborated by 
Madinaveitia and Quibell (1940), has been extensively employed in various modifications 
(Meyer and Rapport, 1952). Viscosimetric units of hyaluronidase have been established by 
defining 1 unit as the amount of enzyme required to reduce the viscosity of a HA solution to 
half the initial viscosity under specified conditions (Madinaveitia and Quibell, 1940; McClean 
and Hale, 1941; Meyer, 1947). However, although the viscosimetric method proved to be 
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sensitive and accurate, comparison of the results obtained by different research groups turned 
out to be difficult, since the half viscosity reduction times were found to be highly dependent 
on the initial viscosity of the hyaluronate solution, which varies depending on the molecular 
mass of the respective HA preparation (Hadidian and Pirie, 1948; Alburn and Whitley, 1951). 
In the viscosimetric assay, which is used for the standardisation of hyaluronidase preparations 
according to the European Pharmacopoeia (2002), the activity of hyaluronidase is quantified 
in terms of International Units (IU) by comparing the rate of viscosity reduction induced by 
the hyaluronidase preparation to be quantified with the rate obtained with the “International 
Standard for Hyaluronidase” (Humphrey, 1957) or a reference preparation calibrated in 
International Units. 
A viscosimetric approach to determine the activity of hyaluronidase expressed as mol of 
bonds broken per unit time was reported by Vercruysse et al. (1995). 
Turbidimetric method 
The turbidimetric assay relies on the observation by Kass and Seastone (1944) that 
hyaluronate of high molecular mass forms precipitates with diluted acidified serum, whereas 
depolymerised hyaluronate remains clear under the same conditions. The average molecular 
mass at which turbidity formation disappears is reported to lie between 6 and 8 kDa (Rapport 
et al., 1950). Several modifications of the method have been described. In addition to horse 
serum, rabbit serum, human serum or human plasma also purified protein fractions as horse 
serum albumin or bovine plasma albumin (Fraction V) are reported to serve as precipitating 
protein reagents (Meyer, 1947; Dorfman and Ott, 1948; Tolksdorf et al., 1949; Schmith and 
Faber, 1950). 
Other turbidimetric methods are based on the formation of insoluble complexes between high 
molecular mass HA and quarternary ammonium salts (Scott, 1955). Hyaluronidase assays 
using cetyltrimethylammonium bromide or cetylpyridinium chloride as precipitating agents 
are described by Di Ferrante (1956) and Bohn et al. (1969), respectively.  
In the turbidimetric assay hyaluronidase activity is expressed in turbidity reduction units 
(TRU): 1 TRU is defined as the amount of enzyme which will reduce the turbidity produced 
by 0.2 mg of HA to that produced by 0.1 mg of HA within 30 min under specified conditions 
(Kass and Seastone, 1944; Meyer, 1947). However, by some authors, employing the    
turbidimetric method, slightly modified arbitrary units were defined: (1) to overcome the 
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problem that different preparations of hyaluronate may produce different turbidities at a given 
concentration, Tolksdorf et al. introduced a new unit based on a standard initial turbidity 
instead of the standard HA concentration (0.2 mg) used in the aforementioned definition: 1 
unit was defined “as the amount of enzyme, which will hydrolise one half of a quantity of 
substrate sufficient to cause a turbidity corresponding to 50 ± 5 per cent light transmission” 
(Tolksdorf et al., 1949). (2) By Gerlach and Köhler (1972) 1 unit was defined as the amount 
of enzyme, which produces a 50 per cent reduction of the turbidity given by the initial 
quantity (0.1 mg) of hyaluronate.  
In 1957 an “International Standard for Hyaluronidase” was established: tablets were prepared 
from lyophilised bovine testicular hyaluronidase blended with lactose, and their activity was 
assayed turbidimetrically. On the basis of this examination the International Unit (IU) of 
hyaluronidase was defined as the activity of 0.1 mg of the international standard preparation, 
which is almost equal to one TRU (Humphrey, 1957). 
The turbidimetric method, using horse serum as precipitating agent, is used for the 
standardisation of hyaluronidase preparations according to the United States Pharmacopeia 
(USP) (2002). Enzyme activity is quantified in terms of “USP Hyaluronidase Units” by 
comparing the turbidity reduction induced by the hyaluronidase preparation to be quantified 
with the turbidity reduction obtained with the “USP Hyaluronidase Reference Standard”.  
1.3.1.3 Chemical methods 
Quantification of reducing sugars 
The determination of the increase in reducing sugars resulting from the cleavage of the 
glucosidic bonds of hyaluronan molecules has been widely used for the quantification of 
hyaluronidase activity (Meyer, 1947). The reductimetric procedure provides a method to 
measure product formation. However, it is more sensitive than the physicochemical methods 
and requires highly purified substrate (Rapport et al., 1950). 
Determination of reducing N-acetylglucosamine (NAG)  
As the hyaluronidases of the enzyme classes EC 3.2.35 (hyaluronate 4-glycanohydrolases) 
and EC 4.2.2.1 (hyaluronate lyases) liberate N-acetylglucosamine end groups from 
hyaluronan (cf. to Fig. 1-3), these enzymes can be assayed by a colorimetric method based on 
the Morgan-Elson reaction for the determination of carbohydrates containing terminal N-
acetylhexosamine moieties (Morgan and Elson, 1934). This colorimetric method (Morgan-
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Elson assay), which was optimised by Reissig et al. (1955) and further modified for the 
estimation of hyaluronidase acitivity in human plasma (Gacesa et al., 1981; Muckenschnabel 
et al., 1998b), represents one of the most frequently used hyaluronidase assays. Recently new 
modifications of this colorimetric assay were published (Asteriou et al., 2001; Takahashi et 
al., 2003). 
The principle of the Morgan-Elson assay is illustrated in Fig.1-7. NAG moieties at the 
reducing ends of HA and its fragments generated by the hydrolase (and transglycosylase) 
activity of hyaluronidase are determined after derivatisation to a red-colored product with p-
dimethylaminobenzaldehyde (Ehrlich’s reagent).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-7: Mechanism of the Morgan-Elson reaction as proposed by Muckenschnabel et al. (1998b). 
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physicochemical properties of the substrate solution, by the colorimetric method product 
formation is detected. Therefore, in the Morgan-Elson assay hyaluronidase activity can be 
quantified according to the definition of the International Union of Biochemistry by defining 
1 unit (U) as the amount of enzyme that catalyses the liberation of 1 µmol of NAG at the 
reducing ends of sugars per min under specified conditions.  
For bovine testicular hyaluronidase it was shown that, according to the aforementioned 
definition, 0.1 mU (0.1 nmol NAG/min) is equivalent to approximately 1 TRU and 1 IU, 
respectively, when using HA from rooster comb as substrate (Oettl, 2000). However, this 
relation may not be generalised, since it may depend on various factors like the molecular 
mass of the substrate or the pH of the incubation medium (Hoechstetter et al., 2001). In 
addition, it has to be pointed out that an entirely different relation may be observed in case of 
bacterial hyaluronidases due to their different mechanism of HA degradation. 
1.3.2 Other methods 
In addition to the classical methods quantitative hyaluronidase assays are also performed by 
spectrophotometry of complexes between hyaluronan and dyes (Benchetrit et al., 1977; 
Turner and Cowman, 1985; Homer et al., 1993), chromatography (Cramer and Bailey, 1991; 
Cramer et al., 1994; Vercruysse et al., 1994), capillary zone electrophoresis (Pattanaargson 
and Roboz, 1996) or polyacrylamide gel electrophoresis (Ikegami-Kawai and Takahashi, 
2002). Also a variety of assays using fluorogenic hyaluronate as substrate have been reported 
(Nakamura et al., 1990; Calabro et al., 2000; Krupa et al., 2003; Nagata et al., 2004). An 
ELISA-like assay for hyaluronidase and hyaluronidase inhibitors was developed by the group 
of Robert Stern (Stern and Stern, 1992; Frost and Stern, 1997; Nawy et al., 2001). A new 
method combining agarose gel electrophoresis and enhanced chemoluminescence-assisted 
detection was recently described by Mülleger et al. (2001) as a sensitive assay for the Hyal-2 
enzyme, which is difficult to assay by most other methods due to its unusual substrate 
specificity (see 2.3.1.). Furthermore zymographic methods are used for the detection of 
hyaluronidases (Liefländer and Stegemann, 1968; Steiner and Cruce, 1992; Miura et al., 
1995) and hyaluronidase inhibitors (Mio et al., 2001). 
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2 Scope and objectives 
Hyaluronidases represent a heterogeneous group of enzymes from different sources. They 
catalyse the degradation of hyaluronate (HA) and other acidic glycosaminoglycans with 
varying substrate specificities by different reaction mechanisms. Bovine testicular 
hyaluronidase (BTH) has been therapeutically applied as a spreading factor degrading the 
glycosaminoglycans of the extracellular matrix for many years. However, in the context with 
the risk of BSE, several companies stopped the production of BTH preparations (e.g. Hylase® 
“Dessau”, Neopermease®, Wydase®) which led to a shortage of this drug, characterised by a 
unique mechanism of action.  
A major goal of this thesis was to find out if hyaluronate lyase from Streptococcus agalactiae, 
which can be produced biotechnologically, may serve as a substitute for BTH as a spreading 
factor and activity enhancer in cancer chemotherapy. In the first part of this thesis a 
preparation of hyaluronate lyase from S. agalactiae and two BTH preparations (Hylase® 
“Dessau”, Neopermease®) were compared with respect to purity (composition) and enzyme 
activity. In subsequent preclinical in vitro and in vivo studies it was investigated if the 
adjuvant administration of S. agalactiae hyaluronate lyase results in an improved intratumoral 
accumulation of coinjected chemotherapeutics and, thus, enhances the efficacy of cancer 
chemotherapy. Due to the different mechanisms of hyaluronan degradation by bovine and 
bacterial hyaluronidase enzyme concentrations being equiactive in the frequently used 
colorimetric assay (Morgan-Elson assay) are not necessarily pharmacologically equieffective. 
The Morgan-Elson assay detects the formation of N-acetylglucosamine end groups liberated 
from hyaluronan during enzymatic cleavage and not the reduction of the molecular mass of 
the substrate chains, the latter being responsible for the pharmacological spreading effect. 
Therefore, the activities of the bacterial and bovine enzyme preparations were investigated by 
turbidimetry and viscosimetry. The results obtained by these physicochemical methods, by 
which hyaluronidase acitivity is quantified according to the reduction of the size of high 
molecular mass HA, were supposed to correlate with the spreading effect. 
Another goal of this thesis was to get more detailed information about the influence of pH on 
hyaluronan degradation by BTH and hyaluronate lyase from S. agalactiae, respectively. As 
several methods, differing with respect to the incubation conditions (ionic strength, type of 
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salt and buffer) and the type of assay, are used for the determination of hyaluronidase activity, 
the pH activity profiles reported in the literature for BTH are inconsistent in part or even 
contradictory. To understand the influence of the type of assay, the two most frequently used 
techniques, the colorimetric assay and the turbidimetric assay, were compared under identical 
conditions. In addition, anion exchange HPLC and CE analysis of the oligosaccharide 
mixtures produced by the digestion of HA with BTH at varying pH was performed to detect 
pH-dependent differences in the mechanism of HA degradation by BTH. Additionally, the 
degradation of hyaluronan by hyaluronate lyase from S. agalactiae was investigated with 
respect to the effect of pH on the kinetic parameters Vmax and Km in order to find out if the pH 
dependency observed for the activity of inhibitors of S. agalactiae hyaluronate lyase may be 
explained by a different affinity of the enzyme to the substrate depending on pH. 
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3 Comparative characterisation of bovine testicular hyaluronidase 
(BTH) and a hyaluronate lyase from Streptococcus agalactiae in 
pharmaceutical preparations 
3.1 Introduction 
Preparations of bovine testicular hyaluronidase (BTH) have been applied therapeutically in 
the fields of orthopaedia, ophthalmology and internal medicine for many years (Baumgartner 
and Moritz, 1988; Menzel and Farr, 1998). A common field of application of BTH is its 
addition to local anesthetic agents for ophthalmic anesthesia, as it is known to improve the 
rapidity of onset, dispersion, depth and duration of the local anesthesia (Kallio et al., 2000). In 
the course of systemic oncological therapies with vinca alkaloids hyaluronidase is the only 
highly effective antidote to the extravasation of these antineoplastic agents, especially 
vinblastine, as it prevents local necrosis by improving the absorption of the paravasate 
(Bertelli et al., 1994; Albanell and Baselga, 2000). As, in context with the risk of BSE, 
companies have stopped the production of BTH preparations (e.g. Hylase® “Dessau”, 
Neopermease®, Wydase®) there has been a shortage of this drug having an unique mechanism 
of action. As a consequence of the depleted supplies of pharmaceutical BTH preparations in 
surgical facilities a number of cases of postoperative complications, such as strabismus, 
diplopia and ptosis are reported in the context with cataract surgeries carried out after 
periocular anesthesia without hyaluronidase (Brown et al., 2001; Jehan et al., 2001). 
Considering the various methods used for the isolation and purification of BTH (Borders and 
Raftery, 1968; Yang and Srivastava, 1975; Lyon and Phelps, 1981) an identical composition 
of the different commercially available hyaluronidase preparations seems unlikely. However, 
according to different pharmacopoeia, the enzyme activity of hyaluronidase preparations from 
mammalian testes is the only test criterion, regardless whether the individual preparation is a 
single enzyme or a complex mixture of proteins.  
In continuation of our preclinical studies on hyaluronidase as an adjuvant in cancer 
chemotherapy (Spruß et al., 1995; Muckenschnabel et al., 1996), we compared two BTH 
preparations (Hylase® “Dessau”, Neopermease®) with respect to purity (composition) and 
enzyme activity. To find a substitute for the bovine enzyme preparation, the enzymatically 
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active constituents of BTH preparations were identified by size exclusion chromatography 
and characterised with respect to molecular mass, glycosylation and specific activity.  
A hyaluronate lyase from Streptococcus agalactiae, strain 4755, which can be produced 
biotechnologically, and therefore in higher purity compared to the testicular extracts, proved 
to retain enzyme activity after limited proteolysis with trypsin. In view of a potential 
therapeutic application, such enzymatically active fragments of low molecular mass are of 
particular interest as they are expected to have more favourable pharmacokinetic properties 
compared to the parent protein. 
3.2 Materials and methods 
3.2.1 Chemicals 
Hyaluronic acid from Streptococcus zooepidemicus was purchased from Aqua Biochem 
GmbH (Dessau, Germany). Hyaluronic acid from rooster comb and bovine serum albumin 
(BSA) were from Serva (Heidelberg, Germany). Chondroitin 6-sulphate was a preparation 
from shark cartilage and purchased from Fluka (Buchs, Switzerland). Chondroitin 4-sulphate 
from bovine trachea was purchased from Sigma (Deisenhofen, Germany). The investigated 
hyaluronidases were either approved drugs or enzyme preparations from different sources. 
Neopermease®, containing 200 000 units# of lyophilised bovine testicular hyaluronidase  
(4 mg) plus 25 mg gelatin per vial and the stabiliser (25 mg gelatin per vial) were gifts from 
Sanabo (Vienna, Austria), whereas lyophilised bovine testicular hyaluronidase (50 000 
units#⋅mg-1), the basic material of Neopermease®, was kindly provided by Dr. R. Domanig 
(Biochemie GmbH, Kufstein, Austria). 
Hylase® “Dessau”, containing 1 500 units# of lyophilised bovine testicular hyaluronidase per 
vial, stabilised with gelafusal (partially hydrolysed gelatin), the dialysed basic material of 
Hylase® “Dessau” and gelafusal were gifts from Pharma Dessau (Dessau, Germany). 
Stabilised hyaluronate lyase, i.e. 200 000 units# of lyophilised hyaluronidase (0.572 mg) from 
Streptococcus agalactiae, strain 4755, plus 2.2 mg BSA and 37 mg Tris-HCl per vial, and an 
                                                 
# according to the declaration of the supplier 
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ammonium sulphate precipitate of the hyaluronate lyase from S. agalactiae were kindly 
provided by id-pharma GmbH (Jena, Germany).  
All other chemicals were of analytical grade and were obtained from Merck (Darmstadt, 
Germany). Water was purified by a Milli-Q system (Millipore, Eschborn, Germany). 
3.2.2 Determination of hyaluronidase activity  
3.2.2.1 Colorimetric method 
Hyaluronidase activity was measured by colorimetric (Morgan-Elson reaction) determination 
of N-acetyl-D-glucosamine (NAG) at the reducing ends of sugars liberated from hyaluronic 
acid according to the method of Reissig et al. (1955). Enzyme activity was quantified by 
comparing the absorbance of the samples with the absorbance of standard solutions, 
containing known amounts of NAG (Sigma, Deisenhofen, Germany). The assay was 
performed as described elsewhere in detail (Muckenschnabel et al., 1998b). The composition 
of the different incubation mixtures used in the various experiments is given in the following: 
incubation mixture 3-I: 100 µl of formate buffer (0.2 M sodium formate, 0.1 M NaCl, pH 
3.7), 150 µl of H2O, 100 µl of BSA (0.2 mg BSA per ml of H2O: solution 1), 50 µl of 
substrate (5 mg hyaluronic acid from rooster comb per ml of H2O: solution 2);  
incubation mixture 3-II: 100 µl of citrate-phosphate buffer (solution A: 0.2 M Na2HPO4/0.1M 
NaCl, solution B: 0.1 M citric acid/0.1 M NaCl; solutions A and B were mixed in appropriate 
portions to adjust the required pH), 150 µl of H2O, 100 µl of BSA (solution 1), 50 µl of 
substrate (solution 2);  
incubation mixture 3-III: 200 µl of citrate-phosphate buffer, 100 µl of BSA (solution 1), 50 µl 
of substrate (solution 2);  
incubation mixture 3-IV: 150 µl of citrate-phosphate buffer, 150 µl of H2O, 50 µl of BSA 
(solution 1), 50 µl of substrate (solution 2). 
3.2.2.2 UV difference spectroscopy  
The activity of hyaluronate lyase from S. agalactiae was additionally determined by 
quantifying the unsaturated degradation product 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-ene-
pyranosyluronic acid)-D-glucose (?DiHA) photometrically at 232 nm according to Greiling 
(1957). The incubation mixture consisted of 300 µl of citrate-phosphate buffer (see 3.2.2.1.), 
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150 µl of H2O, 100 µl of BSA (solution 1, see 3.2.2.1.) and 250 µl of substrate  
(2 mg hyaluronic acid (HA) from rooster comb per ml of H2O: solution 3).  
To quantify product (?DiHA) formation, a set of matched tandem cuvettes (Hellma®, No. 
230-QS, Müllheim, Germany), containing two compartments of equal pathlength (l = 4.375 
mm) was used. The described mixture (800 µl) was filled into the left compartment of the 
sample cuvette, whereas the right compartment of the cell was filled with 300 µl of citrate-
phosphate buffer, 400 µl of H2O and 200 µl of BSA (solution 1). The left compartment of the 
reference cuvette contained 300 µl of citrate-phosphate buffer, 150 µl of H2O, 200 µl of BSA 
solution and 250 µl of substrate (solution 3), the right compartment contained 300 µl of 
citrate-phosphate buffer, 400 µl of H2O, 100 µl of BSA (solution 1), and 100 µl of the enzyme 
(5 units#, dissolved in BSA (solution 1)). The cuvettes were placed in the sample and the 
reference beam of the spectrophotometer (Uvikon 930, Kontron Instruments, Eching, 
Germany) and equilibrated at 37 °C for 10 minutes. After addition of 100 µl of the enzyme 
into the left compartment of the sample cell and thorough mixing, the increase in absorbance 
was monitored at 232 nm as a function of time at 37 °C.  
From the increase in absorbance (?A) at 232 nm per time (?t) the velocity of the enzymatic 
reaction was calculated according to the following equation (eq. 3-1):  
 
v [µmol · l-1 · min-1] = ?A / (?t  · ε  · l)   (eq. 3-1) 
 
where ε = 4550 l·mol-1·cm-1. The molar absorptivity (ε232) of unsaturated hyaluronate 
disaccharide (?DiHA) was determined at 37 °C by measuring the absorbance of a known 
concentration of ?DiHA (sodium salt, Calbiochem®, Bad Soden, Germany) at 232 nm under 
the conditions prevalent in the incubation mixture as described above. 
3.2.3 Separation of the basic material of Neopermease® by size exclusion 
chromatography 
Size exclusion chromatography was performed on a TSK 2000 SW column (7.5 mm x 600 
mm, LKB, Bromma, Sweden) with a model 420 pump, a 430 UV-VIS detector (Kontron 
Instruments, Eching, Germany) and a Rheodyne 7725 injector, equipped with a 20 µl loop. 
For separation 0.2 mg of the Neopermease® basic material were dissolved in 20 µl of mobile 
                                                 
# according to the declaration of the supplier 
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phase (25 mM KH2PO4, 25 mM K2HPO4, 0.2 M NaCl, pH 6.7) and applied onto the column, 
which was equilibrated with mobile phase for at least 2 h. Intensity was monitored at 210 nm 
at a flow rate of 0.2 ml/min. 
3.2.4 Dialysis of the ammonium sulphate precipitate of the hyaluronate lyase 
The ammonium sulphate precipitate of the hyaluronate lyase from S. agalactiae was desalted 
by dialysis against 10 mM Tris-HCl, pH 7.5, using a dialysis bag with a pore size of 5000 Da 
(Zellu Trans, Roth, Karlsruhe). After dialysis the enzyme preparation was aliquoted and 
stored at –20 °C until use.  
3.2.5 Determination of protein content 
The amount of protein in the investigated enzyme preparations and the gel filtration fractions 
was determined by the method of Bradford (1976) using the Bio-Rad protein assay with BSA 
as standard. The assay was carried out according to the supplier’s instructions. In case of 
Neopermease® the concentration of the stabiliser was taken into account by preparing the 
BSA standards in the presence of identical gelatin concentrations. As the amount of gelafusal 
in Hylase® “Dessau” is not declared by the manufacturer, it was proven that a concentrated 
gelafusal solution does not interfere with the Bradford protein assay. 
3.2.6 Molecular mass determination 
The molecular mass of the proteins in the enzyme preparations and the gel filtration fractions 
of Neopermease® basic material was determined by SDS-PAGE under reducing conditions. 
Electrophoresis was performed in a Mini-Protean II Electrophoresis System (Bio-Rad, 
München, Germany) following the protocol of Laemmli (1970).  Molecular masses were 
assigned by a set of molecular mass standards (Dalton Mark VII-L in case of the bovine 
enzymes, and a high molecular mass marker in case of the bacterial enzyme, respectively 
(Sigma, Deisenhofen, Germany)). 
3.2.7  Identification of glycosylated proteins 
After SDS-PAGE glycoproteins were stained by the periodic acid-Schiff (PAS) technique 
according to the procedure of Zacharius et al. (1969). 
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3.2.8 Identification of IgG 
IgG was identified by precipitation with anti bovine IgG antiserum (whole molecule, 
developed in goat, Sigma, Deisenhofen, Germany) according to the Ouchterlony method as 
described by Drews (1983). 
3.2.9 Isoelectric focussing (IEF) 
For IEF, carried out with a PhastSystem apparatus (Pharmacia Biotech, Freiburg, Germany), 
0.6 µg of the dialysed bacterial enzyme were applied on a PhastGel of broad pH range (pH 
3.5 – 9.5, Pharmacia Biotech, Freiburg, Germany) at 1570 V, 4.5 mA (7.0 W), at 15 °C for 30 
min. Gels were stained with Coomassie/CuSO4 (0.5 g of Coomassie Brilliant Blue R-250 
were dissolved in 25 ml of methanol and mixed with a solution of 1 g of CuSO4 in 650 ml of 
H2O and 190 ml of acetic acid) for 2 hours prior to treatment with a destaining solution (30 % 
methanol/7 % acetic acid). The pI values of the enzyme proteins were determined by using a 
set of pI marker proteins (Broad pI Kit (pH 3.5 - 9.3), Pharmacia Biotech, Freiburg, 
Germany). 
3.2.10 Zymography 
Substrate gel electrophoresis of the dialysed bacterial enzyme was essentially performed 
according to the method described by Cherr et al. (1996). SDS polyacrylamide gels were 
prepared with the Laemmli buffer system (1970), containing 66.6 µg of hyaluronic acid from 
S. zooepidemicus per ml in the separating gel. The stacking gel did not contain hyaluronic 
acid. After electrophoresis SDS was removed from the gels by washing with a solution of 2.5 
% Triton-X-100 (Sigma, St. Louis, USA), and the gels were incubated in NaCl-containing 
citrate-phosphate buffer, pH 5.0 (c.f. 2.2.1.), for 30 minutes. To visualize regions of 
hyaluronan digestion the gels were stained with 0.5 % alcian blue in 7 % acetic acid (pH 2.5) 
for 1 h, destained in 7 % acetic acid and counterstained with Coomassie Brilliant Blue G-250. 
3.2.11 Densitometric analysis 
SDS, IEF and substrate gels were analysed with a Bio-Rad gel detection system (GS-710 
Imaging Densitometer) using Quantity One quantitation software, version 4.0.3  (Bio-Rad, 
München, Germany). 
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3.2.12 Limited proteolysis of the bacterial enzyme  
10 µl of the dialysed bacterial enzyme (350 µg/ml) were mixed with 10 µl of trypsin (0.35 
µg/ml, dissolved in 25 mM Tris-HCl, pH 7.5) and incubated at 37 °C. After defined 
incubation times (0 – 7 h, at intervals of 10 min within the first hour, and 30 min, 
respectively) the proteolytic digestion of the bacterial enzyme was stopped by addition of 
SDS reducing sample buffer (Laemmli, 1970) and boiling for 2 min prior to separation by 
SDS-PAGE  and SDS substrate-PAGE, respectively. 
3.3 Results and discussion 
3.3.1 Comparison of the pharmaceutical preparations Neopermease® and Hylase® 
“Dessau” 
3.3.1.1 Quantification of enzyme activity 
Enzyme activity was quantified according to the definition of the International Union of 
Biochemistry, i.e. 1 unit (U) of hyaluronidase catalyses the liberation of 1 µmol N-acetyl-D-
glucosamine (NAG) at the reducing ends of sugars per minute under specified conditions. The 
hydrolysis of hyaluronan was measured under optimised conditions (pH, substrate, NaCl and 
BSA concentration) after varying incubation periods by the colorimetric method of Reissig et 
al. (1955). Enzyme activity was calculated from the formation of the red-colored product per 
unit time, using standards with known NAG concentration (Muckenschnabel et al., 1998b). 
One designated unit of Neopermease® amounted to 5.0⋅10-5 µmol NAG per minute, i.e. 0.050 
mU according to the aforementioned definition, whereas in case of Hylase® “Dessau” one unit 
(as declared by the manufacturer) corresponds to 8.6⋅10-5 µmol NAG per minute (0.086 mU) 
in the Morgan-Elson assay. Thus, the equieffective concentrations differ by a factor of 1.7 for 
the two pharmaceutical preparations.  
Comparing the specific activities of these preparations, it becomes obvious that the enzyme 
activity per mg of protein of Neopermease® is about 12.5 times higher than that of Hylase® 
“Dessau” (cf. to Table 3-1). 
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Table 3-1: Comparison of the enzyme activities of Neopermease® and Hylase® “Dessau” 
50 µl of enzyme solution (7.5 unitsa) were incubated with incubation mixture 3-I (400 µl) and NAG at 
the reducing ends was determined as a function of time at intervals of 5 min over a period of 1 h. 
 
Hyaluronidase  
Preparation 
Liberation of NAG per Unita 
[µmol⋅min-1] 
Specific Activityb  
[µmol⋅min-1⋅mg-1] 
Neopermease® 5.0 ⋅ 10-5 2.5 
Hylase® “Dessau” 8.6 ⋅ 10-5 0.23 
 
a according to the declaration of the supplier 
b for calculation the protein content, determined by the method of Bradford, was used 
 
The data are consistent with the results published for mammalian hyaluronidases depending 
on the degree of purification. Zaneveld et al. (1973) reported in acrosomal extracts from bull 
spermatozoa a specific hyaluronidase activity of 0.221 µmol⋅min-1⋅mg-1, which increased to 
3.54 µmol⋅min-1⋅mg-1 by further purification. Likewise, in purified bull seminal plasma, a 
specific activity of 3.63 µmol⋅min-1⋅mg-1 was reported by Srivastava and Farooqui (1979). 
3.3.1.2 Effect of pH on enzyme activity  
To determine the activity of Neopermease® and Hylase® “Dessau” as a function of pH 
aliquots of each enzyme preparation were incubated in NaCl-containing citrate-phosphate 
buffer of varying pH for 1 h at 37 °C, and NAG at the reducing end of the produced 
hyaluronan fragments was measured (Fig. 3-1). 
Within the limits of experimental error both pharmaceutical BTH preparations are 
characterised by identical pH profiles. Interestingly, the complex curves are asymmetric with 
a steep increase in activity at low pH and a maximum around pH 3.5. As shown in Fig. 3-1, 
enzyme activity was measured over a broad range up to pH 8, with a second maximum at  
pH 5. These pH profiles are similar to those reported by Zaneveld et al. (1973), Yang and 
Srivastava (1975) and Muckenschnabel et al. (1998a). However, there are reports on 
maximum BTH activity at weak acidic and neutral pH (Allalouf et al., 1975; Highsmith et al., 
1975; Tung et al., 1994) or on the existence of two distinct activity maxima at pH 4 and pH 7, 
respectively (Frost and Stern, 1997). 
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Fig. 3-1: Effect of pH on the activities of Neopermease® (—●—) and Hylase® “Dessau” (—□—). To 
determine the pH-profiles, aliquots of the enzyme were incubated in the Morgan-Elson assay at 37 °C 
for 1 h. 50 µl of enzyme solution (10 units, as declared by the supplier) were incubated with 
incubation mixture 3-II (400 µl). 
These discrepancies may result from differences in the enzyme assay (Hoechstetter et al., 
2001), especially with respect to the composition of the buffer, which is known to diversely 
affect the activity of BTH (Gorham et al., 1975; Gacesa et al., 1981). It can also be speculated 
that the complex pH profiles of Neopermease® and Hylase® “Dessau” may reflect the 
presence of different enzymatically active proteins. 
3.3.1.3 Effect of buffer composition on enzyme activity 
Neopermease® and Hylase® “Dessau” were examined with respect to the effect of BSA and 
NaCl concentration on enzyme activity. For this purpose the activities of the two preparations 
were determined as a function of the BSA and the NaCl concentration in the incubation 
mixture. The activities of both preparations were higher in the presence of BSA and NaCl. 
Optimum enzyme activities were measured at 0.05 - 0.2 M NaCl and around 0.8 mg of BSA 
per ml, respectively. However, higher concentrations of the investigated additives were shown 
to exert an inhibitory effect on BTH activity (data not shown). 
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3.3.1.4 SDS-PAGE 
As the enzymatic properties (specific activity, pH profile, activation by NaCl and BSA) of the 
basic materials of Neopermease® and Hylase® “Dessau”, which are devoid of the stabiliser 
gelatin, proved to be essentially the same as those of the corresponding drugs (data not 
shown), subsequent studies were performed with the basic materials to avoid a potential 
interference of the gelatin with electrophoresis. The BTH preparations were separated by 
SDS-PAGE in order to determine the purity and the molecular mass of the individual 
proteins. SDS-PAGE revealed that Neopermease® is an inhomogeneous preparation, 
containing a 58 kDa and a 33 kDa protein as the main constituents after Coomassie staining. 
Additional bands of very weak intensity correspond to a 77 kDa and a 22 kDa protein, 
respectively. Compared to Neopermease®, Hylase® “Dessau” appeared to be much more 
heterogeneous. In addition to two prominent bands of comparable intensity, corresponding to 
an apparent molecular mass of 54 and 24 kDa, respectively, several weakly stained bands 
were detected on the gel (Fig. 3-2, right lanes). 
Glycoproteins were identified by the periodic acid-Schiff (PAS) technique. The 58 kDa 
protein in Neopermease® shows the highest staining intensity, whereas the 77 kDa band 
appears only faint. Likewise, the 93 kDa and 54 kDa components of Hylase® “Dessau” are 
stained very weakly (Fig. 3-2, left lanes). The fact that in both preparations only the high 
molecular mass proteins are glycosylated suggests that deglycosylation processes might be 
involved in the formation of the smaller proteins (Meyer et al., 1997), present in the 
investigated hyaluronidase preparations.   
Densitometric analysis revealed that, although Neopermease® and Hylase® “Dessau” are 
enzyme preparations with comparable hyaluronidase activity (including activation by NaCl 
and BSA) and similar pH profiles, they do not contain identical constituents, except for the 
weakly stained 22 kDa protein (Fig. 3-3). 
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Fig. 3-2: SDS-PAGE of the basic materials of Neopermease® and Hylase® “Dessau”. The basic 
materials of Neopermease® (6.8 µg) and Hylase® “Dessau” (6.5 µg) were separated on a 12.0 % gel. 
The gel was stained according to the periodic acid-Schiff (PAS) technique (left lane) prior to staining 
with Coomassie Brilliant Blue G-250 (right lane). Molecular masses were assigned by the use of 
marker proteins. 
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Fig. 3-3: Densitograms of the basic materials of Neopermease® (solid line) and Hylase® “Dessau” 
(dotted line) after separation by SDS-PAGE (see Fig. 2, right lanes). After staining with Coomassie 
Brilliant Blue G-250 the gels were subjected to densitometric analysis using the Quantity One 
quantitation software. The numbers given with the individual peaks indicate the apparent molecular 
masses (kDa) of the respective proteins. 
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3.3.1.5 Identification of IgG by immunodiffusion 
IgG was identified in both preparations by precipitation with anti-bovine IgG antiserum 
according to the Ouchterlony method (results not shown). Compared to Neopermease® basic 
material, the basic material of Hylase® “Dessau” was found to contain an approximately 5 
times higher concentration of bovine IgG. Merging of the precipitation lines indicated 
serological identity. 
3.3.2 Characterisation of the individual proteins of  Neopermease®   
3.3.2.1 Separation of the basic materials of  Neopermease®and  Hylase® “Dessau”  by size 
exclusion chromatography 
To investigate, if the basic material of Neopermease® contained the two enzymatically active 
proteins described by Meyer et al. (1997), the preparation was separated on a LKB TSK 2000 
SW column. The chromatogram (Fig. 3-4) showed three peaks, consistant with the results 
published by Meyer et al. (1997). 
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Fig. 3-4: Size exclusion chromatography of Neopermease® basic material. Chromatogram (solid line): 
0.2 mg of Neopermease® basic material were applied to a TSK 2000 SW column; intensity was 
monitored at 210 nm at a flow rate of 0.2 ml/min. The eluate was collected and the protein content of 
the fractions was determined by the method of Bradford (?, dotted line). 
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On the contrary, the elution profile for the basic material of Hylase® “Dessau” was more 
complex  showing 5 peaks corresponding to elution volumes of  16, 19, 21, 23.5 and 26.5 ml. 
Enzyme acitvity was only detected in the 16 and 19 ml fraction with the main activity in the 
first eluate (data not shown).  
Due to the high specific activity of the Neopermease® basic material compared with the basic 
material of  Hylase® “Dessau” three fractions of the former were collected for subsequent 
characterisation, i.e. the ascending range of peak A, the central range of peak B and the 
descending range of peak C. 
3.3.2.2 SDS-PAGE of fractions from size exclusion chromatography  
The molecular mass of the individual proteins present in the different fractions obtained by 
size exclusion chromatography was determined, i.e. 77 kDa in A, 60 and 58 kDa in B and 33 
kDa in C (results not shown). The fact that fraction B contained two proteins of nearly 
identical molecular mass became obvious by the densitometric analysis of a gel with an 
acrylamide/bisacrylamide content of 8.1 %.  
3.3.2.3 Determination of enzymatic activity in fractions from size exclusion 
chromatography  
Subsequently, enzyme activity of the three fractions was determined by the Morgan-Elson 
reaction. In Fig. 3-5 activities are plotted as a function of pH. The high and the low molecular 
mass fractions A and C show comparable pH profiles with a maximum at pH 6 and a shoulder 
around pH 4, probably due to traces of fraction B (Table 3-2). Fraction B is characterised by 
two maxima at pH 3.6 and pH 4.8.  
The specific activity of the three fractions was determined as described in 3.3.1.1.The highest 
activity per mg of protein was found in fraction B, whereas the high (A) and low (C) 
molecular mass fractions showed markedly lower specific activities (Table 3-2). These results 
can explain the complex effect of pH on the hydrolytic activity of Neopermease® (Fig. 3-1) 
as the sum of the pH profiles of several proteins, differing in specific activity. With 15.1 
µmol⋅min-1⋅mg-1 the specific activity of the 58 kDa fraction appears to be considerably high 
compared to the specific activity (3.36 µmol⋅min-1⋅mg-1), which is reported for a 62 kDa bull 
seminal plasma hyaluronidase (Srivastava and Farooqui, 1979). However, it is in good 
agreement with the results of Lyon and Phelps (1981), who determined a specific activity of 
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19.1 µmol⋅min-1⋅mg-1 for a purified BTH preparation consisting of two components with 
molecular weights of 61 kDa and 67.2 kDa, respectively. 
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Fig. 3-5: Activity of the size exclusion chromatography fractions as a function of pH. Samples of each 
fraction were tested for hyaluronidase activity by the Morgan-Elson reaction. 100 µl of eluate were 
incubated with incubation mixture 3-III (350 µl). (fraction A: —?—; fraction B: —□—;  
fraction C: —?—). 
Table 3-2: Characterisation of the various eluate fractions after gel filtration of 
Neopermease® basic material  
NAG at the reducing ends was measured as a function of time at optimal pH in each fraction, and the 
protein content was determined. 100 µl of eluate were incubated with incubation mixture 3-III  
(350 µl).  
 
Fraction 
 
Apparent molecular 
massa (kDa) 
 
Optimum pH  Specific activity
 
[µmol⋅min-1⋅mg-1] 
 
A 
 
B 
 
 
C 
 
77 
 
58 
 
 
33 
 
6.2 
 
3.6 
4.8 
 
6.2 
 
3.6 
 
15.1 
8.8 
 
0.5 
 
a determined by SDS-PAGE 
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3.3.3 Characterisation of a hyaluronate lyase from S. agalactiae  
3.3.3.1 Quantification of enzyme activity 
As hyaluronan degradation by hyaluronate lyase from group B streptococci yields an 
unsaturated disaccharide (?DiHA) as product (Pritchard et al., 2000), enzymatic activity was 
measured at 232 nm. When measured under similar conditions as used for the bovine enzyme 
one designated unit of the stabilised bacterial hyaluronidase catalysed the formation of  
2.8⋅10-3 µmol ?DiHA per minute, which is equivalent to 2.8 mU according to the definition 
of the International Union of Biochemistry (cf. section 3.3.1.1). The specific activity was 980 
U per mg for the stabilised enzyme preparation and 1080 U per mg for the ammonium 
sulphate precipitate (table 3-3). To compare the activities of the bacterial hyaluronidase 
preparation and the two BTH preparations, the activity of the bacterial enzyme was also 
determined by the Morgan-Elson reaction. 
Table 3-3: Activity of hyaluronate lyase from S. agalactiae  
Enzyme activity was determined by UV difference spectroscopy and by the colorimetric method at 
optimum pH (pH 5) under identical conditions, which are described in the materials and methods 
section. In case of the colorimetric method 50 µl of enzyme (1 unita dissolved in BSA (solution 1)) 
were incubated with incubation mixture 3-IV (400 µl).  
 
Specific activity 
[µmol⋅min-1⋅mg-1] 
Method 
Product formation per 
unita of the stabilised 
hyaluronate lyase 
[µmol⋅min-1] Stabilised hyaluronate lyaseb 
Ammonium 
sulphate 
precipitatec 
 
UV difference 
spectroscopy 
 
Colorimetric 
method 
 
 
2.8 ⋅ 10-3 
 
 
2.9 ⋅ 10-3 
 
980 
 
 
1015 
 
1080 
 
 
1150 
 
a according to the declaration of the supplier 
b for calculation the amount of enzyme protein per vial, as indicated by the supplier, was used 
c for calculation the protein content, determined by the method of Bradford, was used 
 
As shown in table 3-3 the results obtained by the different methods are in good agreement. As 
one designated unit of the stabilised bacterial hyaluronidase catalysed the formation of  
2.9⋅10-3 µmol of product per minute in the colorimetric assay, the equiactive concentration of 
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the bacterial enzyme preparation was by a factor of 60 and 35 lower, when compared with the 
two pharmaceutical preparations Neopermease® and Hylase® “Dessau”, respectively. 
However, equiactive concentrations with respect to product formation are not necessarily 
pharmacologically equieffective considering the different hyaluronan degradation 
mechanisms of the bovine and the bacterial enzyme. While hyaluronan degradation by 
hyaluronate lyase from group B streptococci involves an initial random endolytic cleavage 
followed by rapid exolytic and processive release of unsaturated disaccharide (Baker and 
Pritchard, 2000; Li and Jedrzejas, 2001), the bovine enzyme acts as an endolytic enzyme 
(Vercruysse et al., 1994) with tetra- and hexasaccharides as the main degradation products 
(Cramer et al., 1994; Takagaki et al., 1994). Thus, every cleavage of hyaluronic acid chains 
by BTH results in the formation of two shorter chains, whereas in case of the bacterial 
enzyme the chain is shortened by only one disaccharide per cleavage step. In view of the 
different catalytic mechanisms, the administration of equiactive amounts of the two 
hyaluronidases as a spreading factor should result in a faster reduction of the viscosity of the 
extracellular matrix in case of BTH. 
When comparing the preparations with respect to their specific activities, the bacterial 
hyaluronidase preparation was 410 times more active than Neopermease® and 5100 times 
more active than Hylase® “Dessau”. 
3.3.3.2 Effect of pH on enzyme activity  
By analogy with the BTH preparations the activity of the hyaluronidase from S. agalactiae 
was determined as a function of pH. Aliquots of the enzyme were incubated in NaCl-
containing citrate-phosphate buffer of varying pH for 1 h at 37 °C, and NAG at the reducing 
end of the produced hyaluronan fragments was measured. Under identical incubation 
conditions the influence of pH on the initial velocity of the enzyme reaction was investigated 
by monitoring the product formation at 232 nm. The pH profiles obtained with both methods 
were identical as shown in Fig. 3-6. 
The highest hydrolytic activity was determined at pH 5.0. At acidic pH a marked decrease in 
enzyme activity was observed within 1 pH unit, resulting in approx. 10 % of the maximum 
activity at pH 4.0, whereas considerable activity was detected at neutral pH with 45 % of the 
maximum activity at pH 7.0. In this context it is noteworthy that Ozegowski et al. (1994) 
reported maximal activity at pH 6.3 for a 116 kDa hyaluronate lyase from S. agalactiae.  
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Fig. 3-6: Effect of pH on the activity of S. agalactiae hyaluronate lyase. Activity of the stabilised 
hyaluronate lyase was determined as a function of pH by UV difference spectroscopy (—●—) and by 
the colorimetric method (—□—) using the incubation conditions which are described in the materials 
and methods section. In case of the colorimetric method 50 µl of enzyme (1 unit (as declared by the 
supplier) dissolved in BSA (solution 1)) were incubated with incubation mixture 3-IV (400 µl). 
3.3.3.3 SDS-PAGE 
To obtain information about the purity of the bacterial hyaluronidase preparations and the 
molecular mass of the contained proteins the stabilised hyaluronate lyase and the ammonium 
sulphate precipitate were separated by SDS-PAGE. 
In addition to the intense broad band of BSA (66 kDa), which is present in the stabilised 
preparation, the Coomassie stained gel shows two prominent bands corresponding to a protein 
with an apparent molecular mass of 85 kDa and 100 kDa, respectively (Fig. 3-7A, left lane). 
Bands of relatively poor staining intensity were assigned to 46 kDa and 55 kDa proteins. The 
weakly stained high molecular mass proteins (215 kDa, 255 kDa) may represent dimers and 
trimers of the two main components. SDS-PAGE of the ammonium sulphate precipitate 
revealed the existence of only two proteins of an apparent molecular mass of 100 and 85 kDa, 
respectively, corresponding to the two main components of the stabilised enzyme (Fig. 3-7A, 
right lane). 
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Fig. 3-7: SDS-PAGE of the S. agalactiae hyaluronate lyase preparations. A: stabilised hyaluronate 
lyase (2.15 µg, left lane) and the ammonium sulphate precipitate (0.9 µg, right lane) were separated on 
a 7.5 % gel (left lane) and a 8% gel (right lane), respectively. Both gels were stained with Coomassie 
Brilliant Blue G-250. B: Densitogram of the right lane (ammonium sulphate precipitate).   
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No additional protein components were detected on the gels, neither by Coomassie nor by the 
more sensitive silver staining technique (results not shown). Densitometric analysis of the 
Coomassie stained gel (Fig. 3-7B) shows that the amount of the 85 kDa protein in the 
ammonium sulphate precipitate is about 60 % higher compared with the 100 kDa protein. The 
symmetry of the peaks indicates a high purity of the two proteins. The fact that hyaluronate 
lyase preparations from S. agalactiae consist of two different proteins, has also been reported 
by Gase et al. (1998) and Jedrzejas and Chantalat (2000), although the assigned molecular 
masses differ for the individual proteins. 
3.3.3.4 Determination of pI  
By means of isoelectric focussing (IEF) the ammonium sulphate precipitate was separated 
into two proteins corresponding to pI values of 9.2 and 8.9 (results not shown). Densitometric 
analysis of the IEF gel revealed that the band at pH 9.2 showed a considerably higher staining 
intensity than the band at pH 8.9. Combining the IEF results with the results of SDS-PAGE 
(Fig. 3-7) the polypeptide with an apparent pI of 9.2 corresponds to the 85 kDa protein, 
whereas the band with an apparent pI of 8.9 corresponds to the 100 kDa protein. Interestingly, 
the densitometric analysis revealed that the band at pI = 9.2 consists of at least three proteins 
with slightly different pI values, which were not resolved by SDS-PAGE. For the 116 kDa 
hyaluronate lyase from S. agalactiae Ozegowski et al. (1994) determined a pI value of 8.75. 
3.3.3.5 Detection of enzymatically active proteins by zymography 
As the ammonium sulphate precipitate was found to contain two proteins, which differ with 
respect to molecular mass and pI, it was of interest to find out if both proteins were 
enzymatically active. For this reason the capability of the two proteins to degrade hyaluronic 
acid was investigated by zymography. SDS substrate-PAGE, using hyaluronic acid 
immobilised in the gel, demonstrated that both the 85 kDa and the 100 kDa protein exhibit 
enzymatic activity (Fig. 3-8). From the densitogram it can be estimated that the enzyme 
activity, present in the 85 kDa band, was 25 % higher than that associated with the 100 kDa 
band, a finding consistent with the different amounts of protein, determined by SDS-PAGE 
(Fig. 3-7B). In principle, these results are in agreement with the investigations of Gase et al. 
(1998) and Jedrzejas and Chantalat (2000), who identified two different enzymatically active 
proteins in hyaluronidase preparations from S. agalactiae. However, the apparent molecular 
masses of the proteins reported by these authors were 94 kDa and 110 kDa (Gase et al., 1998) 
and 92 kDa and 111 kDa (Jedrzejas and Chantalat, 2000), respectively. 
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Fig. 3-8: Zymography of the S. agalactiae hyaluronate lyase. A: 3.5 ng of the ammonium sulphate 
precipitate were separated by SDS substrate-PAGE on a 5 % gel. The gel was stained with alcian 
blue/acetic acid, pH 2.5. B: densitogram of A. 
 
3.3.3.6 Limited proteolysis of S. agalactiae hyaluronate lyase 
S. agalactiae hyaluronate lyase is composed of three structural domains which are connected 
by two peptide linkers: the N-terminal β-sheet domain (βI-domain), the middle α-helical 
domain (α-domain) and the C-terminal β-sheet domain (βII-domain) (Li and Jedrzejas, 2001). 
The catalytic region, where the substrate is bound, is located in the α-domain of the enzyme, 
while the two β-domains are not involved in the hyaluronan degradation process (Li and 
Jedrzejas, 2001). It can be assumed that removal of one or both of the β-domains by 
proteolytic cleavage retains the hyaluronidase activity of the residual protein fragment. Such 
fragments with an expected molecular mass of about 50 to 75 kDa might have more 
favourable pharmacokinetic properties compared to the holoenzyme. Therefore, limited 
proteolysis was performed with the ammonium sulphate precipitate, and the products were 
analysed by SDS-PAGE and zymography. Densitometric analysis of Coomassie stained gels, 
loaded with samples after various incubation times from 0 to 120 min (trypsin/hyaluronate 
lyase ratio of 0.001), showed decreasing amounts of the 85 kDa and the 100 kDa protein with 
increasing incubation time. While the 100 kDa protein was hardly detectable after an 
incubation time of 120 min, considerable amounts of the 85 kDa protein were present, 
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reflecting the higher stability of the latter against proteolytic cleavage by trypsin (results not 
shown). Although Coomassie staining demonstrated a time-dependent decrease in the 100 
kDa and the 85 kDa protein, no cleavage products were detected, except for a 20 kDa 
polypeptide, which became obvious after 90 min. With the more sensitive silver staining 
method several degradation products with apparent molecular masses between 20 and 75 kDa 
were detected in samples which had been digested with trypsin for 2 h (results not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-9: Zymography of the S. agalactiae hyaluronate lyase after proteolytic digestion with trypsin. 
3.5 µg of the ammonium sulphate precipitate were digested with trypsin (trypsin-hyaluronidase ratio 
of 0.001) for varying times prior to separation by SDS substrate-PAGE on a 10 % gel. The gel was 
stained with alcian blue/acetic acid, pH 2.5, and counterstained with Coomassie Brilliant Blue G-250. 
The unstained areas on the gels are indicative for enzymatic activity, whereas the dark bands are 
proportional to the protein content. 
The respective zymograms (Fig. 3-9) demonstrate that enzyme activity is present in the 
fragments with molecular masses of 75 kDa, 70 kDa, 62 kDa, 60 kDa and 50 kDa. A 
comparison of the zymograms of the samples, which had been incubated with trypsin at 
varying times, indicates that with increasing incubation time the enzymatically active 
fragments are further degraded to smaller proteins which are devoid of the capabiliy to 
degrade hyaluronic acid. Interestingly, as the 85 kDa parent protein, the 75 kDa degradation 
product appears to be quite stable against trypsin cleavage. 
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3.3.3.7 Activiy against chondroitin 4-sulphate and chondroitin 6-sulphate 
For hyaluronidases from mammalian testes it is known that their substrate specificity is not 
limited to hyaluronan. Other glycosaminoglycans, i.e. chondroitin, chondroitin 4- and 6-
sulphate and, to a limited extent, dermatan sulphate, are also degraded by BTH, albeit at a 
much slower rate (Meyer, 1971; Saitoh et al., 1995).  
To find out, if the S. agalactiae hyaluronate lyase acts also on other glycosaminoglycans of 
the extracellular matrix, the capability of the enzyme to degrade preparations of chondroitin 
4- and 6-sulphate was investigated. The structure of chondroitin differs from that of 
hyaluronic acid only in the epimeric configuration at the C-4 carbon of the amino sugar, i.e. 
the N-acetyl-D-glucosamine of hyaluronic acid is replaced by N-acetyl-D-galactosamine.  
4- and 6-sulphation of chondroitin occur at the C-4 and C-6 position of the N-acetyl-D-
galactosamine (Fig. 3-10). Chains of chondroitin sulphate also contain unsulphated regions. 
The degree of sulphation and the arrangement of sulphated and unsulphated disaccharide 
repeats vary depending on the tissue source of the respective chondroitin sulphate (Baker et 
al., 1997). 
 
 
Fig. 3-10: Structures of the repeating disaccharide units of chondroitin 4-sulphate (Di4S/DiOH) and 
chondroitin 6-sulphate (Di6S/DiOH), respectively. 
Enzyme activity was determined by UV difference spectroscopy at 232 nm under similar 
conditions as used for the substrate hyaluronan (standard conditions, see 3.2.2.2). 
Measurements were performed at pH 5.0 and hyaluronic acid was replaced with preparations 
of chondroitin 4-sulphate (from bovine trachea) and chondroitin 6-sulphate (from shark 
cartilage), respectively. 
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In case of chondroitin 6-sulphate product formation was very slow when using enzyme and 
substrate concentrations equivalent to the standard conditions (5.56 units# of enzyme per ml; 
0.56 mg of substrate per ml, results not shown). Even when the concentrations of enzyme and 
substrate were increased to 55.6 units# per ml and 33.3 mg per ml, respectively, the increase 
in absorbance at 232 nm per unit time was about tenfold less compared to the measurements 
with hyaluronic acid as substrate under standard conditions (Fig. 3-11A). 
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Fig. 3-11: Activity of the S. agalactiae hyaluronate lyase against various substrates determined by UV 
difference spectroscopy (cf. Section 2.2.2.) using various incubation conditions with respect to the 
concentration of the stabilised hyaluronate lyase (units#/ml) and the respective substrate (mg/ml). A: 
black line (—): HA from rooster comb (0.56 mg/ml), 5.56 units#/ml; red line (—): chondroitin 6-
sulphate (33.3 mg/ml), 55.6 units#/ml; B: red line (—): chondroitin 6-sulphate (33.3 mg/ml), 55.6 
units#/ml; blue lines (—): chondroitin 4- sulphate (33.3 mg/ml), (a) 55.6 and (b) 111 units#/ml. 
Similar results were obtained with chondroitin 4-sulphate. As shown in Fig. 3-11B the 
absorbance at 232 nm increased at the same rate in the presence of chondroitin 4-sulphate or 
chondroitin 6-sulphate, when equal concentrations of the respective substrate were applied. 
Doubling of the enzyme concentration in the incubation mixture resulted in a twofold increase 
in the velocity of product formation.  
The fact that the investigated hyaluronate lyase from S. agalactiae, strain 4755, is capable of 
degrading preparations of chondroitin sulphate at a slow rate is in agreement with the results 
described in the literature for a hyluronate lyase from S. agalactiae, strain 3502. Pritchard et 
al. (1994) showed that S. agalactiae hyaluronate lyase cleaves chondroitin sulphate 
preferentially at unsulphated regions, and found that the extent of digestion was remarkably 
increased by prior chemical desulphation of the polysaccharide.  
                                                 
# as declared by the supplier 
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By Baker et al. (1997) it was shown that tetrasaccharides consisting of unsulphated (DiOH) 
and/or 4-sulphated (Di4S) disaccharide units of chondroitin were cleaved by the hyaluronate 
lyase from S. agalactiae, strain 3502, only when there was no sulphation of the disaccharide 
unit at the reducing end, i.e. the tetrasaccharides DiOH(1?4)DiOH and Di4S(1?4)DiOH were 
substrates, whereas DiOH(1?4)Di4S and Di4S(1?4)Di4S were not cleaved. In addition, it is 
reported by Baker and Pritchard (2000) that tetrasaccharides consisting of 4-sulphated (Di4S) 
and/or 6-sulphated (Di6S) disaccharide units of chondroitin were cleaved only when there 
was a 6-sulphated disaccharide unit at the reducing end, i.e. the tetrasaccharides 
Di6S(1?4)Di6S and Di4S(1?4)Di6S were cleaved, whereas Di6S(1?4)Di4S and 
Di4S(1?4)Di4S were not. 
These results suggest that S. agalactiae hyaluronate lyase cleaves the β1,4 linkages of 
macromolecular chondroitin 4-sulphate (containing unsulphated regions) only when there is 
no sulphation at the nonreducing side of the β1,4 linkage (see Fig. 3-12A), whereas in 
polymers of chondroitin 6-sulphate every β1,4 linkage is susceptible to cleavage (see Fig.  
3-12B).  
 
 
 
Fig. 3-12: Schematic representation of macromolecular chondroitin 4-sulphate (A) and chondroitin 6-
sulphate (B), respectively. The arrows point at the β1,4 linkages susceptible to cleavage by S. 
agalactiae hyaluronate lyase, as suggested by Baker et al. (1997; 2000). 
According to the aforementioned considerations chondroitin 6-sulphate is expected to be a 
better substrate for the hyaluronate lyase from S. agalactiae compared to chondroitin 4-
sulphate. However, in our experiments no difference in the extent and velocity of product 
formation was observed during the action of S. agalactiae hyaluronate lyase on preparations 
of chondroitin 4-sulphate and chondroitin 6-sulphate, respectively (Fig. 3-11B).  
· · · (1?4) Di4S (1?4) DiOH (1?4) DiOH (1?4) Di4S (1?4) Di4S (1?4) · · ·A 
· · · (1?4) Di6S (1?4) DiOH (1?4) DiOH (1?4) Di6S (1?4) Di6S (1?4) · · ·B 
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3.3.3.8 Stability of hyaluronate lyase from S. agalactiae  
The effect of different storage conditions on the activity of the stabilised hyaluronate lyase, 
dissolved in BSA [50 units#/ml, i.e. the concentration of the enzyme solution, used for UV 
difference spectroscopy under standard conditions (cf. Section 3.2.2.2)], was investigated by 
UV difference spectroscopy. 
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Fig. 3-13: Stability of hyaluronate lyase from S. agalactiae under different storage conditions. 
Hyaluronidase activiy was determined by UV difference spectroscopy (cf. Section 3.2.2.2.) at 
optimum pH (pH 5.0) after storage of the enzyme solution in portions of 2 ml [50 units# per ml of 
BSA (solution 1)] at 4 °C (—●—) and room temperature (—○—), respectively. Inset: Activity of the 
S. agalactiae hyaluronate lyase after repeated freezing and thawing of the enzyme solution (50 units# 
per ml, see above). Immediately after the determination of the enzyme activity, the solution was stored 
at -26 °C for at least 1 day, before activity was redetermined after thawing of the solution at room 
temperature.  
As shown in Fig. 3-13, 92 % of the activity is retained after 4 weeks, when the enzyme 
solution is kept at 4 °C, whereas storage at room temperature over the same period results in a 
continuous decrease of hyaluronidase activity down to 58 % (day 28) compared to the activity 
measured at the beginning of the experiment (day 0). In addition, it was shown that 
hyaluronidase activity was not affected by multiple freezing and thawing of the investigated 
enzyme solution (Fig. 3-13, inset).  
                                                 
# as declared by the supplier 
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These results indicate that the investigated solution of S. agalactiae hyaluronate lyase 
(working solution for UV difference spectroscopy) is quite stable, i.e. almost 100 % of the 
activity is retained after storage for one day at 4 °C. If necessary, working solutions can 
readily be stored at -26 °C and used after thawing without loss of activity. However, it should 
be emphasized that these results are not valid for any hyaluronate lyase solution, as the 
stability of enzymes in solution generally depends on the concentration of the protein. 
3.4 Conclusion 
Our results show that Neopermease® and Hylase Dessau® are hyaluronidase preparations with 
nearly the same enzymatic properties, though identical enzymatically active proteins were not 
detected. Although the existence of isoenzymes can not be definitely ruled out, the pattern of 
proteins appears mainly to depend on different partial proteolytic cleavage, e.g. during the 
isolation and purification procedure.  
Bacterial hyaluronidases such as the enzyme from S. agalactiae seem to meet the 
requirements for a pharmaceutical preparation with respect to purity and specific activity, 
being an appropriate substitute (Ozegowski et al., 2001) for the outdated bovine testicular 
hyaluronidase. 
Moreover, the bacterial enzyme may be advantageous over the bovine enzyme especially as 
an adjuvant in cancer chemotherapy as hyaluronan degradation by the former does not yield a 
heterogenous mixture of oligosaccharides and hyaluronan fragments of different size, to 
which certain biological functions have been ascribed (Noble, 2002), e.g. induction of 
irreversible phenotypic and functional maturation of dendritic cells during inflammation 
(Termeer et al., 2000), induction of angiogenesis (West and Chen, 2000) by stimulation of the 
proliferation and migration of vascular endothelial cells via multple signaling pathways 
(Slevin et al., 2002). The generation of the aforementioned degradation products of 
hyaluronan may harbour the risk of increased tumor metastasis and angiogenesis when BTH 
is applied in combination with antitumor agents.  
Furthermore, since enzyme activity is retained in fragments of lower molecular mass, these 
polypeptides are supposed to have an advantage over the holoenzyme with respect to faster 
tissue penetration.  
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4 Preclinical investigations on the adjuvant administration of a 
hyaluronate lyase from S. agalactiae in cancer chemotherapy  
4.1 Introduction 
Sufficient penetration of cytostatics into solid tumors is essential for the satisfactory outcome 
of cancer chemotherapy. In the treatment of solid tumors a major problem results from the 
fact that a uniform spreading of the chemotherapeutics within the neoplasm is impaired by the 
elevated intratumoral pressure, which counteracts drug penetration, and by natural barriers 
such as the basal laminae and the tumor stroma (Jain, 1994).  
As a major component of the extracellular matrix hyaluronan (HA) plays a crucial role in 
controlling diffusion processes (Levick, 1987). Although the prevalence of hyaluronan is not 
a universal feature of all tumors, numerous cancers, both of epithelial and mesenchymal 
origins, have been shown to exhibit elevated levels of hyaluronan relative to normal tissues. 
Highly increased levels of hyaluronan are reported e.g. for human Wilms` tumor and 
mesothelioma, as well as for malignant breast carcinoma and malignant melanoma (Knudson 
and Knudson, 1995). The tumor-associated hyaluronan can be synthesised either by 
fibroblasts, which are induced to increase their HA synthesis following direct cell-to-cell 
contact with the tumor cells or by a paracrine mechanism, or by the tumor cells themselves 
(Decker et al., 1989; Knudson and Knudson, 1995). The increased synthesis and deposition of 
hyaluronan in tumor tissues results in an expansion and hydration of the extracellular matrix 
and, thus, provides an extracellular milieu, which is supposed to be conducive to cellular 
invasion and migration (Knudson and Knudson, 1995).  
A number of clinical pilot studies are reported, in which hyaluronidase was added to 
conventional chemotherapy regimens (Baumgartner, 1987; Baumgartner and Moritz, 1988; 
Smith et al., 1997; Klocker et al., 1998) or combined with radiochemotherapy (Schumer et al., 
1990). The adjuvant application of hyaluronidase improved the prognosis of most patients and 
induced responses in previously chemoresistant patients. The clinically observed recoveries 
are generally explained by the assumption that degradation of the hyaluronate-enriched 
extracellular matrix by hyaluronidase reduces the edemas around and within the tumors, thus 
providing higher effective concentrations of the co-injected chemotherapeutics in the tumor 
area (Baumgartner and Moritz, 1988; Beckenlehner et al., 1992; Spruß et al., 1995). Indeed, 
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this assumption could be confirmed by the work of Muckenschnabel et al. (1996; 1998) and 
Gürtler (2001), who showed that s.c. injected chemotherapeutics were accumulated (3-8fold) 
by human malignant melanoma, implanted in nude mice, after combined administration of 
bovine testicular hyaluronidase (BTH).  
The reported preclinical and clinical trials using hyaluronidase as an additive in cancer 
chemotherapy were all performed with preparations of bovine testicular haluronidase, which 
had been commercially available for therapeutic use at that time (e.g. Neopermease®, 
Permease®, Hylase® “Dessau”). However, in the context with the risk of BSE, several 
companies have stopped the production of BTH preparations, which led to a shortage of this 
drug. To find a substitute for BTH a hyaluronate lyase from Streptococcus agalactiae, which 
can be produced biotechnologically, was recently characterised with respect to purity and 
specific activity and was found to meet the requirements for a pharmaceutical preparation 
(Oettl et al., 2003). Furthermore, Ozegowski et al. (2001) reported that hyaluronate lyase from 
S. agalactiae may be useful to improve the tissue absorption of drugs.  
In the present work it was therefore investigated in preclinical in vitro and in vivo studies, if 
bacterial hyaluronate lyase may serve as an appropriate substitute for BTH as an additive in 
cancer chemotherapy. Especially as an adjuvant in cancer chemotherapy the hyaluronate lyase 
from S. agalactiae may be of advantage over the bovine enzyme, since - in contrast to the 
hydrolysis of HA by BTH - the degradation of HA by bacterial hyaluronidase does not yield a 
heterogenous mixture of low molecular mass HA fragments, which are discussed to induce 
biological effects, which may promote tumor growth and invasion, e.g. increased 
angiogenesis (Slevin et al., 2002) or enhanced tumor cell motility (Sugahara et al., 2003). 
4.2 Materials and methods 
4.2.1 Chemicals 
Eagle’s minimum essential medium (EMEM) and Mc Coy’s medium were from Sigma 
(Deisenhofen, Germany). Fetal calf serum (FCS) was purchased from Gibco (Eggenstein, 
Germany). Trypsin/EDTA solution was obtained from Boehringer (Mannheim, Germany). 
Potassium sorbate was from Merck (Darmstadt, Germany), chloramphenicol was from Sigma 
(München, Germany). N-phenyl-2,2´-iminodiethanol was purchased from Merck (Darmstadt, 
Germany). Sodium dodecyl sulphate (SDS) was purchased from Serva (Heidelberg, 
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Germany). Methanol was of HPLC grade (Baker, Groß-Gerau, Germany) and water was 
purified by a Milli-Q system (Millipore, Eschborn, Germany). All other chemicals were of 
analytical or HPLC grade and were from Merck. 
4.2.2 Drugs 
Alkeran® (one vial contained melphalan-HCl equivalent to 50 mg of melphalan and 20 mg of 
povidone as lyopilized powder) was from Glaxo Wellcome (Bad Oldesloe, Germany). 
Melphalan-HCl (ca. 95 %) was purchased from Sigma (Deisenhofen, Germany). 
Velbe® (10 mg vinblastine sulphate per vial) was obtained from Lilly (Giessen, Germany). 
Stabilised hyaluronate lyase, i.e. 200 000 units# of lyophilised hyaluronidase (0.572 mg) from 
Streptococcus agalactiae, strain 4755, plus 2.2 mg BSA and 37 mg Tris-HCl per vial, and the 
pure stabiliser BSA were kindly provided by id-pharma GmbH (Jena, Germany). 
Neopermease®, containing 200 000 units# of lyophilised bovine testicular hyaluronidase (4 
mg) plus 25 mg of gelatin per vial, was a gift from Sanabo (Vienna, Austria), 
4.2.3 Tumor cell lines and culture conditions 
The human malignant melanoma cell lines (SK-MEL-3 and SK-MEL-24) and the human 
glioblastoma/astrocytoma cell line U-87 MG (HTB 14) were purchased from the American 
Type Culture Collection (ATCC; Rockeville, Md., USA). Cell banking and quality control 
were performed according to the seed stock concept reviewed by Hay (1988). SK-MEL-24 
and U-87 MG cell were grown in EMEM containing L-glutamine, 2.2 g/l NaHCO3 and      
110 mg/l sodium pyruvate, whereas SK-MEL-3 cells were grown in McCoy’s medium 
containing 2.2 g/l NaHCO3. FCS was added to the culture media to a final concentration of  
10 %. The cells were cultured in a water-saturated atmosphere of 95 % air and 5 % CO2 at  
37 °C in 75 cm2 culture flasks (Costar, Tecnomara, Fernwald, Germany) and were serially 
passaged following trypsination using trypsin (0.05 %)/EDTA (0.02 %) solution. Detailed 
characterisation of the melanoma cell lines with respect to morphology, karyology and 
proliferation kinetics is described in the work of Christl (1992), whereas the U-87 MG cells 
were characterised by Altenschöpfer (1998).  
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For tumor cell transplantation (SK-MEL-3 and -24) into nude mice cells were harvested 
mechanically, spun down at 100 g for 10 min and washed twice with serum-free medium. The 
cell concentration was adjusted to approx. 107 cells per ml of serum-free medium. 
4.2.4  Animals and housing conditions  
NMRI nu/nu mice were randomly bred in the nude mouse laboratory of the university of 
Regensburg under specified pathogen-free conditions at 25 ± 1 °C, 65 ± 5 % relative 
humidity, and a 12-h/12-h light/dark cycle (Spruß et al., 1996). Nude mice were fed ad 
libitum with combined breeding-maintenance diet 1434 (Altromin, Lage, Germany) and water 
containing 1.3 g/l potassium sorbate and 2g/l chloramphenicol; the pH was adjusted to pH 2.5 
with HCl (Fortmeyer, 1981). The animals were housed in macrolon cages of size III (Ehret, 
Emmendingen, Germany) in groups of 7 animals per cage. 
4.2.5  Tumor transplantation  
Solid tumors were established in NMRI nu/nu mice by injection of about 2 - 3 · 106 melanoma 
cells s.c. into the right flank of the thorax (passage 0). For serial passage the tumors were cut 
into 2-mm3 pieces and were transplanted s.c. into the right thoracic flank with a trocar (gauge 
13) (passage 1). A detailed description of the procedure is given by Gürtler (2001). 
4.2.6 Chemosensitivity assay 
A standardised kinetic microassay based on crystal violet staining was used. The technical 
details of the procedure and the method of evaluating drug action have been described in 
detail by Bernhardt et al. (1992). In brief: cells were seeded (100 µl/well) in 96-well flat-
bottomed microtitration plates (Greiner Bio-One GmbH, Kremsmünster, Austria) at an 
appropriate density of about 15 cells/ microscopic field (magnification 320 x ). The plates 
were incubated at 37 °C (water-saturated atmosphere; 5 % CO2). After 42-48 h the culture 
medium was carefully removed by suction and replaced by fresh medium (200 µl/well) 
containing drug or pure solvent. Drugs were added as a 1000-fold concentrated stock solution. 
The hyaluronate lyase preparation and the stabiliser BSA were dissolved in water, whereas 
Doxorubicin and Vinblastin were dissolved in 70 % ethanol. No influence on the growth 
characteristics caused by the properties of the organic solvent was observed. On every plate 
two rows (n = 16) served as controls and two rows (n = 16) were used per drug concentration.  
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After various times of incubation the culture medium was shaken off and the cells were fixed 
with glutardialdehyde and stored at 4 °C. At the end of the experiment all plates were stained 
with crystal violet simultaneously. Absorbance was measured at 578 nm using a Biotek 309 
Autoreader (Tecnomara, Fernwald, Germany). Processing procedure, data analysis and 
evaluation were performed as described previously (Reile et al., 1990; Bernhardt et al., 1992).  
Results are presented as plots of absorbance or corrected T/C values versus time of incubation 
according to T/Ccorr (%) = 100 · (T – C0)/(C – C0), where T is the absorbance of the treated 
cells, C the absorbance of the controls, and C0 the absorbance of the cells at the time when 
drug was added (t = 0). The proliferation curves were fitted with a polynom (3rd), using 
SigmaPlot (Version 8.0).  
4.2.7 In vivo experiments 
4.2.7.1 Influence of hyaluronidase on melphalan enrichment in solid melanoma 
The influence of hyaluronidase on melphalan enrichment in solid melanomas was 
investigated according to the experimental design described by Muckenschnabel et al. (1996). 
The experiments were carried out with NMRI nu/nu mice (male and female; mean body 
weight approx. 25 g) bearing solid human SK-MEL-3 and SK-MEL-24 melanoma, 
respectively. The average tumor burden was approximately 200 mg. The number of the 
passage of the tumors used in the different experiments is given in the context with the 
respective experiments in the results section.  
Melphalan (Alkeran® or melphalan-HCl from Sigma) was dissolved in 0.01 N HCl containing 
0.9% NaCl immediately before use. The drug was injected in a volume of 0.1 ml/20 g body 
weight, yielding a dose of 50 µmol/kg. Hyaluronidase (S. agalactiae hyaluronate lyase and 
Neopermease®, respectively) was dissolved in 0.9 % NaCl and also applied in a volume of  
0.1 ml/20 g body weight to provide an enzyme activity of 250 000 units#/kg and  
500 000 units#/kg in case of S. agalactiae hyaluronate lyase and of 100 000 units#/kg in case 
of Neopermease®.  
Melphalan alone or both, melphalan and hyluronidase, were given peritumorally (s.c.) to 5-8 
animals per treatment group. In the treatment group of the hyaluronidase/melphalan 
combination therapy hyaluronidase was injected 1 h prior to melphalan application, whereas 
                                                 
# according to the declaration of the supplier 
Adjuvant administration of hyaluronate lyase from S. agalactiae in cancer chemotherapy 
 68
in the control group (melphalan alone) 0.9 % NaCl was injected 1 h prior to melphalan 
application in a volume of 0.1 ml/ 20 g body weight. Injection of the drugs and the vehicle  
0.9 % NaCl, respectively, was carried out in the vicinity of the melanoma ca. 5 mm away 
from the neoplasms with care being taken to avoid mechanical irritation of the tumor. Exactly 
1 h after melphalan administration the tumors were resected, instantly shock-frozen in liquid 
nitrogen and stored at -78 °C until analysis (cf. 4.2.8). 
4.2.7.2 Co-application of hyaluronidase in the regional chemotherapy of malignant 
melanoma 
The chemotherapeutic experiments to study the effect of hyaluronidase on the efficacy of 
regional chemotherapy of malignant melanoma (SK-MEL-3) were performed according to 
Spruß et al. (1995) and Gürtler (2001). Solid tumor pieces (approx. 2 mm3) were implanted 
subcutaneously on day 0 into the right flank of NMRI nu/nu mice (only male animals; 6-8 
weeks old in case of the melphalan-experiment; 3-4 weeks old in case of the vinblastine 
experiment). The treatment was started when the solid tumors were visible, measuring at least 
2 mm in diameter (day 8 in both experiments). The regional therapy with either melphalan 
(vinblastine) alone or in combination with hyaluronidase was carried out weekly (4 therapy 
cycles) by injecting the agents s.c. in the vicinity of the tumors in a volume of 0.1 ml/20 g 
body weight. Hyaluronidase was administered 1 h before melphalan (vinblastine). Each 
treatment group consisted of 12 animals. In the control group (also 12 animals) instead of 
melphalan (vinblastine) the respective solvents were injected in a volume of 0.1 ml/20 g body 
weight.  
Melphalan (Alkeran®) was dissolved in 0.01 N HCl containing 0.9 % NaCl immediately 
before use. The drug was injected in a volume of 0.1 ml/20 g of body weight, yielding a dose 
of 6 mg Alkeran® (4 mg melphalan) /kg. Vinblastine (Velbe®) was dissolved in 0.9 % NaCl 
and injected in a volume of 0.1 ml/20 g of body weight, yielding a dose of 0.3 mg/kg. 
Hyaluronidase (S. agalactiae hyaluronate lyase) was dissolved in 0.9 % NaCl and also 
applied in a volume of 0.1 ml/20 g body weight to provide an enzyme activity of 250 000 
units#/kg (melphalan experiment) and 500 000 units#/kg (vinblastine experiment), 
respectively.  
Tumor growth kinetics was recorded by measuring tumor diameters with an electronic caliper 
twice a week. Tumor areas were calculated as the product of two perpendicular diameters, one 
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measured across the greatest width of the tumor. To evaluate the tolerance of the therapy the 
body weight of the animals was documented twice a week. The tumor growth and change of 
body weight were registered until slight cachexia appeared in several animals, otherwise the 
experiment was terminated on day 71 (melphalan experiment) or day 66 (vinblastine 
experiment).  
T/C values were calculated according to the following equation: 
1)-4 (eq.100
)(mm group control of areaor median tum
)(mm group therapy of areaor median tum(%) T/C 2
2
⋅=
 
4.2.8 Quantitative analysis of melphalan in solid tumor samples  
Quantification of melphalan accumulation in solid tumor samples was performed according to 
the HPLC method, which was developed by Muckenschnabel et al. (1996; 1997) and slightly 
modified by Gürtler (2001). 
4.2.8.1 Instrumentation 
Melphalan analysis was performed on a stainless-steel column (250 mm x 4 mm I.D.) with a 
guard column (25 mm x 4 mm i.d.), both packed with 5 µm LiChrosorb RP-18 material 
(Merck, Darmstadt, Germany). Measurements were carried out on a TSP (tsp Thermo 
Separation Products GmbH, Egelsbach, Germany) liquid chromatograph consisting of a SN 
4000 controller, a P 4000 pump, an SCM 400 degasser, an AS 3000 autosampler and a FL 
3000 fluorescence detector. The chromatograms were recorded with the TSP software on a 
microcomputer running on OS2/Warp.  
4.2.8.2 HPLC conditions 
The mobile phase consisted of methanol buffer (50:50, v/v) and was degassed with helium 
prior to use. The mobile phase buffer (MPB) contained 10 mM NaH2PO4 · H2O and 2.3 mM 
SDS as ion pairing reagent; the pH was adjusted to 3.0 by the dropwise addition of 
concentrated phosphoric acid. Isocratic analyses were performed at a flow rate of 1 ml/min at 
40 °C. As internal standard (I.S.) N-phenyl-2,2´-iminodiethanol was used. Detection of the 
analytes was carried out fluorimetrically using an excitation wavelength of 250 nm and an 
emission wavelength of 350 nm. 
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4.2.8.3 Standards and calibration 
Standard mixtures containing melphalan (L-PAM; (S)-3-{4-[bis(2-chloroethyl)amino]-
phenyl}alanine), “dihydroxymelphalan” (L-DOH; (S)-3-{4-[bis(2-hydroxyethyl)amino]-
phenyl}alanine) and N-phenyl-2,2´-iminodiethanol (I.S.) were used for calibration.  
The preparation of the calibration mixtures was carried out as described in detail by Gürtler 
(2001). In brief: stock solutions were prepared for each of the 3 components: L-PAM: 4 mM, 
dissolved in methanol; L-DOH: 0.4 mM, prepared by treating melphalan with H2O at 60 °C 
for 4 h; I.S.: 0.4 mM, dissolved in H2O. To preclude hydrolysis reactions, calibration mixtures 
were freshly prepared by adding certain volumina of the respective stock solutions (L-PAM: 
20 µl; L-DOH: 40 µl; I.S.: 110 µl) to 630 µl of mobile phase, adjusted to pH 1.6 with HCl. 
Appropriate dilution of this calibration mixture with mobile phase (pH 1.6) produced standard 
concentrations ranging from 100 µM to 1 µM for L-PAM, from 20 µM to 0.2 µM for L-DOH 
and from 55 µM to 0.55 µM for I.S. 
To quantify the melphalan concentration in the tumor samples calibration curves were run 
daily by injecting 30 µl of each calibration mixture.  
4.2.8.4 Sample preparation 
The frozen tumor samples (cf. 4.2.7.1) were cut up in an agate mortar with a scalpel, covered 
with liquid nitrogen and crumbled. The homogenised tumor samples were weighed (approx. 
80 - 100 mg) and transferred to glass centrifugation tubes to guarantee efficient cooling 
during subsequent sonication. After the addition of 1 ml of MPB (pH 3) the crude 
homogenates were sonicated with a type G 15 sonifier equipped with a microtip (Branson 
Ultraschall GmbH, Heusenstamm, Germany) at step 4 for 10 min. Sonication was applied in 
an ice bath and the procedure was interrupted when the temperature of the sample rose above 
5 °C. The lysates were centrifuged at 4300 g and 4 °C for 10 min.  
200 µl aliquots of the supernatants were diluted with 300 µl of MPB (pH 3) and 25 µl of I.S. 
solution (50 µM) were added. This mixture was passed through an activated 200 mg 
LiChrolut reversed-phase RP-18 cartridge (Merck), where the analytes and the I.S. were 
adsorbed. After washing with 2 ml of MPB (pH 3), the cartridge was left at room temperature 
for exactly 10 min. Then the compounds of interest were eluted with 1.5 ml methanol and 
collected in 2-ml polyethylene reaction vessels (Eppendorf, Hamburg, Germany). The solvent 
was evaporated in a vacuum concentrator (Bachofer, Reutlingen, Germany) at 40 °C. The 
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solid residue was dissolved in 200 µl of mobile phase, which was adjusted to pH 1.6 with 
HCl, and aliquots of 30 µl were injected for HPLC analysis. For a more detailed description 
of the sample preparation procedure see the work of Gürtler (2001). 
4.3 Results and discussion 
4.3.1 In vitro experiments 
As a first approach to characterise the potential efficacy of the adjuvant administration of S. 
agalactiae hyaluronate lyase in cancer chemotherapy, we systematically assayed the effect of 
hyaluronate lyase on the in vitro chemosensitivity of two different human cancer cell lines 
(SK-MEL-3 and U-87 MG) against the chemotherapeutics doxorubicin and vinblastine.  
4.3.1.1 Effect of hyaluronidase on the cell proliferation of tumor cells in vitro  
In a preliminary study the effect of hyaluronate lyase on the cell proliferation of the human 
SK-MEL-3 malignant melanoma cells and human glioblastoma/astrocytoma cells (U-87 MG) 
was investigated. Proliferation curves were determined with the kinetic crystal violett assay 
(cf. 4.2.6) in the presence of increasing concentrations of hyaluronate lyase.  
As shown in figure 4-1 (left side), monotherapy with 2700, 27 000 and 80 000 units#/l of 
hyaluronate lyase did not affect the growth kinetics of the investigated cells. Also a solution 
of pure BSA, which is contained in the hyaluronate lyase preparation as a stabiliser, was 
found to have no effect on the proliferation of the cells, when applied at a concentration 
contained in the enzyme preparation at 80 000 units#/l (Fig. 4-1, right side). 
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Fig. 4-1: Proliferation curves of SK-MEL-3 cells (passage 7) and U-87 MG cells (passage 137) in the 
presence of increasing concentrations of S. agalactiae hyaluronate lyase (left side) and in the presence 
of BSA, which is contained in the hyaluronate lyase preparation as a stabiliser (right side). Growth 
curves were determined with a kinetic microassay based on crystal violet staining (cf. 4.2.6.).  
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4.3.1.2 Combination therapy with hyaluronidase and doxorubicin in vitro 
SK-MEL-3 cells 
The chemosensitivity of the SK-MEL-3 cell line against different antitumor drugs 
(doxorubicin, vinblastine, melphalan, methotrexate, cisplatin) was investigated in a previous 
study by Christl (1992). For doxorubicin a cytocidal effect was determined at a concentration 
of 1 µM by applicaton of long-term exposure (300 h), whereas at a concentration of 100 nM 
only cytotoxicity was observed.  
In the following experiment it was investigated, if the treatment of SK-MEL-3 cells with a 
combination of doxorubicin, at suboptimal concentrations, and hyaluronidase leads to an 
enhancement of the antineoplastic activity of doxorubicin - as it was observed by 
Beckenlehner et al. (1992), who report on a significant enhancement of doxorubicin activiy 
by combination with high dose hyaluronidase (Neopermease®) in the therapy of MXT+ breast 
cancer cells in vitro and in vivo. In principle, the experiment with the SK-MEL-3 cells was 
carried out according to Beckenlehner et al. (1992), however, instead of the bovine testicular 
hyaluronidase (BTH) preparation Neopermease®  the bacterial hyaluronate lyase preparation 
from S. agalactiae was used. The hyaluronidase activity applied in our experiment (80 000 
units# of hyaluronate lyase per liter) was by a factor of 1.6 higher compared to the experiment 
of Beckenlehner et al. (50 000 units# of Neopermease® per liter) according to the activity 
declaration of the respective supplier. However, taking the results of the investigations 
concerning the activity of the different enzyme preparations into account (cf. Table 5-3), it 
turned out, that in the present experiment the hyaluronidase activity was higher compared to 
the experiment of Beckenlehner et al. by a factor of 6 according to the results of a 
turbidimetric hyaluronidase assay and even by a factor of 96 according to the results of a 
colorimetric hyaluronidase assay.   
Using the kinetic crystal violet chemosensitivity assay the effects of doxorubicin 
monotherapy (50 nM, 100 nM, 500 nM) and combination therapy (50 or 100 nM doxorubicin 
plus 80 000 units#/l of hyaluronate lyase) on cell proliferation were compared. The results are 
summarised in Fig. 4-2.  
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Fig. 4-2: Treatment of SK-MEL-3 cells (passage 7) with doxorubicin alone and with doxorubicin in 
combination with S. agalactiae hyaluronate lyase. Left side: proliferation curves, determined with the 
crystal violet assay (cf.. 4.2.6); right side: plots of corrected T/C values (cf. 4.2.6) versus time.  
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As expected from the investigations of Christl (1992), by doxorubicin monotherapy a 
cytocidal effect was observed at a drug concentration of 500 nM, whereas cytotoxic effects 
were observed at the lower concentrations of the drug. However, neither the cytostatic effect 
of 50 nM doxorubicin nor that of 100 nM doxorubicin (results not shown) was enhanced by 
the combination therapy with high dose hyaluronidase. 
U-87 MG cells 
As described for the SK-MEL-3 cell line the human glioblastoma cell line U-87 MG was 
investigated with respect to the effect of S. agalactiae hyaluronate lyase on the 
chemosensitivity of the cells against doxorubicin. The chemosensitivity of U-87 MG cells 
against doxorubicin monotherapy had been investigated previously by Altenschöpfer (1998), 
who reported on a cytocidal effect at a doxorubicin concentration of 1 µM and a cytotoxic 
effect for 100 nM doxorubicin, respectively.  
In the following experiment the effects of doxorubicin monotherapy (50 nM, 100 nM, 500 
nM) and combination therapy (50 or 100 nM doxorubicin plus 80 000 units#/l of hyaluronate 
lyase) on the cell proliferation were compared. The results are presented in figure 3. The 
growth curves obtained with doxorubicin monotherapy are in agreement with the results of 
Altenschöpfer, i.e. the 500 nM concentration of doxorubicin was cytocidal, whereas at drug 
concentration of 50 nM and 100 nM, after initial inhibition of proliferation, the cells showed a 
slight tendency to regain proliferative activity with prolonged incubation time.The cytotoxic 
effects observed at the 50 nM and 100 nM concentration of doxorubicin were not enhanced 
by the combination therapy with high dose hyaluronidase. A comparison of the plots of 
corrected T/C values versus incubation time shows that in the hyaluronidase/doxorubicin (50 
nM) combination therapy the initial inhibitory effect on cell proliferation was even less 
pronounced compared to the doxorubicin (50 nM) monotherapy. 
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Fig. 4-3: Treatment of U-87 MG cells (passage 137) with doxorubicin alone and with doxorubicin in 
combination with S. agalactiae hyaluronate lyase. Left side: proliferation curves, determined with the 
crystal violet assay (cf.. 4.2.6); right side: plots of corrected T/C values (cf. 4.2.6) versus time.  
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4.3.1.3 Combination therapy with hyaluronidase and vinblastine in vitro 
SK-MEL-3 cells 
In a previous study it was demonstrated on SK-MEL-3 melanoma that the adjuvant 
administration of hyaluronidase (Neopermease®) enhanced the efficacy of regional 
vinblastine chemotherapy in vivo (Spruß et al., 1995). Further investigations showed that the 
concentration of the drug in the SK-MEL-3 tumor, obtained after s.c. peritumoral injection, 
was enhanced by a factor of 2.5 by the adjuvant s.c. administration of Neopermease® 
(Muckenschnabel et al., 1998).  
In the following experiment it was investigated if the treatment of SK-MEL-3 cells with a 
combination of vinblastine, at suboptimal concentrations, and hyaluronidase from S. 
agalactiae leads to an enhancement of the antiproliferative activity of vinblastine in vitro. In 
figure 4-4 the results of vinblastine monotherapy (10 nM, 30 nM, 100 nM) are presented in 
comparison with those obtained by the vinblastine/hyaluronidase combination therapy (10 nM 
vinblastine, 80 000 units#/l of hyaluronate lyase). In monotherapy vinblastine was cytocidal 
against the SK-MEL-3 cells at a concentration of 100 nM, whereas at vinblastine 
concentrations of 30 nM or 10 nM, respectively, after an initial inhibition of cell growth, a 
slight tendency of the cells to regain proliferative activity was observed. Under combination 
therapy (vinblastine (10 nM)/ hyaluronidase) the tendency of the culture to recover was 
slightly lower compared to the 10 nM and 30 nM vinblastine monotherapies, indicating that 
the chemosensitivity of the SK-MEL-3 cells against vinblastine was slightly increased by 
hyaluronidase. However, due to the relatively high antiproliferative activity of the 10 nM 
vinblastine monotherapy per se, only a marginal activity enhancing effect of hyaluronidase 
could be detected. Therefore, further experiments, using less effective concentrations of 
vinblastine, would be necessary to confirm an activity enhancing effect of hyaluronidase. 
U-87 MG cells 
In case of the U-87 MG cell line vinblastine proved to be cytocidal at each of the investigated 
concentrations (10 nM; 30 nM; 100 nM). It was therefore impossible to detect a potential 
activity enhancing effect in the combination therapy with hyaluronidase (cf. Fig. 4-4).  
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Fig. 4-4: Treatment of SK-MEL-3 cells (passage 7) and U-87 MG cells (passage 137) with vinblastine 
alone and with vinblastine in combination with S. agalactiae hyaluronate lyase. Proliferation curves 
were determined with the crystal violet assay (cf. 4.2.6). Proliferation curve of the untreated control 
(?); the results of the treatment groups are presented as plots of corrected T/C values (cf. 4.2.6) versus 
time.   
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4.3.1.4 Resume of the in vitro experiments 
The effect of S. agalactiae hyaluronate lyase on the in vitro chemosensitivity of the human 
cancer cell lines SK-MEL-3 and U-87 MG against the chemotherapeutics doxorubicin and 
vinblastine was systematically investigated.  
From the literature it is known that hyaluronan can influence the processes of mitosis, cell 
differentiation and cell proliferation in cultured cells in a complex way (Decker et al., 1989; 
Laurent and Fraser, 1992). Degradation of hyaluronate by treatment of cells with 
hyaluronidase can thus directly affect proliferation kinetics. However, in case of the cell lines 
investigated in this work hyaluronidase monotherapy was found to have no effect on the 
growth kinetics of the cells (cf. Fig. 4-1), suggesting that a potential enhancement of the 
chemosensitivity of cells against chemotherapeutics by the combination with hyaluronidase 
can be ascribed to an indirect effect of hyaluronidase, i.e. improved availability of the 
chemotherapeutics due to degradation of the cell associated hyaluronan.  
To compare the monotherapy (doxorubicin, vinblastine) with the combination therapy 
(hyaluronidase and chemotherapeutic) concentrations of the chemotherapeutic drug, which 
were not cytocidal per se were used. In case of doxorubicin no enhancement of the 
antineoplastic activity was observed in the combination therapy compared to the monotherapy 
- neither against SK-MEL-3 cells nor against U-87 MG cells (cf. figures 4-2 and 4-3). For 
vinblastine a slight tendency to improved activity was observed against SK-MEL-3 cells, 
when the drug was combined with hyaluronate lyase, whereas in case of the U-87 MG cells 
already the lowest concentration of vinblastine showed a cytocidal effect in the monotherapy, 
which was not improved in the combination therapy (cf. Fig. 4-4). 
Summarising the results of the in vitro experiments it was shown that the coapplication of 
hyaluronidase did not result in an improved antiproliferative activity of the chemotherapeutics 
- except for the slight but statistically insignificant activity enhancing effect that was observed 
in case of the vinblastine therapy of the SK-MEL-3 cell line. Compared to the amount of 
hyaluronan produced in cell culture, the amount of hyaluronan found in solid tumors is often 
much higher due to overproduction of hyaluronan in the tumor stroma (Knudson and 
Knudson, 1995). Despite the results obtained in the in vitro experiments it can thus not be 
ruled out that the adjuvant administration of S. agalactiae hyaluronate lyase can significantly 
enhance the efficacy of the regional chemotherapy of tumors of the investigated cell lines in 
vivo. 
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4.3.2 Regional therapy of human malignant melanoma implanted in nude mice  
4.3.2.1 Regional therapy with hyaluronidase and vinblastine  
In the following in vivo experiment it was investigated if the adjuvant administration of S. 
agalactiae hyaluronate lyase enhances the efficacy of the regional vinblastine chemotherapy 
of malignant melanoma implanted in nude mice. The experiment was based on the results of 
Spruß et al. (1995) who showed that in the regional chemotherapy of malignant melanoma a 
peritumoral pre-treatment with bovine testicular hyaluronidase drastically increased the 
activity of low-dose vinblastine, administered in the vicinity of the tumor.  
Using a vinblastine dose of 0.3 mg/kg body weight (s.c.), which had been shown to be 
ineffective per se against the SK-MEL-3 tumor by Spruß et al. (1995), the efficacy of 
vinblastine monotherapy was compared with that of a hyaluronidase/vinblastine combination 
therapy, in which S. agalactiae hyaluronate lyase was administered peritumorally (s.c.) 1 h 
before vinblastine application. According to the activity declaration of the respective supplier, 
the hyaluronidase activity applied in our experiment (500 000 units# of hyaluronate lyase per 
kg) was by a factor of 5 higher compared to the experiment of Spruß et al., who used 100 000 
units# of Neopermease® per kg. Substance administration began on day 8 after tumor 
transplantation and was repeated weekly. A total of four treatment cycles was performed from 
day 8 to day 29 and the observation of tumor growth and change of body weight was 
continued until day 66.  
The results of the different therapy regimens are presented in figure  
4-5. Other than expected from the results of Spruß et al. (1995), in this experiment in the 
treatment group which received vinblastine monotherapy a moderate tumor growth delay was 
observed in comparison to the untreated control (T/C = 37 % (day 28) and 43 % (day 38)). 
However, the moderate antitumoral activity of vinblastine was not enhanced by pre-treatment 
with S. agalactiae hyaluronate lyase (T/C = 36 % (day 28) and 29 % (day 38)). Figure 4-5 
shows that in the course of the therapy up to day 28 the tumor growth curves were identical 
for the vinblastine monotherapy and the combination therapy with hyaluronate lyase. Further 
registration of the median tumor area revealed a slightly delayed tumor growth in the 
combination therapy compared to the vinblastine monotherapy until day 59. However, in this 
context it has to be considered that, starting at day 35, animals had to be removed from the 
experiment due to the occurrence of a slight cachexia or ulcerated tumors. 
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Fig. 4-5: Regional chemotherapy of the human SK-MEL-3 melanoma (passage 34) implanted into 
NMRI nu/nu mice (all drugs administered perimtumorally (s.c.); arrow: start of therapy). Untreated 
control (—?—): 0.9 % NaCl (n = 12); vinblastine monotherapy (—○—): vinblastine 0.3 mg/kg (n = 
12); combination therapy (—●—): S. agalactiae hyaluronate lyase (500 000 units#/kg) 1 h prior to 
vinblastine (0.3 mg/kg) treatment (n = 12). Therapy was carried out weekly (4 treatment cycles). Inset: 
change of mean body weight (BW) during the course of the experiment. 
In the group of the combination therapy 6 animals were removed in the period from day 35 to 
49, whereas in the vinblastine monotherapy group only 3 animals showed cachexia or 
ulcerated tumors from day 38 to 45. As these animals were not taken into account for the 
calculation of the median tumor area of the respective treatment group, beginning at day 35, 
the growth curves of figure 4-5 do not reflect the efficacy of the therapy without fail.   
As indicated in figure 4-6, which shows the tumor growth curves of the individual animals, 
the slightly delayed increase in the median tumor area of the group receiving combination 
therapy compared to the monotherapy group (cf. Fig. 4-5) results from the fact that in the 
combination therapy group two animals bearing large tumors were removed from the 
experiment. In general, comparison of the tumor growth in the individual animals revealed 
high interindividual variations in both therapy groups. 
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Fig. 4-6: Tumor growth curves of individual animals treated with vinblastine (A) and a combination of 
vinblastine and S. agalactiae hyaluronate lyase (B). For the experimental conditions confer to Fig. 4-5. 
The arrow indicates the start of therapy. 
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Comparison of the change of the mean body weight of the animals in the different treatment 
groups (cf. inset of Fig. 4-5) revealed a similar development in all three groups. Referring to 
the mean body weight at the start of the therapy the highest loss of body weight was observed 
in the group receiving the hyaluronidase combination therapy (- 5.7 % (day 59)).  
Summarising the results of the regional chemotherapy of the SK-MEL-3 melanoma, it was 
found that pre-treatment with S. agalactiae hyaluronate lyase did neither increase the 
antitumoral activity of peritumorally applied vinblastine nor exhibit a positive effect on the 
physical condition of the animals. The finding, that cachexia occurred earlier in animals of the 
group receiving the combination therapy than in animals of the monotherapy group, indicates 
that S. agalactiae hyaluronate lyase was not well tolerated by the animals - maybe due to the 
reactivity of the unsaturated disaccharides resulting from HA degradation by the bacterial 
hyaluronidase. However, since the results obtained so far indicate that the enzyme is lacking 
the desired therapeutic effect, no further efforts were made to investigate the reason for the 
observed intolerance to the bacterial enzyme preparation so far. 
4.3.2.2 Regional therapy with hyaluronidase and melphalan 
4.3.2.2.1 Effect of hyaluronidase on melphalan enrichment in solid melanoma 
The preclinical and clinical observations, showing that the efficacy of anticancer drugs is 
increased by the adjuvant administration of hyaluronidase, are generally explained by the 
assumption that hyaluronidase facilitates the diffusion of the chemotherapeutics into the 
tumors by degradation of the hyaluronate-enriched extracellular matrix around and within the 
tumors (Baumgartner et al., 1988; Baumgartner and Moritz, 1988; Beckenlehner et al., 1992; 
Spruß et al., 1995). Indeed, in a previous study it was shown that s.c. injected melphalan was 
dramatically accumulated by SK-MEL-2 tumors, implanted in nude mice, after both i.p. and 
s.c. administration of bovine testicular hyaluronidase (BTH, Neopermease®) 1 h before 
melphalan application. Compared with s.c. administration of melphalan alone the melphalan 
concentration in the tumor was found to be increased by a factor of 6.6 (hyaluronidase i.p.) 
and 7.8 (hyaluronidase s.c.), respectively (Muckenschnabel et al., 1996). Analogous studies 
on the SK-MEL-3 melanoma also revealed accumulation of the chemotherapeutics in the 
tumors after co-administration of Neopermease®, however, to a lesser extent: 
Muckenschnabel et al. (1998) report that combined administration of Neopermease® (s.c.) 
with vinblastine (s.c.) enhanced the intratumoral vinblastine concentration by a factor of 2.4,  
Adjuvant administration of hyaluronate lyase from S. agalactiae in cancer chemotherapy 
 84
and Gürtler (2001) observed a 3fold increase of the intratumoral melphalan concentration 
after s.c. administration of Neopermease® 1 h prior to melphalan (s.c.). 
In the following experiments it was investigated if an increased intratumoral accumulation of 
chemotherapeutics is also obtained by the combined administration of S. agalactiae 
hyaluronate lyase. Following the experimental design of Gürtler (2001) the effect of 
hyaluronidase co-administration on melphalan enrichment in tumors was determined in nude 
mice bearing the SK-MEL-3 melanoma. Melphalan alone (50 µmol/kg) or a combination of 
melphalan (50 µmol/kg) and hyaluronate lyase (500 000 units#/kg) was injected s.c. in the 
vicinity of the tumors. The administration of hyaluronate lyase was carried out 1 h before that 
of melphalan. Exactly 1 h after melphalan administration the tumors were resected and 
melphalan concentrations were analysed by HPLC according to the method which was 
characterised in detail by Muckenschnabel et al. (1996; 1997). The melphalan concentration 
of the tumors was calculated on a molar basis assuming a density of 1.0 g/cm3 for the tumors. 
The results obtained in two independent test series are presented in figure 4-7. 
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Fig. 4-7: Effect of hyaluronidase application on the accumulation of melphalan in the human SK-
MEL-3 melanoma implanted into NMRI nu/nu mice (all drugs administered s.c. in the vicinity of the 
tumors). S. agalactiae hyaluronate lyase (500 000 units#/kg) was injected 1 h before melphalan 
application (50 µmol/kg; (A): Alkeran®, (B): melphalan-HCl from Sigma). Exactly 1 h after 
melphalan administration the tumors were resected and melphalan was analysed by HPLC (n = 6-9; 
mean ± SEM).  
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The SK-MEL-3 melanoma in passage 32 was a serial passage of the SK-MEL-3 tumor 
(passage 25) used by Gürtler (2001) for the analogous experiment with Neopermease®, where 
he observed a 3fold increase in the intratumoral melphalan concentration after hyaluronidase 
pre-treatment. As shown in Fig. 4-7A, the pre-treatment with bacterial hyaluronate lyase 
produced only a minor augmentation (1.6fold) of the intratumoral melphalan concentration, 
compared to melphalan monoapplication. But even this slight increase in melphalan 
accumulation, induced by hyaluronate lyase, was not reproducible in further experiments.  
Considering that the investigated SK-MEL-3 melanoma were tumors of an advanced serial 
passage, the low effect of hyaluronate lyase co-application and the lacking reproducibility 
might have been caused by the genetical instability of the tumors, e.g. with respect to the HA 
content, over the course of the different passages. Therefore, SK-MEL-3 tumors were newly 
established (cf. 4.2.5) in nude mice, and two more experiments were performed on tumors of 
the freshly established melanoma (passage 2 (results not shown) and passage 7 (cf. Fig. 4-
7B), respectively). However, in both experiments, enhancement of melphalan accumulation in 
the tumors was not observed by pre-treatment with hyaluronate lyase. 
By contrast, an additional experiment with Neopermease® on the freshly established 
melanoma (passage 6) revealed a 3fold increase in melphalan enrichment in the tumors by co-
administration of the bovine hyaluronidase (Fig. 4-8). Although the treatment groups were 
small in this experiment (n = 2/3), the results indicate that the assumption the experiment is 
based on, i.e. that the uptake of melphalan into the tumors is facilitated by hyaluronidase 
induced degradation of the extracellular matrix, was valid in the investigated tumor model.  
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Fig. 4-8: Effect of hyaluronidase application on the enrichment of melphalan in the human SK-MEL-3 
melanoma implanted into NMRI nu/nu mice (all drugs administered s.c. in the vicinity of the tumors). 
Neopermease® (100 000 units#/kg) was injected 1 h before melphalan application (50 µmol/kg; 
melphalan-HCl from Sigma). Exactly 1 h after melphalan administration the tumors were resected and 
melphalan was analysed by HPLC (n = 2/3; mean ± SEM).  
It is thus surprising that melphalan accumulation was not observed by co-application of the 
bacterial hyaluronate lyase, although the hyaluronidase activity applied in the experiments 
with the bacterial enzyme (500 000 units#/kg) was – according to the declaration of the 
supplier – by a factor of 5 higher compared to the activity used in the experiments with 
Neopermease® (100 000 units#/kg). Comparison of the enzyme preparations with respect to 
their activity in a colorimetric hyaluronidase assay (cf. Table 3-3) revealed that the 
preparations differed in the activity measured for 1 designated unit: in the colorimetric assay, 
which detects product formation by derivatization of N-acetylglucosamine residues at the 
reducing end of hyaluronan fragments, 1 designated unit of the bacterial enzyme showed 60 
times higher activity compared to 1 designated unit of Neopermease®. According to the 
results of the colorimetric assay the hyaluronidase activity applied in the above described 
experiments was thus higher in the experiments with the bacterial enzyme, compared to those 
with Neopermease®, even by a factor of 300.  
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An explanation for the discrepancy between the enzyme activity applied in the experiments 
and the observed pharmacological effect may be found when considering that the bacterial 
and the bovine hyaluronidase differ in their mechanism of hyaluronan degradation. While 
hyaluronan degradation by group B streptococcal hyaluronate lyase involves an initial random 
endolytic cleavage followed by rapid exolytic and processive release of unsaturated 
disaccharide (Baker and Pritchard, 2000; Li and Jedrzejas, 2001), the bovine enzyme acts as 
an endolytic enzyme (Vercruysse et al., 1994) with tetra- and hexasaccharides as the main 
degradation products (Cramer et al., 1994; Takagaki et al., 1994). Thus, every cleavage of 
hyaluronic acid chains by BTH results in the formation of two shorter chains, whereas in case 
of the bacterial enzyme the chain is shortened by only one disaccharide per cleavage step. 
Equiactive concentrations with respect to product formation, as determined in the colorimetric 
assay, are therefore not necessarily equieffective in reducing the molecular mass of the 
substrate chains and thus in reducing the viscosity of the hyaluronate-enriched extracellular 
matrix.  
Indeed, comparison of the enzyme preparations with respect to their activity in a turbidimetric 
hyaluronidase assay, where hyaluronidase activity is quantified according to the ability to 
reduce the molecular mass of substrate chains (residual high molecular mass substrate is 
detected by precipitation), revealed that 1 designated unit of the bacterial enzyme showed 
only 3.86 times higher activity compared to 1 designated unit of Neopermease® (cf. Table  
5-3). In addition, the activity in the turbidimetric assay was found to be well correlated with 
the activity in a viscosimetric hyaluronidase assay, which quantifies the activity of 
hyaluronidases according to their ability to reduce the viscosity of hyaluronate solutions (cf. 
chapter 5).  
However, although - according to the results of the turbidimetric and viscosimetric assay - the 
difference in the hyaluronidase activities applied for the investigation of the effect on 
melphalan enrichment was less pronounced than indicated by the results of the colorimetric 
assay, the activity applied in the experiments with the bacterial hyaluronate lyase was still by 
a factor of 19.3 higher compared to the experiments with Neopermease®. The different 
mechanisms of hyaluronate degradation by the bacterial and bovine hyaluronidase do thus not 
provide a satisfactory explanation for the observation that, by contrast to Neopermease®, the 
hyaluronate lyase from S. agalactiae did not show the desired therapeutic effect.  
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Another possible explanation for the lacking efficacy of hyaluronate lyase co-application may 
be that under in vivo conditions enzyme activity may be inhibited by compounds of the 
extracellular matrix. However, concerning this, no systematic investigations have been carried 
out so far.  
4.3.2.2.2 Regional chemotherapy  
The tumor growth curves which were obtained by the regional chemotherapy of the  
SK-MEL-3 melanoma, implanted in nude mice, with melphalan alone and with a combination 
of S. agalactiae hyaluronate lyase and melphalan, respectively, are presented in figure 4-9.  
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Fig. 4-9: Regional chemotherapy of the human SK-MEL-3 melanoma (passage 31) implanted into 
NMRI nu/nu mice (all drugs administered peritumorally (s.c.); arrow: start of therapy). Control  
(—?—): 0.01 N HCl containing 0.9 % NaCl (n = 12); melphalan monotherapy (—○—): melphalan 4 
mg/kg (n = 12); combination therapy (—●—): S. agalactiae hyaluronate lyase (250 000 units#/kg) 1 h 
prior to melphalan (4 mg/kg) treatment (n = 12). Therapy was carried out weekly (4 therapy cycles). 
Inset: change of mean body weight (BW) during the course of the experiment. 
The almost identical tumor growth curves of the different therapy regimens clearly 
demonstrate that the efficacy of melphalan monotherapy was not increased by the co-
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administration of S. agalactiae hyaluronate lyase. In both treatment groups (monotherapy 
(MT) and combination therapy (CT)) the median tumor area was reduced after the third (day 
22) and forth (day 29) treatment cycle, resulting in T/C values ≤ 10 % (day 31: T/C = 10.4 % 
(MT) and 5.6 % (CT); day 38: T/C = 2.5 % (MT) and 1.7 % (CT)), before a recovery of tumor 
growth was observed after day 40 of the experiment. 
Observation of the change of the mean body weight of the animals revealed that in the final 
stage of the experiment (after day 40) the physical condition of the animals was worse in the 
group receiving the combination therapy compared to the monotherapy group (cf. inset of Fig. 
4-9). In addition, cachexia was observed earlier and on more animals in the group receiving 
the combination therapy (5 animals; on days 16, 44, 51, 55, 59 and 65) than in the 
monotherapy group (3 animals; on days 55 and 71). These findings indicate that S. agalactiae 
hyaluronate lyase was not well tolerated by the animals, as it was also observed in case of the 
hyaluronate lyase/vinblastine combination therapy (cf. section 4.3.2.1). 
Comparison of the results with those obtained by Gürtler (2001) in the corresponding 
experiments with Neopermease® revealed, that the tumor growth curves of the untreated 
controls were in good agreement, whereas the antitumoral effect of the melphalan 
monotherapy was slightly more pronounced in the present experiment, since in the 
experiment of Gürtler a reduction of the mean tumor area was not observed at any stage of the 
experiment. However, also in the present experiment tumor growth was not fully inhibited by 
melphalan alone and thus allowed for the detection of a potential activity enhancing effect of 
hyaluronate lyase co-administration.  
The finding that an increased inhibition of tumor growth, as it is reported for the adjuvant 
administration of Neopermease® (Gürtler, 2001), was not observed after hyaluronate lyase 
pre-treatment, is in agreement with the results of the preceding section, considering, that the 
activity enhancing effect of hyaluronidase is ascribed to an increased accumulation of the 
chemotherapeutic into the tumor, which was observed in case of pre-treatment with the 
bovine enzyme but not in case of co-application of the bacterial enzyme (cf. 4.3.2.2.1). 
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4.4 Conclusion 
Systematic investigation of the effect of hyaluronate lyase from S. agalactiae on the in vitro 
chemosensitivity of the human cancer cell lines SK-MEL-3 and U-87 MG against the 
chemotherapeutics doxorubicin and vinblastine revealed that the coapplication of the bacterial 
hyaluronidase did not result in an improved antiproliferative activity of the drugs.  
Also in the regional chemotherapy of SK-MEL-3 tumors, implanted in nude mice, the 
coapplication of hyaluronate lyase from S. agalactiae did not enhance the efficacy of the 
monotherapy with vinblastine or melphalan, respectively. In fact, it turned out that the 
bacterial hyaluronidase preparation was not well tolerated by the animals, which may be 
ascribed to the reactivity of the unsaturated disaccharides produced during the degradation of 
hyaluronate by the bacterial enzyme. 
Determination of the effect of hyaluronidase co-administration on the accumulation of 
peritumorally (s.c.) injected melphalan in SK-MEL-3 melanoma revealed that pre-treatment 
with bacterial hyaluronate lyase did not increase the intratumoral melphalan concentration, 
whereas the adjuvant application of Neopermease® resulted in a 3fold increase in melphalan 
enrichment in the tumors, as it was also observed by Gürtler (2001).  
Taken together, the results of the reported preclinical investigations indicate that the bacterial 
hyaluronate lyase preparation does not represent an appropriate substitute for bovine testicular 
hyaluronidase as a spreading factor and activity enhancer in cancer chemotherapy. 
The hyaluronate lyase from S. agalactiae did not show the desired spreading effect, although 
it was administered at concentrations showing - according to the results of the colorimetric 
assay - 300 times higher hyaluronidase activity compared to the activity applied in the 
corresponding experiments with Neopermease®. As outlined in the results section (cf. 
4.3.2.2.1), the apparent discrepancy between the activities determined in the colorimetric 
assay and the observed pharmacological effect may in part be ascribed to the different 
mechanims of HA degradation by the bacterial and the bovine hyaluronidase. The 
investigations which have been carried out to test this hypothesis are subject of the following 
chapter.  
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5 Comparative analysis of the apparent enzymatic activities of 
bovine testicular hyaluronidase, a hyaluronate lyase from S. 
agalactiae and bee venom hyaluronidase by turbidimetric and 
viscosimetric methods 
5.1 Introduction 
Preclinical investigations on the adjuvant administration of a hyaluronate lyase from S. 
agalactiae in cancer chemotherapy, which are reported in the preceding chapter, revealed that 
the bacterial enzyme preparation did not show the therapeutic effect that was observed in 
analogous experiments with a preparation of bovine testicular hyaluronidase (BTH, 
Neopermease®). In contrast to Neopermease®, which is reported to serve as a spreading factor 
increasing the access and, thus, the effectiveness of anticancer drugs in tumors due to 
degradation of the hyaluronate (HA) of the extracellular matrix (Spruß et al., 1995; 
Muckenschnabel et al., 1996), the bacterial hyaluronate lyase was found to lack the desired 
spreading effect, as its administration shortly before that of melphalan did not lead to 
enhanced concentrations of the chemotherapeutic in malignant melanoma.  
The spreading effect of BTH is based on the ability of the enzyme to degrade HA of the 
extracellular matrix (ECM), which results in a reduced viscosity of the ECM and facilitates 
the diffusion of substances through tissues. Quantification of HA degradation by bovine and 
bacterial hyaluronidase using a colorimetric assay, which detects product formation by 
derivatisation of liberated NAG residues, revealed that 1 unit# of hyaluronate lyase from S. 
agalactiae showed a 60-times higher activity than 1 unit# of Neopermease® (cf. chapter 3). 
The apparent discrepancy between the activities determined in the colorimetric assay and the 
observed pharmacological effect may result from the different HA degradation mechanisms of 
the bacterial and the bovine hyaluronidase. In case of BTH, which acts as an endolytic 
enzyme (Vercruysse et al., 1994), every cleavage of HA chains results in the formation of two 
shorter chains and, thus, effectively reduces the viscosity of the ECM. By contrast, the 
degradation of HA by the bacterial enzyme occurs via an initial endolytic attack followed by 
exolytic and processive release of unsaturated disaccharides (Baker and Pritchard, 2000; Li 
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and Jedrzejas, 2001), i.e. HA chains are shortened by only one disaccharide per cleavage step 
resulting in a minimal reduction of the molecular mass of the HA chains and, thus, in a much 
slower reduction of the viscosity of the ECM compared to the action of BTH. 
Humphrey and Jaques (1953) investigated a number of hyaluronidase preparations with 
respect to their activity in a biological assay measuring the effect of hyaluronidase co- 
administration on the spreading of an indicator dye injected into the skin of animals. By 
comparison of the spreading activity observed in the biological assay with the activities of the 
respective enzyme preparations in a turbidimetric and a viscosimetric in vitro assay the 
authors found a quite good correlation of the results obtained by the three methods for 
preparations of both testicular hyaluronidase and bacterial hyaluronate lyase. 
Both, the turbidimetric and the viscosimetric hyaluronidase assay, are physico-chemical in 
vitro methods in which the activity of hyaluronidase is quantified according to the reduction 
of the size of high molecular mass HA molecules. The turbidimetric assay relies on the 
principle that high molecular mass HA forms precipitates with acidified serum albumine 
reagent or quartery ammonium salts (e.g. cetyltrimethylammonium bromide, cetylpyridinium 
chloride), whereas precipitation does not occur after degradation of HA with hyaluronidase to 
HA fragments < 6-8 kDa. In the viscosimetric assay the depolymerisation of HA by the action 
of hyaluronidase is detected by measuring the reduction in the viscosity of HA solutions. 
In the present study Neopermease® and hyaluronate lyase from S. agalactiae were compared 
with respect to their activity in a turbidimetric and a viscosimetric assay. Since, according to 
Humphrey and Jaques (1953) the activities obtained by turbidimetry and viscosimetry are 
well correlated to the pharmacological acitivity of the enzymes when applied as a spreading 
factor, the results of the following turbidimetric and viscosimetric investigations were 
expected to provide a plausible explanation for the lacking spreading activity of S. agalactiae 
hyaluronate lyase described in the preceding chapter.  
In addition, a recombinant bee venom hyaluronidase (BVH), which belongs to the same 
family of glycosyl hydrolases (EC 3.2.1.35) as BTH, was investigated with respect to its 
activity in the different assays, and the results were compared with those obtained with the 
bovine testicular enzyme. 
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5.2 Materials and methods 
5.2.1 Chemicals 
The preparations of bovine testicular hyaluronidase (BTH) and the S. agalactiae hyaluronate 
lyase are characterised in chapter 3. Bee venom hyaluronidase (BVH) (Gmachl and Kreil, 
1993; Soldatova et al., 1998) (2.4 mg/ml dissolved in 5 mM sodium acetate, pH 5.4) was a 
gift from Dr. Zora Markovic-Housley, University of Basel (Switzerland). 
Hyaluronic acid (HA) from Streptococcus zooepidemicus was purchased from Aqua Biochem 
GmbH (Dessau, Germany). HA from rooster comb and bovine serum albumin (BSA) were 
purchased from Serva (Heidelberg, Germany). Cetyltrimethylammonium bromide (CTAB) 
was from Roth (Karlsruhe, Germany). Deuteriumoxide (D2O, isotopic enrichment 99.98 %) 
was purchased from Deutero GmbH (Kastellaun, Germany). All other chemicals were of 
analytical grade and were obtained from Merck (Darmstadt, Germany). Water was purified by 
a Milli-Q system (Millipore, Eschborn, Germany). 
5.2.2 Determination of hyaluronidase activity 
5.2.2.1 Turbidimetric method 
The turbidimetric determination of hyaluronidase activity was carried out according to the 
method described by Di Ferrante (Di Ferrante, 1956), i.e. cetyltrimethylammonium bromide 
(CTAB) was used as a precipitating agent for the residual high molecular weight hyaluronic 
acid (HA) after incubation with hyaluronidase. Experiments were performed under different 
incubation conditions concerning the composition of the incubation mixture, the enzyme 
concentration and the time of incubation: 
incubation mixture 5-I: 0.2 mg HA from rooster comb per ml of 0.1 M sodium acetate buffer, 
pH 6.0, containing 0.01 M MgCl2;  
incubation mixture 5-II: 200 µl of substrate (0.2 mg HA from rooster comb per ml of water), 
380 µl of phosphate buffer (solution A: 0.01M KH2PO4/0.01M NaCl, solution B: 0.01 M 
Na2HPO4/0.01M NaCl; solutions A and B were mixed in appropriate portions to adjust the 
required pH);  
incubation mixture 5-III: 200 µl of substrate (0.5 mg HA from rooster comb per ml of water), 
150 µl of citrate-phosphate buffer (solution A: 0.2 M Na2HPO4/0.1M NaCl, solution B: 0.1 M 
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citric acid/0.1 M NaCl; solutions A and B were mixed in appropriate portions to adjust the 
required pH), 50 µl of BSA (0.2 mg BSA per ml of water, i.e. solution 1);  
incubation mixture 5-IV: 100 µl of substrate (1 mg HA from rooster comb per ml of water), 
200 µl of citrate-phosphate buffer, 50 µl of BSA (solution 1), 50 µl of water.  
Incubation was carried out at 37 °C using varying incubation times and enzyme 
concentrations, specified in the results section. In all experiments the required dilutions of the 
investigated enzyme preparations were prepared with solution 1 (0.2 mg/ml BSA). Reference 
samples without substrate and enzyme, respectively, were prepared by using the respective 
solvents. 
Unless otherwise noted, the enzyme reaction was stopped by addition of 1200 µl of CTAB 
(2.5 g CTAB dissolved in 100 ml of 0.5 N NaOH) and turbidity was allowed to develop for 
20 min at 25 °C. The mixtures were then transferred to cuvettes (l = 1 cm) and optical density 
was measured at 600 nm using an Uvikon 930 spectrophotometer (Kontron Instruments, 
Eching, Germany).  
Calculation of relative activities: 
For the determination of enzyme activity as a function of pH, relative activities were 
calculated according to the following equation (eq. 5-1): 
)OD - (OD
)OD - (OD
activity relative
optimum pHat  samplesubstrate
samplesubstrate=    (eq. 5-1)  
where ODsubstrate is the OD of the reference sample without enzyme. 
5.2.2.2 Viscosimetric method 
The viscosimetric determination of hyaluronidase activity was performed according to the 
official method for the standardisation of hyaluronidase preparations as described in the 
European Pharmacopoeia (2002), i.e. the decrease in viscosity of the substrate solution 
induced by the action of hyaluronidase was determined as a function of time by the use of an 
Ubbelohde capillary viscosimeter.  
The instrumentation was from SCHOTT-GERÄTE (Mainz, Germany): the viscosimeter (Ref. 
No. 53210, capillary diameter 0.63 mm) was clamped into an AVS measurement tripod 
(AVS/ST), which was connected to an AVS automated measuring device (AVS/N). The 
Turbidimetric and viscosimetric determination of hyaluronidase activity 
 99
viscosimeter was immersed in a water bath together with the tripod and maintained at 37 °C. 
In a reaction vessel 18 ml of substrate solution were equilibrated at 37 °C for at least 15 min. 
The experiment was started by the addition of 100 µl of enzyme solution. After thorough but 
careful mixing (to avoid the formation of air bubbles) the reaction mixture was transferred to 
the viscosimeter, drawn into the capillary tube, and the viscosity was determined by 
automated measuring of the outflow time t, i.e. the time required for the liquid to pass 
between two light barriers along the capillary tube. The time period between addition of the 
enzyme and triggering the upper light barrier is termed incubation time (T). The 
determination of the outflow time t was repeated after increasing incubation times T. Outflow 
times for reference mixtures were determined in triplicate in the absence of enzyme (t(substrate)) 
and in the absence of substrate (t(buffer)), respectively.  
The relative viscosity (ηr) was calculated according to the following equation: 
ηr = (k ⋅ t) / (k ⋅ t (buffer))       (eq. 5-2) 
with k being the viscosimeter constant (0.00991 mm2/s2). ηr or (ln ηr)-1 were plotted as a 
function of the reaction time. Since the enzymatic reaction continues during the measurement 
of the outflow time the reaction time equals T+t/2. 
Calculation of relative activities: 
For the determination of enzyme activity as a function of pH relative activities were 
calculated according to the following equation:  
optimum) pH at T after (sampleoptimum) pH at (substrate
T after (sample)(substrate )
rr
rr
η - η
η -η
 activity  rel. =  (eq. 5-3) 
The composition of the incubation mixtures used in the various experiments is given in the 
following:  
incubation mixture 5-V: 6 ml of substrate (5 mg HA from S. zooepidemicus per ml of water), 
12 ml of citrate-phosphate buffer (cf. 5.2.2.1), 120 µl of BSA (10 mg BSA per ml of water); 
incubation mixture 5-VI: 6 ml of substrate (5 mg HA from S. zooepidemicus per ml of water), 
12 ml of phosphate buffer, pH 6.0 (2.114 g NaH2PO4, 0.3409 g Na2HPO4 and 6.67 mg BSA 
were dissolved in 100 ml of water);  
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incubation mixture 5-VII: 6 ml of substrate (5 mg HA from S. zooepidemicus per ml of 
water), 12 ml of NaCl containing phosphate buffer, pH 6.0 (2.114 g NaH2PO4, 0.3409 g 
Na2HPO4, 6.67 mg BSA and 0.584 g NaCl were dissolved in 100 ml of water);  
incubation mixture 5-VIII: 66.67 mg of substrate (HA from S. zooepidemicus) were dissolved 
in 40 ml of NaCl containing phosphate buffer, pH 6 (cf. incubation mixture 5-VII, instead of 
water D2O was used as solvent). 
In all experiments the required dilutions of the investigated enzyme preparations were 
prepared with solution 1 (0.2 mg/ml BSA). 
5.2.2.3 Colorimetric method 
The colorimetric determination of the activity of the bee venom hyaluronidase (BVH) was 
based on the method of Reissig et al. (1955) and essentially performed as described in the 
material and methods section of chapter 3. Briefly, 50 µl of enzyme solution (24 ng; the stock 
solution (cf. 5.2.1) was diluted 1:5000 with solution 1 (0.2 mg/ml BSA)) were incubated with 
incubation mixture 5-IX: 50 µl of substrate (5 mg HA from rooster comb per ml of water), 
250 µl of citrate-phosphate buffer, pH 3.6 (cf. 5.2.2.1), 50 µl of BSA (solution 1), 50 µl of 
water. The specific activity was calculated using the enzyme concentration of the stock 
solution as indicated by the supplier.  
5.2.3 Molecular mass determination 
The molecular mass of the bee venom hyaluronidase was determined by SDS-PAGE under 
reducing conditions as described in the material and methods section of chapter 3. A low 
molecular mass marker (Sigma, Deisenhofen, Germany) was used for the assignment of the 
molecular masses.  
5.2.4 Identification of glycosylated proteins 
After SDS-PAGE glycoproteins were stained by the periodic acid-Schiff (PAS) technique 
according to the procedure of Zacharius et al. (1969). 
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5.3 Results and discussion 
5.3.1 Optimisation of the test conditions of the turbidimetric method 
5.3.1.1 Incubation in sodium acetate buffer containing MgCl2 
Using the turbidimetric hyaluronidase assay according to Di Ferrante (1956) Ozegowski et al. 
(1994) obtained maximum hydrolytic activity of a S. agalactiae hyaluronate lyase at pH 6.3 
and found that activity was stimulated in the presence of Mg2+. With respect to these results 
the turbidimetric determination of hyaluronidase activity was performed in sodium acetate 
buffer, pH 6, containing MgCl2, in a subsequent publication (Rodig et al., 2000).  
To compare the hydrolytic activity of our stabilised hyaluronate lyase with the results 
reported by Ozegowski et al. (1994) and Rodig et al. (2000) for the hyaluronate lyase from S. 
agalactiae, the turbidimetric assay was performed according to the method described by these 
authors with respect to the incubation conditions and the type of precipitating agent.  
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Fig. 5-1: Relation between the turbidity, measured at 400 nm, and the hyaluronate concentration in the 
incubation mixture. 500 µl of hyaluronate (0-200 µg per ml of 0.1 M sodium acetate buffer, pH 6.0, 
containing 0.01 M MgCl2) were equilibrated at 37 °C for 10 min. before 1 ml of CTAB was added. 
Turbidity was allowed to develop for 10 min at 37 °C. 
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In a preliminary study, it was shown that the turbidity developed by the addition of CTAB 
was proportional to the hyaluronate concentration in the incubation mixture (Fig. 5-1). 
However, it is noteworthy that considerable turbidity (OD = 0.06) was measured even in the 
absence of hyaluronate, which is likely due to the formation of insoluble Mg(OH)2 under the 
alkaline conditions prevalent in the sample after addition of the CTAB reagent.  
In a subsequent experiment the effect of different concentrations of hyaluronate lyase 
incubated in the presence of a constant concentration of hyaluronate (200µg/ml) was 
examined.  
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Fig. 5-2: Turbidity as a function of hyaluronate lyase concentration in the incubation mixture. 20 µl of 
enzyme solution (appropriately diluted to achieve the concentrations indicated) were incubated with 
incubation mixture 5-I (480 µl) for 15 min. at 37 °C. After addition of 1 ml of CTAB, turbidity was 
allowed to develop for 10 min at 37 °C. The dashed lines indicate the optical densities measured in the 
absence of enzyme (upper line) and in the absence of hyaluronate (lower line), respectively.  
Interestingly, this experiment revealed that incubation with low concentrations of hyaluronate 
lyase caused an increase in turbidity (Fig. 5-2). This phenomenon has also been observed by 
Alburn and Whitley, when assaying a hyaluronidase from bull testes by the turbidimetric 
method (Alburn and Whitley, 1951) and might be explained by the occurrence of endolytic 
cleavage of the high MW hyaluronate chains, leading to an increasing concentration of 
                                                 
  # as declared by the supplier 
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hyaluronate molecules, which are still large enough to produce turbidity with the precipitating 
agent. 
Turbidity reduction was observed at enzyme concentrations > 0.8 units#/ml. However, even at 
high enzyme concentrations turbidity was not decreased to the turbidity, measured in the 
absence of hyaluronate (OD = 0.6). Considering the fact that in this test system the measured 
turbidity can not exclusively be ascribed to the insoluble complexes formed between high 
MW hyaluronate and CTAB, but is also partly caused by insoluble Mg(OH)2, this system was 
considered inappropriate for an exact determination of hyaluronidase activity.  
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5.3.1.2 Incubation in phosphate buffer  
Concerning the effect of pH on the hydrolytic activity of S. agalactiae hyaluronate lyase, the 
results, i.e. optimum activity at pH 5.0 (cf. chapter 3), obtained by the colorimetric 
hyaluronidase assay and UV difference spectroscopy disagree with those reported by 
Ozegowski et al (1994), who found optimum activity at pH 6.3 in the turbidimetic assay. To 
rule out the possibility that this discrepancy is due to the different assays or incubation buffers 
used, the activity of the investigated hyaluronate lyase preparation was determined as a 
function of pH by the procedure described by Ozegowski et al. (1994), too.  
To assure that the selected test conditions give rise to reliable results a series of preliminary 
experiments were carried out. As depicted in Fig. 5-3, the development of turbidity proved to 
be directly proportional to the concentration of hyaluronate in the incubation mixture (for 
hyaluronate concentrations ranging from 10 µg/ml and 66.7 µg/ml) and no turbidity was 
measured in the absence of hyaluronate. In addition, it was verified that the turbidity induced 
by a certain hyaluronate concentration was not affected by the pH of the incubation mixture 
(results not shown).  
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Fig. 5-3: Relation between the turbidity, measured at 600 nm, and the hyaluronate concentration in the 
incubation mixture. 200 µl of hyaluronate (0-200 µg per ml of water) were mixed with 400 µl of 
phosphate buffer, pH 4.65 (cf. section 5.2.2.1). The precipitation of hyaluronate was then performed as 
described in the materials and methods section. 
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Incubation of a certain hyaluronate concentration (66.7µg/ml) with increasing amounts of 
hyaluronate lyase revealed a constant decrease in turbidity down to the value, obtained in the 
absence of hyaluronate (Fig. 5-4), which is in contrast to the corresponding experiment using 
acetate buffer containing MgCl2 (cf. 5.3.1.2.1), where turbidity only decreased to the value 
corresponding to 10 % of the initial turbidity (Fig. 5-2). Furthermore, an increase in turbidity 
at low enzyme concentrations (Fig. 5-2) was not observed under these incubation conditions. 
In fact, the relationship between the concentration of hyaluronate lyase (0 – 0.52 units#/ml) 
and turbidity was found to be approximately linear (indirectly proportional). However, it was 
not investigated if enzyme concentrations lower than 0.10 units#/ml would cause an increase 
in turbidity compared to the value obtained in the absence of enzyme (initial turbidity). 
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Fig. 5-4: Turbidity as a function of the hyaluronate lyase concentration in the incubation mixture. 20 
µl of enzyme solution (appropriately diluted to achieve the indicated concentrations) were incubated 
with incubation mixture 5-II (580 µl; pH 4.65) for 15 min at 37 °C. The dashed lines indicate the 
optical densities measured in the absence of enzyme (upper line) and in the absence of hyaluronate 
(lower line), respectively. 
To determine the activity of S. agalactiae hyaluronate lyase as a function of pH, aliquots of 
the enzyme were incubated in NaCl-containing phosphate buffer of varying pH for 15 min at 
37 °C. With 0.42 units#/ml an enzyme concentration, that has been shown to reduce turbidity 
                                                 
# as declared by the supplier 
Turbidimetric and viscosimetric determination of hyaluronidase activity 
 106
by about 75 % at pH 4.65 under the given test conditions (cf. Fig. 5-4), was used. The 
obtained pH activity profile is shown in Fig. 5-5.  
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Fig. 5-5: Effect of pH on the activity of S. agalactiae hyaluronate lyase. 20 µl of enzyme solution 
(appropriately diluted to achieve a concentration of 0.42 units#/ml in the incubation mixture) were 
incubated with incubation mixture 5-II (580 µl) for 15 min at 37 °C. 
Maximum activity was measured at pH 5, being consistent with the results obtained by the 
colorimetric assay and UV difference spectroscopy (cf. chapter 3). Based on this result it can 
be ruled out that the discrepancies in the pH activity profiles of our hyaluronate lyase 
preparation and the enzyme investigated by Ozegowski et al. (1994), who found maximum 
activity at pH 6.3, are due to different test conditions. 
Interestingly, at neutral pH, after an initial decrease resulting in about 40 % of maximum 
activity at pH 6, the curve shows an additional small maximum with around 50 % of the 
maximal activity at pH 7. This second pH optimum might be explained by the presence of 
two enzymatically active proteins in the investigated hyaluronate lyase preparation (cf. 
chapter 3). However, the fact that the second maximum was not observed in our former 
experiments using the colorimetric assay and UV difference spectroscopy caused us to 
systematically compare the different assays, i.e. to perform turbidimetric determination of 
enzyme activity after incubation under identical conditions as used in case of the colorimetric 
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assay and UV difference spectroscopy. Moreover, it was of interest to study the effect of pH 
on enzyme activity in the turbidimetric assay also at the acidic side of the maximum obtained 
so far. 
5.3.1.3 Incubation in citrate-phosphate buffer containing BSA  
The turbidimetric determination of enzyme activity after incubation under identical conditions 
as used in the colorimeric assay and in UV difference spectroscopy allows for a comparison 
of the results obtained by the different methods and assures that possible discrepancies in the 
apparent activity are due to the different principles of the assays and can not be ascribed to 
differences in the composition of the incubation mixture, which is known to affect the 
hydrolytic activity of hyaluronidases significantly. 
By analogy to the previously used incubation buffers the selected incubation mixture of the 
colorimetric assay (i.e. standard incubation mixture) was examined with respect to its 
suitability for the use in the turbidimetric assay in preliminary studies. 
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Fig. 5-6: Relation between the turbidity, measured at 600 nm, and the hyaluronate concentration in the 
incubation mixture. 200 µl of hyaluronate (0-500 µg per ml of water) were mixed with 100 µl of BSA 
(solution 1) and 150 µl of citrate-phosphate buffer, pH 5.0 (cf. section 5.2.2.1). The precipitation of 
hyaluronate was then performed as described in the materials and methods section. 
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A linear relationship between turbidity and hyaluronate concentration in the incubation 
mixture was observed for hyaluronate concentrations up to 222 µg/ml (Fig. 5-6). Although the 
substrate concentration of the standard incubation mixture is higher (555 µg/ml), a 
concentration of 222 µg/ml was used for the following turbidimetric experiments to guarantee 
a linear relationship between the concentration of high molecular weight hyaluronate in the 
incubation mixture and the measured optical density. Furthermore, it was assured that the 
turbidity induced by a certain substrate concentration was not affected by the pH of the 
investigated incubation mixture (results not shown). 
Fig. 5-7 shows that turbidity is constantly reduced to the value, obtained in the absence of 
substrate by the action of increasing amounts of hyaluronate lyase, i.e. no interfering 
components are present in the buffer system. The incubation conditions prevailing in the 
colorimetric assay proved to be applicable for the turbidimetric determination of 
hyaluronidase activity, too, and they were used for the subsequent investigations.  
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Fig. 5-7: Turbidity as a function of the hyaluronate lyase concentration in the incubation mixture.  
50 µl of enzyme solution (appropriately diluted to achieve the indicated concentrations) were 
incubated with incubation mixture 5-III (400 µl; pH 5.0) for 30 min at 37 °C. The dashed lines 
indicate the optical densities measured in the absence of enzyme (upper line) and in the absence of 
hyaluronate (lower line), respectively. 
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5.3.2  Characterisation of S. agalactiae hyaluronate lyase in the turbidimetric assay 
5.3.2.1 Effect of pH on enzyme activity 
To determine the activity of S. agalactiae hyaluronate lyase as a function of pH, aliquots of 
the enzyme were incubated in NaCl-containing citrate-phosphate buffer of varying pH for 30 
min at 37 °C and the residual high molecular weight substrate was turbidimetrically detected 
by precipitation with CTAB. An appropriate enzyme concentration of 1.67 units#/ml inducing 
a decrease in turbidity by about 80 % at pH 5.0, i.e. at the expected pH optimum, was selected 
from the turbidity reduction curve in Fig. 5-7. 
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Fig. 5-8: Effect of pH on the activity of S. agalactiae hyaluronate lyase, determined by the 
turbidimetric method (—●—). 50 µl of enzyme solution (appropriately diluted to achieve a 
concentration of 1.67 units#/ml in the incubation mixture) was incubated with incubation mixture 5-III 
(400 µl) for 30 min at 37 °C. pH activity profile, obtained by the colorimetric method (—□—; cf. 
chapter 3) 
As illustrated in Fig. 5-8, the pH activity profile obtained by turbidimetry is in good 
agreement with the results of the colorimetric assay with respect to the determined activity 
optimum at pH 5 and the steep decrease in activity at acidic pH. However, at neutral pH it is 
noteworthy that the turbidimetrically determined relative activity (20 % of the maximum 
activity at pH 7) is considerably lower compared to the relative activity detected in the 
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colorimetric assay (45 % of the maximum activity at pH 7). Interestingly, as observed in 
former experiments with phosphate buffer as incubation medium (cf. section 5.3.1.2.2), the 
pH activity curve obtained with the turbidimetric assay shows an additional small maximum 
at neutral pH (pH 7.4), which is not existent in the pH activity profile, determined in the 
Morgan Elson assay using the identical incubation buffer. 
5.3.2.2 Determination of the turbidity reducing unit (TRU) 
According to other authors (Gerlach and Köhler, 1972; Ozegowski et al., 1994) one turbidity 
reduction unit was defined as the amount of enzyme, which will reduce the turbidity produced 
by 100 µg of hyaluronate to the turbidity produced by 50 µg of hyaluronate within 30 min 
under specified conditions.  
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Fig. 5-9: Turbidity as a function of the amount of hyaluronate lyase in the incubation mixture. 50 µl of 
enzyme solution (appropriately diluted to achieve the required concentrations in the incubation 
mixture) were assayed with incubation mixture 5-IV (400 µl; pH 5.0) for 30 min at 37 °C. The dashed 
lines indicate the turbidity induced by incubation mixtures containing 100 µg and 50 µg of 
hyaluronate, respectively, in the absence of enzyme.   
For the determination of hyaluronidase activity in terms of TRU, increasing amounts of 
enzyme were added to incubation mixtures containing 100 µg of hyaluronate in citrate-
phosphate buffer of optimal pH (pH 5.0) and incubated for 30 min at 37 °C. In addition 
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reference samples containing 100 µg and 50 µg of hyaluronate in the absence of enzyme were 
prepared in triplicate. Plotting the measured turbidities as a function of the amount of enzyme 
in the incubation mixture allows for graphical determination of the TRU, i.e. the turbidity 
produced by 50 µg of hyaluronate can be assigned to a certain amount of enzyme (Fig. 5-9). 
As shown in Fig. 5-9, 1 TRU of the investigated S. agalactiae hyaluronate lyase was found to 
correspond to 0.45 units, according to the declaration of the supplier. With reference to the 
results of the colorimeric assay and UV difference spectroscopy (cf. chapter 3) a correlation 
can be made between the turbidity reducing unit and the unit (U) as defined according to the 
International union of Biochemistry (cf. chapter 3). Thus, 1 TRU of hyaluronate lyase 
amounts to 1.3 mU, i.e. it will catalyse the formation of 1.3 ⋅ 10-3 µmol of N-acetyl-D-
glucosamine (NAG) at the reducing ends of sugars per minute under the conditions used in 
the performed experiments (citrate-phosphate buffer, pH 5.0). The relation between the 
different units used for the declaration of the activity of S. agalactiae hyaluronate lyase is 
summarised in table 5-1. 
Table 5-1: Correlation between different units used for the declaration of the activity of 
S. agalactiae hyaluronate lyase 
 
Turbidity reducing 
units (TRU) 
Units (U) according to the 
definition of the International 
union of Biochemistry 
Units according to the 
declaration of the supplier 
1 TRU 1.3 mU 0.45 
 
5.3.3 Characterisation of BTH in the turbidimetric assay 
5.3.3.1 Neopermease® 
5.3.3.1.1 Effect of pH on enzyme activity 
By analogy with the bacterial hyaluronate lyase the activity of the BTH preparation 
Neopermease® was determined as a function of pH by the turbidimetric method under 
identical incubation conditions as used for the colorimetric determination of the pH activity 
profile of the enzyme (cf. chapter 3). In contrast to the investigations on the bacterial enzyme, 
where the results from both assays were in good agreement, in case of Neopermease® almost 
inverted pH activity profiles were obtained by the two methods (Fig. 5-10). 
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Fig. 5-10: Effect of pH on the activities of Neopermease® (—●—) and the basic material of 
Neopermease® (—○—) as determined by the turbidimetric method. 50 µl of enzyme solution 
(Neopermease®: 1.5 units#; basic material: 1.75 units#) were incubated with incubation mixture 5-IV 
(400 µl) for 1h at 37 °C. pH activity profile of Neopermease®, obtained by the colorimetric method 
(—□—; cf. chapter 3). 
Like the colorimetric assay the turbidimetric determination yielded an asymmetric curve 
when enzyme activity was measured over a broad range from pH 3 up to pH 8. However, 
maximum activity was found at pH 5.8, whereas at pH 3.5, which is the optimum pH in the 
colorimetric assay, a second small maximum with 60 % of the maximal activity was detected. 
For the colorimetric assay it has been shown that the complex effect of pH on the activity of 
Neopermease® can be explained as the sum of the pH profiles of the three different 
enzymatically active proteins contained in the enzyme preparation (cf. chapter 3). 
Interestingly, two of the three fractions - the 33 kDa and 77 kDa fraction - were found to 
exhibit maximum activity at pH 6 in the colorimetric assay, while the activity maximum of 
Neopermease® at pH 3.6 results from the high specific activity of the main 58 kDa fraction, 
which is characterised by two maxima at pH 3.6 and pH 4.8.  
Based on these results one can assume that the maximum at pH 5.8 in the turbidimetrically 
determined pH activity profile might result from the fact that the turbidimetric assay detects 
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the activities of the 33 kDa and 77 kDa fractions more sensitively compared to the main 58 
kDa fraction. However, this can be excluded, since, like in the colorimetric assay, by the 
turbidimetric method the highest activity was detected in the 58 kDa fraction (results not 
shown). A comparison of the isolated components of Neopermease® with respect to their pH 
profiles obtained by both methods revealed that the 58 kDa fraction gave the inverse profiles 
typical for the whole preparation (Fig. 5-11), whereas the pH profiles of the high and low 
molecular mass fraction were not affected by the type of assay (Hoechstetter et al., 2001). 
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Fig. 5-11: Effect of pH on the activity of the 58 kDa fraction of Neopermease®, determined by the 
turbidimetric method (—●—). 50 µl of enzyme solution (14.0 ng) were incubated with incubation 
mixture 5-IV (400 µl) for 1h at 37 °C. pH activity profile of the 58 kDa fraction as obtained by the 
colorimetric method (—□—; cf. chapter 3). 
 
Assuming, that the 58 kDa fraction contains two enzymatically active proteins with different 
pH optima (pH 3.6 and 4.8) the turbidimetrically obtained pH profile may be explained by a 
higher sensitivity of the turbidimetric assay towards the isoform, which is active at weak 
acidic pH (pH 5 – 6) compared to the isoform exhibiting activity at pH 3.6. 
The observed phenomenon reflects the fundamentally different principals of the colorimetric 
and the turbidimetric assay (cf. chapter 1), i.e. the discrepancies in the apparent activity of the 
investigated BTH preparation may result from the fact that hydrolysis and transglycosylation 
taking place on substrates falling below a certain length (6-8 kDa) are not detected by the 
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turbidimetric method but do affect the results of the colorimetric assay. To test this 
hypothesis, the effect of pH on the composition of the oligosaccharide mixtures produced by 
digestion of hyaluronate with hyaluronidase under various conditions was investigated in 
detail in further studies (cf. chapter 6). 
5.3.3.1.2 Determination of the turbidity reducing unit (TRU) 
To allow for a comparison with the S. agalactiae hyaluronate lyase the TRU of 
Neopermease® was determined at optimal pH (pH 5.8) according to the procedure described 
for the bacterial enzyme (cf. section 5.3.2.2) using identical incubation conditions. 
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Fig. 5-12: Turbidity as a function of the amount of Neopermease® in the incubation mixture. 50 µl of 
enzyme solution (appropriately diluted to achieve the required concentrations in the incubation 
mixture) were incubated with incubation mixture 5-IV (400 µl; pH 5.8) for 30 min at 37 °C. The 
dashed lines indicate the turbidity induced by incubation mixtures containing 100 µg and 50 µg of 
hyaluronate, respectively, in the absence of enzyme.  
The resulting plot of the measured turbidities as a function of the amount of enzyme in the 
incubation mixture revealed that the TRU of Neopermease® corresponds to 1.75 units 
according to the declaration of the supplier (Fig. 5-12). As done in case of the bacterial 
enzyme, the TRU of Neopermease® was related to the unit (U) as defined according to the 
International union of Biochemistry with reference to the results of the colorimetric assay (cf. 
                                                 
  # as declared by the supplier 
Turbidimetric and viscosimetric determination of hyaluronidase activity 
 115
chapter 3). Thus, 1 TRU of Neopermease® amounts to 0.0875 mU, i.e. it will catalyse the 
formation of 0.0875 ⋅ 10-3 µmol of N-acetyl-D-glucosamine (NAG) at the reducing ends of 
sugars per minute under the conditions used in our experiments (citrate-phosphate buffer, pH 
3.6). In this context it has to be noted that the quantification of enzyme activity in terms of 
TRU and in units according to the definition of the International union of Biochemistry has 
been performed at optimum pH for the enzyme in the respective assay, i.e. at pH 3.6 in the 
colorimetric assay and at pH 5.8 in the turbidimetric assay, respectively. The relation between 
the different terms used for the declaration of the activity of Neopermease® is shown in table 
5-2. 
Table 5-2: Correlation between the different units used for the declaration of the activity 
of Neopermease® 
 
Turbidity reducing 
units (TRU) 
Units (U) according to the 
definition of the International 
union of Biochemistry 
Units according to the 
declaration of the supplier 
 
1 TRU 0.0875 mU 1.75 
 
The liberation of NAG per one designated unit (as declared by the respective supplier) of the 
S. agalactiae enzyme and Neopermease® was found to differ by a factor of 60 (cf. chapter 3). 
It is interesting to notice that in the turbidimetric assay the equiactive concentration of the 
bacterial enzyme was only by a factor of 3.86 lower when compared with Neopermease® 
(tables 5-1 and 5-2). This result reflects the different catalytic mechanisms of bacterial and 
bovine hyaluronidases (cf. chapter 1). In case of BTH, which acts as an endolytic enzyme 
(Vercruysse et al., 1994), every cleavage is accompanied by both the formation of NAG and 
the formation of two shorter substrate chains, i.e. precipitation of the substrate with CTAB is 
continuously reduced. By contrast, in case of the bacterial enzyme, after the first endolytic 
cleavage, the following exolytic and processive release of unsaturated disaccharide (Baker 
and Pritchard, 2000; Li and Jedrzejas, 2001) does not effectively decrease the length of the 
substrate chain and thus its capability to precipitation with CTAB. 
In view of the fact that in the turbidimetric assay the activity of hyaluronidase is quantified 
according to its ability to reduce the MW of the substrate chains, it can be assumed that 
equiactive concentrations of bacterial and bovine enzyme as determined by the turbidimetric 
method are more likely to be pharmacologically equieffective when used as a spreading factor 
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compared with concentrations being equiactive in the colorimetric assay. Table 5-3 
summarises the activities of Neopermease® and the S. agalactiae hyaluronate lyase, 
determined in the colorimetric and the turbidimetric assay, respectively. 
Table 5-3: Comparison of the enzyme activities of Neopermease® and S. agalactiae 
hyaluronate lyase 
Enzyme activities were determined in the colorimetric assay (liberation of NAG, cf. chapter 3) and in 
the turbidimetric assay (TRU), respectively, at optimal pH for each enzyme, using identical incubation 
conditions, which are described in the materials and methods section (incubation mixture 5-IV). 
Activities per designated 
unit 
Specific activities Hyaluronidase 
preparation 
Designated 
units per mg 
Liberation  
of NAG 
per designated 
unit 
(µmol min-1) 
TRU 
per 
designated 
unit 
Liberation 
of NAG 
per mg 
(µmol min-1 
mg-1) 
TRU 
per mg 
Neopermease® 50 000 5⋅10-5 0.57 2.5a 28 500a 
S. agalactiae 
hyaluronate 
lyase 
350 000 2.9⋅10-3 2.2 1015b 770 000b 
 
a for calculation the protein content, determined by the method of Bradford, was used 
b for calculation the amount of enzyme protein per vial, as indicated by the supplier, was used 
 
5.3.3.2 Hylase® “Dessau” 
5.3.3.2.1 Effect of pH on enzyme activity  
Comparison of the two pharmaceutical preparations Neopermease® and Hylase® “Dessau” 
with respect to the effect of pH on enzyme activity in the colorimetric assay revealed that they 
are characterised by almost identical complex pH profiles (cf. chapter 3).  
As shown in Fig. 5-13, by turbidimetric determination of hyaluronidase activity similar pH 
activity profiles were obtained for the two BTH preparations, i.e., as observed in the case of 
Neopermease®, the pH activity profile of Hylase® “Dessau” was also found to depend on the 
type of assay. However, while the turbidimetrically determined curves of the different BTH 
preparations were consistent with respect to the relatively broad maximum at pH 5.8, the 
second maximum at pH 3.5 was with 80 % of maximal activity more pronounced in case of 
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Hylase® “Dessau”. This difference in the relative activities of the two enzyme preparations at 
acidic pH may reflect the fact that they are complex mixtures of proteins, which do not 
contain identical enzymatically active proteins, as has been shown by SDS PAGE  
(cf. chapter 3). 
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Fig. 5-13: Effect of pH on the activities of the basic materials of Hylase® “Dessau” (—●—) and 
Neopermease® (—○—), determined by the turbidimetric method. 50 µl of enzyme solution (Hylase® 
“Dessau”: 1: 143 dilution of the basic material; Neopermease® (basic material): 1.75 units#) were 
incubated with incubation mixture 5-IV (400 µl) for 1h at 37 °C. pH activity profile of the basic 
material of Hylase® “Dessau”, obtained by the colorimetric method (—□—; cf. Oettl (2000)). 
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5.3.4 Viscosimetric estimation of hyaluronidase activity 
According to theoretical considerations concerning polymer degradation, there is a linear 
relationship between the reciprocal value of the number average molecular mass (Mn) and the 
reaction time at the initial stage of the reaction, provided that a polymer sample is degraded in  
an at random way (Tanford, 1961). The slope kn of this relationship provides the reaction rate, 
which can be expressed as the number of bonds broken per unit time. 
Vercruysse et al. (1994) investigated the degradation of HA by BTH using size exclusion 
chromatography. Plotting the reciprocal value of the experimentally determined Mn as a 
function of the reaction time yielded a linear relationship with the slope kn indicating an at 
random degradation of HA by BTH in the intial stage of the reaction. In addition, the authors 
have shown a linear relationship for plots of the reciprocal value of the viscosity average 
molecular mass (Mv) against reaction time. The slope kv of the plot of 1/Mv as a function of 
the reaction time was shown to be related to kn (slope of the plot of 1/Mn versus reaction time) 
according to eq. 5-4.  
( )[ ] 1/αvn α2Γkk +=        (eq. 5-4), 
where α is the exponent of the Mark-Houwink equation (eq. 5-6, see below).  
Eq. 5-4 is in accordance with the relationship theoretically predicted for an at random 
degradation of a polymer (Peebles, 1971). Therefore, by applying eq. 5-4 the reaction rate 
expressed as the number of bonds broken per unit time (kn) can be calculated from the slope 
kv of the plot of 1/Mv versus reaction time.  
Based on this relationship Vercruysse et al. (1995) conceived a viscosimetric approach to 
determine the activity of BTH, expressed as the number of bonds cleaved per unit time: using 
an Ubbelohde capillary viscosimeter the authors determined the decrease in the relative 
viscosity (ηr) of the substrate (HA) solution during the enzymatic reaction by measuring the 
the outflow times (t) after increasing incubation times (T). From ηr the intrinsic viscosity [η] 
was calculated using the Martin equation (eq. 5-5), which has been shown to be appropriate to 
describe the relationship between ηr and [η] in their test system. 
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[ ] [ ] Cηkηlog)
C
1ηlog( Mr ⋅+=−     (eq. 5-5), 
with C being the concentration of HA and kM being the viscosimetric constant (0.138), which 
has been determined under the test conditions.  
From the calculated values of [η] the authors obtained the decrease in the viscosity average 
molecular mass Mv during the enzymatic reaction using the Mark-Houwink equation (eq. 5-6) 
and the Mark-Houwink constants of HA, determined under the test conditions at 37 °C         
(α = 0.72; K = 0.036). 
[ ] αVMKη ⋅=        (eq. 5-6) 
The reciprocal values of Mv were then plotted as a function of the reaction time yielding a 
linear relationship with a slope kv. The reaction rate expressed as the number of bonds broken 
per unit time (kn) was calculated from kv according to eq. 5-4.  
The reactions rates, expressed as the number of cleaved bonds per unit time (in the following 
termed absolute reaction rate), obtained by the viscosimetric approach were found to be in 
good agreement with the reaction rates obtained by size exclusion chromatography, i.e. the 
reaction rates obtained from the slopes of the plots of 1/Mn as a function of the reaction time. 
In continuation of the determination of the absolute reaction rate Vercruysse et al. (1995) 
applied an empirical method for the estimation of enzyme activity from the decrease of ηr of 
the substrate (HA) solution during the enzymatic reaction. In brief, (ln ηr)-1 was plotted as a 
function of the reaction time (T+t/2) and an empirical reaction rate was determined from the 
slope of the plot which showed good linearity at the initial stage of the reaction.  
By comparison of the empirical reaction rates with the absolute reaction rates, expressed as 
the number of cleaved bonds per unit time, it was demonstrated that the slope of the plot of  
(ln ηr)-1 as a function of the reaction time (T+t/2) is related to the number of bonds broken per 
unit time, and thus provides a good estimate of enzyme activity. 
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5.3.4.1 Comparison of the activities of Neopermease® and S. agalactiae hyaluronate lyase  
Comparison of the enzyme activities of Neopermease® and S. agalactiae hyaluronate lyase by 
the colorimetric and the turbidimetric method revealed that the higher activity of the bacterial 
enzyme compared to the bovine enzyme was less pronounced in the turbidimetric assay than 
in the colorimetric assay, i.e. the equiactive concentrations of the two hyaluronidase 
preparations were found to depend on the type of assay (cf. table 5-3).  
Considering the desired pharmacological effect when hyaluronidase is applied as a spreading 
factor, the reduction in viscosity of hyaluronic acid by an enzyme preparation is the most 
direct physicochemical correlate of the therapeutic action (Humphrey and Jaques, 1953). 
Therefore, Neopermease® and hyaluronate lyase from S. agalactiae were also investigated 
with respect to their ability to reduce the viscosity of hyaluronate solutions. Using an 
Ubbelohde viscometer the reduction of the viscosity of substrate solution induced by the 
action of the hyaluronidase preparations was measured as a function of the reaction time 
during incubation under similar conditions as used in case of the colorimetric and 
turbidimetric method, respectively. Taking into account the results of Daubenmerkl et al. 
(1957) who found that the activities of hyaluronidase preparations, measured in the 
turbidimetric assay, are in good correlation with the activities of the respective preparations in 
a viscosimetric assay, it was expected that turbidimetrically equiactive concentrations of 
Neopermease® and S. agalactiae hyaluronate lyase would reduce the viscosity of the 
incubation mixture to an equal extent. 
Indeed, as it is shown in Fig. 5-14, after a reaction time of 30 min, viscosity was reduced to 
the same degree. However, interestingly, the viscosity reduction curves intersect at this point. 
While in the beginning of the reaction the bovine enzyme caused a faster reduction in 
viscosity of the incubation mixture, in the course of the reaction the viscosity reduction rate of 
the bovine enzyme decreased below that of the bacterial enzyme. 
An explanation for this phenomenon might be found when looking at the different catalytic 
mechanisms of the investigated enzymes. As an endolytic enzyme bovine hyaluronidase 
effectively reduces the molecular weight of the high molecular HA chains with every 
cleavage step. In case of the bacterial hyaluronate lyase, after the first endolytic attack the 
molecular weight of the HA chains is reduced rather ineffectively by the processive release of 
disaccharides until one chain is fully degraded and the next endolytic attack occurs. 
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Fig. 5-14: Reduction of the viscosity of substrate (HA) solution induced by the action of 
Neopermease® (—●—) and S. agalactiae hyaluronate lyase (—□—). 100 µl of enzyme solution 
(Neopermease®: 9 units#; hyaluronate lyase: 2.34 units#) were incubated with incubation mixture 5-V 
(pH 5.0, 18 ml) at 37 °C and the relative viscosity (ηr) of the incubation mixture was determined as a 
function of the reaction time (cf. 5.2.2.2). The dashed line indicates the ηr of the reference mixture in 
the absence of substrate. 
The fact that the molecular weight of the high molecular HA chains is more effectively 
reduced by the endolytic action of BTH explains the higher rate of viscosity reduction 
observed for the bovine enzyme compared to the bacterial enzyme in the initial stage of the 
reaction. However, in the further course of the reaction the higher rate of HA cleavage by the 
bacterial enzyme compared to the bovine enzyme (cf. chapter 3) may become the decisive 
factor for the rate of viscosity reduction. The latter explains the observation that the viscosity 
reduction rate of the bacterial enzyme exceeded that of the bovine enzyme.  
Interestingly, when plotting the viscosity reduction curves in Fig. 5-14 according to the 
method applied by Vercruysse et al. (1995) good linearity is obtained for prolonged reaction 
time only for the bacterial enzyme, whereas the curve of the bovine enzyme tends to bend 
downward already at the initial stage of the reaction (Fig. 5-15).  
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Fig. 5-15: Activity of Neopermease® (—●—) and S. agalactiae hyaluronate lyase (—□—) against HA 
monitored by viscosimetry. For the experimental conditions cf. Fig. 5-14. The reciprocal value of ln ηr 
is plotted as a function of the reaction time. 
This observation is rather surprising, since according to the results of Vercruysse et al. (1995) 
linearity would be expected for the bovine enzyme preparation but not necessarily for the 
bacterial enzyme considering the processive, i.e. non random, degradation mechanism of the 
hyaluronate lyase. The deviance from linearity in case of the investigated BTH preparation 
may be explained by the fact that Neopermease® contains three enzymatically active proteins 
differing in molecular mass, specific activity and with respect to their pH activity profiles (cf. 
chapter 3 and section 5.3.3.1.1).  
5.3.4.2 Effect of pH on the activity of Neopermease® 
In our previous investigations concerning the effect of pH on the activity of Neopermease® 
almost inverted pH activity profiles were obtained by the colorimetric (maximum at pH 3.6) 
and the turbidimetric (maximum at pH 6.0) hyaluronidase assay (cf. Fig. 5-10). The 
determination of hyaluronidase activity as a function of pH by an additional method was 
therefore of particular interest. 
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Fig. 5-16: Reduction of the viscosity of substrate (HA) solution induced by the action of 
Neopermease® during incubation at pH 3.8 (—□—) and pH 6.0 (—●—), respectively. 90 µl of enzyme 
solution (3.6 units#) were added to incubation mixture 5-V (16 ml) at 37 °C and the relative viscosity 
(ηr) of the incubation mixture was determined as a function of the reaction time (cf. 5.2.2.2). The 
dashed line indicates the ηr of the reference mixture in the absence of substrate. 
Fig. 5-16 exemplarily shows the viscosity reduction curves obtained by the incubation of 
Neopermease® with hyaluronan at pH 3.6 and pH 6.0 using similar incubation conditions as 
used in the colorimetric and the turbidimetric assay. While the curves run nearly in parallel 
within the first 10 min, in the further course of the reaction the viscosity was reduced to a 
considerably higher extent at pH 6.0. Thus, when analysing the data by analogy to the 
colorimetric and turbidimetric determination of pH activity profiles, i.e. with respect to the 
extent of viscosity reduction after an incubation time of 60 min, a pH activity profile was ob-
tained, which is in quite good agreement with the results of the turbidimetric assay, whereas 
after an incubation time of 8 min the highest viscosity reduction was found at pH 5  
(Fig. 5-17).  
The phenomenon that the decrease in the initial reaction rate is more rapid at lower pH values 
in the viscosimetric assay was also observed by Salegui et al. (1967) who report that BTH 
shows an initial optimum activity for short time periods (2 min) at pH 3.5, which shifts with 
time to a broad plateau between pH 4.5 and 6.  
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Fig. 5-17: Effect of pH on the activity of Neopermease® determined by viscosimetry after a reaction 
time of 8 min (—?—) and 60 min (—●—), respectively. For experimental conditions cf. Fig. 5-16. 
pH activity profile as obtained by the turbidimetric method (—○—; cf. Fig. 5-10) 
From the discrepancy between the viscosimetrically and the colorimetrically determined pH 
activity profiles of Neopermease® it can be concluded that the ability of the enzyme to reduce 
the viscosity of the substrate solution does not correlate with the liberation of NAG at the 
reducing ends of sugars. The pH activity profile obtained by the colorimetric method showed 
that the amount of reducing NAG end groups produced by the action of BTH is higher at  
pH 3.8 compared to pH 6.0. However, the enzymatically active fraction being responsible for 
the high product formation at acidic pH might preferably cleave HA chains of low molecular 
weight and thus contribute less to viscosity reduction. Another factor contributing to the 
discrepancy between the viscosimetrically and colorimetrically determined pH activity 
profiles may be the transglycosylase activity of BTH. The transglycosylation, which is 
favoured at neutral and weakly acidic pH (Saitoh et al., 1995), interferes with the colorimetric 
assay but may have only a marginal if any effect on the viscosity of the incubation mixture as 
it occurs in the low molecular weight region of HA fragments.  
The fact that the mechanism of HA degradation by Neopermease® is not identical at pH 3.8 
and pH 6.0, can also be seen from the different shapes of the respective viscosity reduction 
curves (Fig. 5-16). Interestingly, when plotting the reciprocal value of ln ηr as a function of 
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the reaction time to estimate an empirical reaction rate from the slope of the plot at the initial 
stage of the reaction according to Vercruysse et al. (1995), a rather abrupt bend was observed 
after a reaction time of 10 min in case of the curve obtained at pH 3.8, whereas the slope of 
the curve obtained at pH 6.0 was found to decrease only slightly within 90 min (Fig. 5-18). 
Furthermore, a comparison of the plots of the viscosity reduction data obtained at pH 5.0 and 
pH 6.6 revealed intersecting curves and thus shows that at the initial stage of the reaction the 
empirical reaction rate was higher at pH 5.0 (Fig. 5-18), although the extent of viscosity 
reduction after a reaction time of 60 min was found to be slightly higher at pH 6.6 (Fig. 5-17). 
Another noteworthy observation is the fact that with increasing pH of the reaction mixture 
better linearity becomes obvious in the plots of the reciprocal value of ln ηr as a function of 
the reaction time, independent from the slope of the particular curve. In contrast to the curves 
obtained at pH 5.0 and below, the prolonged linearity of the curves resulting from 
measurements at weak acidic pH (pH 6.0 and pH 6.6) is in good agreement with the results 
reported by Vercruysse et al. (1995), who investigated the degradation of HA by BTH at a pH 
of 6.4.  
As outlined above, Vercruysse et al. suggest an at random mechanism for the degradation of 
HA by BTH at pH 6.4. One could thus speculate that the deviance from linearity of the curves 
obtained at more acidic pH might result from non at random degradation. As mentioned in the 
context with the discrepancy of the colorimetrically and viscosimetrically determined pH 
activity profiles it is conceivable that the enzyme fraction being active at pH 3.8 preferably 
cleaves HA chains of low molecular weight. However, the correlation between the kinetics of 
viscosity reduction and the underlying degradation mechanism of HA by hyaluronidase 
appears to be quite complex, considering the fact that a linear relationship between the 
reaction time and the reciprocal value of ln ηr was obtained in case of two different 
degradation mechanisms, i.e. by incubation with both the endolytically acting Neopermease® 
(at pH 6.6) and the S. agalactiae hyaluronate lyase (cf. Fig. 5-15) which is known to act on 
HA in a non random way. 
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Fig. 5-18: Activity of Neopermease® in the viscosimetric assay at various pH values. For the 
experimental conditions cf. Fig. 5-16. The reciprocal value of ln ηr is plotted as a function of the 
reaction time. Inset: magnified view of the initial part of figure 5-18. 
In the context with the viscosimetric investigation of the effect of pH on the activity of 
hyaluronidase another aspect to be considered is the fact that aqueous solutions of HA vary in 
their rheological properties depending on the pH and on the ionic strength of the solution. 
Previous rheological studies (Balazs, 1966; Gibbs et al., 1968) revealed that by a decrease in 
pH to a value of 2.5 the dynamic viscoelastic properties of HA solution reached a maximal 
value, whereas the limiting viscosity number (intrinsic viscosity) and the sediment volume 
reached a minimal value. Investigations on the optical properties of HA in aqueous solution 
(Chakrabarti and Balazs, 1973) revealed that with increasing hydrogen ion concentration the 
circular dichroic band at 187.5 nm changes abruptly to the positive side below pH 4 and 
reaches a maximum value at pH 2.5. The observed changes in both the rheological and the 
optical properties of solutions of HA at low pH thus indicate the occurrence of conformational 
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changes which can be explained by the formation of ordered crosslink regions due to the 
decrease in the ionization of the carboxyl groups of HA (Chakrabarti and Balazs, 1973). 
It can be speculated that the observed differences in the kinetics of viscosity reduction by the 
action of Neopermease® depending on the pH of the incubation mixture might rather be 
ascribed to the different rheological properties of the incubation mixture than to the pH 
dependent differences in degradation mechanism. However, it seems unlikely that this 
assumption is true, given the fact that in case of HA degradation with bee venom 
hyaluronidase the reduction of viscosity was found to obey kinetics being consistent within 
the investigated pH region (pH 3.8 – pH 6.0, cf. section 5.3.5).  
5.3.4.3 Effect of a H2O/D2O exchange in the incubation mixture  
In view of NMR studies on hyaluronan degradation by the different hyaluronidases the 
activities of Neopermease® and S. agalactiae hyaluronate lyase were measured by the 
viscosimetric method under incubation conditions, applicable for monitoring the enzyme 
reactions by NMR spectroscopy (cf. chapters 6 and 7).  
Incubation was carried out at 21 °C in phosphate buffer, pH 6.0, containing NaCl and BSA. 
To study the effect of H2O/D2O replacement on the activity of the bovine and bacterial 
enzyme viscosimetric measurements were carried out in both solvents. As shown in Fig. 5-19 
the activity of the S. agalactiae hyaluronate lyase was not affected by the replacement of H2O 
with D2O. However, in case of Neopermease® reduced activity was measured under D2O 
conditions: by comparison of the slopes of the plots of the reciprocal value of ln ηr versus 
reaction time the empirical reaction rates differed by a factor of 1.5.  
The observation that in contrast to the bacterial enzyme the activity of the bovine enzyme 
preparation is affected by replacing H2O with D2O reflects the different mechanisms of HA 
degradation by the two hyaluronidases. In case of Neopermease®, which acts as a hydrolase, 
water molecules are directly involved in the degradation process insofar as they are 
transferred to the substrate molecule during the hydrolytic cleavage via a nucleophilic attack 
(cf. chapter 1). In case of the bacterial hyaluronate lyase water molecules are participating the 
degradation process, too, however, not as nucleophiles but as proton donors and acceptors, 
respectively, in the course of the regeneration of the catalytic residues involved in the ß-
elimination reaction (cf. chapter 1). 
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Fig. 5-19: Reduction of the viscosity of the substrate (HA) solution induced by the action of 
Neopermease® (○/●) and S. agalactiae hyaluronate lyase (□/■) as a function of the solvent (H2O (○/□); 
D2O (●/■)) in the incubation mixture. 100 µl of enzyme solution (Neopermease®: 46 units#; 
hyaluronate lyase: 12 units#) were incubated with the incubation mixtures 5-VII (18 ml) and 5-VIII (18 
ml) at 21 °C. The relative viscosities (ηr) of the incubation mixtures and the reciprocal value of ln ηr 
(inset) were plotted as a function of the reaction time (cf. 5.2.2.2). The dashed line indicates the ηr of 
the reference mixtures (in H2O or D2O, respectively) in the absence of substrate. 
5.3.4.4 Effect of NaCl on the activities of Neopermease® and S. agalactiae hyaluronate 
lyase 
The viscosimetric determination of the activities of Neopermease® and S. agalactiae 
hyaluronate lyase in the absence and in the presence of NaCl (0.067 M) revealed that the 
activities of the two hyaluronidase preparations were inversely affected by addition of NaCl 
to the incubation mixture. Comparison of the slopes of the plots of the reciprocal value of ln 
ηr as a function of the reaction time showed that the empirical reaction rate of the bovine 
enzyme was by a factor of 3.3 higher in the presence of NaCl, whereas in case of the bacterial 
enzyme activity was decreased by 33 % (cf. Fig. 5-20).  
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Fig. 5-20: Reduction of the viscosity of substrate (HA) solution induced by the action of 
Neopermease® (○/●) and S. agalactiae hyaluronate lyase (□/■) in the presence (○/□) and in the 
absence (●/■) of NaCl (0.67 M) in the incubation mixture. 100 µl of enzyme solution (Neopermease®: 
46 units#; hyaluronate lyase: 12 units#) were incubated with the incubation mixtures 5-VI (18 ml) and 
5-VII (18 ml) at 21 °C. The relative viscosities (ηr) of the incubation mixtures and the reciprocal value 
of ln ηr (inset) were plotted as a function of the reaction time (cf. 5.2.2.2). The dashed line indicates 
the ηr of the reference mixtures (with or without NaCl, respectively) in the absence of substrate.  
For the bacterial enzyme this result is qualitatively in agreement with measurements of 
product formation at 232 nm (cf. chapter 3) under identical conditions revealing a 45 % 
decrease in activity when NaCl (0.067 M) was added to the incubation mixture (results not 
shown). With Neopermease® no additional assay was performed under identical conditions in 
this work. However, the results obtained by viscosimetry are supported by the data of  
Oettl (2000), who determined an optimal NaCl concentration in the region from 0.045 M to 
0.100 M for the activity of Neopermease® in the colorimetric assay. 
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5.3.5 Characterisation of a hyaluronidase from bee venom (BVH) 
5.3.5.1 Activity of BVH 
In addition to the studies on hyaluronidase preparations from S. agalactiae and bovine testes a 
recombinant bee venom hyaluronidase (BVH), expressed in baculovirus-infected insect cells, 
was investigated with respect to its activity in the different hyaluronidase assays. By analogy 
with the bovine and bacterial enzymes (cf. chapter 3) the activity of BVH was determined by 
measuring the liberated NAG at the reducing ends of sugars after various incubation periods 
by the colorimetric method of Reissig et al. (1955), using standards with known NAG 
concentration. Catalysing the formation of 56.4 µmol of reducing NAG moieties per min and 
mg, the bee venom enzyme showed a specific activity that was 22 times higher compared to 
Neopermease® and 18 times lower compared to the S. agalactiae hyaluronate lyase, 
respectively.  
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Fig. 5-21: Effect of pH on the activity of recombinant hyaluronidase from bee venom determined by 
the colorimetric (—□—), turbidimetric (—●—) and viscosimetric (?/?) method. 50 µl of enzyme 
solution (colorimetric assay: 34. 29 ng; turbidimetric assay: 5.14 ng) were incubated with incubation 
mixture 5-IV (400 µl) for 1h at 37 °C. For the experimental conditions of the viscosimetric assay cf. 
Fig. 5-22. The relative activities in the viscosimetric assay were calculated by comparing both the 
reduction of viscosity after an incubation time of 60 min (—?—; cf. 5.2.2.2) and the slopes of the 
plots of 1/ln ηr as a function of the reaction time (0 – 30 min, —?—). 
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The determination of the activity of BVH as a function of pH yielded nearly identical pH 
activity profiles in the colorimetric and the turbidimetric assay showing maximum activity at 
pH 3.5 (Fig. 5-21).  
The bee venom enzyme and bovine testicular hyaluronidase, which has been shown to be a 
fragment of the membrane bound PH-20 enzyme (Meyer et al., 1997), belong to the same 
family of glycosyl hydrolases (EC 3.2.1.35, glycosyl hydrolase family 56). In addition BVH 
has been found to be homologous to the mammalian PH-20 enzyme showing 37 % sequence 
similarity and conservation of the active site residues, suggesting a similar catalytic 
mechanism for the two enzymes (Gmachl and Kreil, 1993; Markovic-Housley et al., 2000). 
Thus it is surprising that the hyaluronidase from bee venom did not show the inverted pH 
activity profiles which were obtained for Neopermease® in the colorimetric and the 
turbidimetric assay, respectively (cf. Fig. 5-10). While Neopermease® showed enzyme 
activity over a broad range (pH 3 – 8) and was characterised by complex pH activity profiles 
corresponding to the sum of the pH profiles of different enzymatically active fractions (cf. 
chapter 3 and section 5.3.3.1.1), in case of BVH no activity was detected at pH > 6 and the pH 
profiles were almost symmetrically, indicating that the preparation contains only a single 
enzymatically active protein.  
An attempt to explain the shift of the pH optimum of BTH from pH 3.5 in the colorimetric 
assay to pH 6 in the turbidimetric assay was the transglycosylase activity of BTH, which, in 
contrast to hydrolysis, does not result in the formation of new reducing NAG end groups and 
thus affects the results of the colorimetric assay, whereas in the turbidimetric assay changes of 
the substrate length in the low MW region are not detected. Presuming that the 
transglycosylase activity is higher at weak acidic and neutral pH compared to pH 3.5 (Saitoh 
et al., 1995), this provides a plausible explanation for the difference in the ratios of activity at 
pH 3.5 and pH 6 as measured in the different assays in case of BTH. By contrast, in case of 
the bee venom enzyme the low level of detection of reducing NAG in the colorimetric assay 
at weak acidic pH cannot be ascribed to transglycosylase activity since also in the 
turbidimetric assay, which is not affected by the transglycosylation reaction, only very low 
activity was obtained around pH 6.  
Taken together, the results obtained by the viscosimetric determination of the activity of BVH 
at varying pH were in agreement with the pH profiles of the colorimetric and the turbidimetric 
assay (cf. Fig. 5-21). The viscosimteric data were analysed by two methods which yielded 
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qualitatively the same results: the relative activities were calculated both by comparing the 
extent of viscosity reduction after an incubation time of 60 min (cf. 5.2.2.2) and by comparing 
the slopes of the plots of 1/ln ηr as a function of the reaction time (0-30 min), i.e. the 
empirical reaction rates according to Vercruysse et al. (1995). The latter method of analysis 
was possible since, in contrast to the investigations with Neopermease®, linear curves were 
obtained at acidic pH, too, when plotting 1/ln ηr as a function of the reaction time  
(cf. Fig. 5-22). 
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Fig. 5-22: Activity of recombinant hyaluronidase from bee venom in the viscosimetric assay at pH 3.8 
(□), pH 4.8 (?) and pH 5.8 (●), respectively. 90 µl of enzyme solution (21.6 ng) were incubated with 
incubation mixture 5-V (16 ml) at 37 °C and the relative viscosity (ηr) of the incubation mixture was 
determined as a function of the reaction time (cf. 5.2.2.2). The reciprocal value of ln ηr is plotted as a 
function of the reaction time.  
Two remarkable differences in comparison to the bovine enzyme preparation were observed 
in the viscosimetric assay of BVH: the kinetics of the reduction of viscosity was independent 
on the pH of the incubation mixture and the extent of the reduction in viscosity at different pH 
was in good correlation with the liberation of reducing NAG end groups.  
In summary our investigations demonstrate that no discrepancies in the apparent activity of 
recombinant BVH were observed when comparing the pH activity profiles obtained by the 
different methods under identical incubation conditions. However, Allalouf et al. (1975) who 
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determined the activity of bee venom hyaluronidase, isolated from venom sacs, by the 
colorimetric method in the absence of NaCl and BSA, reported a pH activity profile, which 
shows maximum activity at pH 4.5 and remarkable activity at neutral pH but no activity at pH 
3.5. The discrepancy to our results indicates that, as it is known for BTH (Gacesa et al., 1981; 
Oettl, 2000), also the activity of bee venom hyaluronidase is affected by the composition of 
the incubation buffer.  
5.3.5.2 SDS-PAGE 
To obtain information about the purity of the investigated recombinant bee venom 
hyaluronidase and the molecular mass of the contained proteins the enzyme preparation was 
separated by SDS-PAGE. 
 
 
 
 
Fig. 5-23: SDS-PAGE of recombinant bee venom hyaluronidase (BVH). BVH (2.5 µg (lanes 1; 3) and 
1.25 µg (lanes 2; 4)) was separated on an 8 % gel. The gel was stained according to the periodic acid-
Schiff (PAS) technique (lanes 1; 2) prior to staining with Coomassie Brilliant Blue G-250 (lanes 3; 4). 
Molecular masses were assigned by the use of marker proteins. 
As shown in Fig. 5-23 (lanes 3; 4) Coomassie staining revealed the existence of three proteins 
slightly differing in molecular mass. Glycosylation was demonstrated for the two proteins 
with higher molecular mass by staining according to the periodic acid-Schiff (PAS) technique 
(lanes 1; 2). The main constituent of the recombinant BVH was a 43 kDa glycoprotein which 
is in agreement with the molecular mass of the hyaluronidase isolated from honey bee venom 
44.8 kDa
41.5 kDa
42.8 kDa
1 2 3 4
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(Kemeny et al., 1984), whereas the weak band at 41.5 kDa can be ascribed to the 
nonglycosylated form of bee venom hyaluronidase (Soldatova et al., 1998). The finding that 
the recombinant BVH, which was expressed in baculovirus-infected insect cells, did not 
appear as single band on SDS-PAGE is consistent with the results of Soldatova et al. (1998), 
who report on the appearance of “two to three bands at 43 to 44 kDa in SDS-PAGE” 
corresponding to proteins which were shown to differ at the N-terminus due to the fact that in 
addition to the cleavage of the signal sequence at the proper cleavage site additional cleavage 
occurred after the fourth and the tenth position from the first cleavage. 
5.4  Conclusion 
Characterisation of the BTH preparation Neopermease® and a preparation of hyaluronate 
lyase from S. agalactiae with respect to their activities in the turbidimetric assay revealed that 
1 TRU corresponds to 1.75 designated units of Neopermease® and to 0.45 designated units of 
the bacterial hyaluronate lyase preparation, respectively, i.e. in the turbidimetric assay the 
equiactive concentration of the bacterial enzyme preparation was by a factor of 3.86 lower 
compared to Neopermease®. Concentrations of the two enzyme preparations being equiactive 
in the turbidimetric assay were found to reduce the viscosity of the substrate solution to an 
equal extent in the viscosimetric assay. Comparison of these results with the activities 
determined in the colorimetric assay (cf. chapter 3) revealed that in the turbidimetric and the 
viscosimetric assay the higher activity of the bacterial enzyme compared to the bovine 
enzyme was less pronounced than in the colorimetric assay, where the equiactive 
concentrations differed by a factor of 60. Thus, it was shown that equiactive concentrations of 
the two enzyme preparations depend on the type of assay.  
In the turbidimetric and the viscosimetric assay hyaluronidase activity is quantified according 
to the ability of the enzyme to reduce the molecular mass of substrate chains. The 
aforementioned results thus demonstrate that, when one compares preparations of bovine and 
bacterial hyaluronidase, equiactive concentrations with respect to product formation, as 
determined in the colorimetric assay, are not equieffective in reducing the molecular mass of 
the substrate chains and, thus, in reducing the viscosity of the hyaluronate-enriched 
extracellular matrix. 
The fact that in the turbidimetric and the viscosimetric assay the activity of the bacterial 
hyaluronate lyase was relatively low compared to its high activity in the colorimetric assay 
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partly explains the observation that, in constrast to Neopermease®, the hyaluronate lyase from 
S. agalactiae did not show the spreading effect when applied to enhance the intratumoral 
accumulation of melphalan (cf. chapter 4). However, this explanation is compromised by the 
fact that the activity administered in the in vivo experiments with the bacterial hyaluronate 
lyase was, compared to the activity applied in the corresponding experiments with 
Neopermease®, by a factor of 19.3 higher when extrapolated from the results of the 
turbidimetric and viscosimetric assay. 
The turbidimetrically determined pH activity profile of hyaluronate lyase from S. agalactiae 
with a maximum at pH 5.0 is in good agreement with the results of the colorimetric assay. By 
contrast, in case of the two BTH preparations Neopermease® and Hylase® “Dessau” the 
different methods yielded almost inverted pH profiles showing maximum activity at pH 3.6 in 
the colorimetric assay and at pH 6.0 in the turbidimetric assay, respectively. Comparison of 
the isolated enzymatically active proteins contained in Neopermease® with respect to their pH 
profiles by both methods revealed that in both assays the complex effect of pH on the activity 
of Neopermease® can be explained as the sum of the pH profiles of the individual proteins 
differing in specific activity. While the pH profiles of the 33 kDa and the 77 kDa fraction 
(maximum activity at pH 6) were not affected by the type of assay, the main 58 kDa fraction 
gave the inverse profiles typical for the whole preparation.  
The determination of pH-dependency of the activity of Neopermease® by viscosimetry 
confirmed the pH profile of the turbidimetric assay (activity optimum at pH 6.0).  
The higher activity of BTH at pH 6.0 compared to pH 3.6 in the turbidimetric and the 
viscosimetric assay indicates that the molecular mass of the substrate chains is more 
effectively reduced at pH 6.0 than at pH 3.6, regardless of the higher rate of liberation of 
NAG end groups detected in the colorimetric assay at pH 3.6. It can thus be speculated that at 
pH 3.6 oligosaccharides are preferentially generated in the presence of high molecular mass 
HA, resulting in the low activity in the turbidmetric and the viscosimetric assay, whereas at 
pH 6.0 all types of molecules of the polydisperse substrate are processed to the same extent. 
Another possible explanation for the different pH optima of BTH, depending on the type of 
assay, may be the transglycosylation activity of BTH which is favoured at neutral and weak 
acidic pH (Saitoh et al., 1995) and interferes with the colorimetric but not with the 
turbidimetric and the viscosimetric assay. 
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Determination of the activity of a recombinant bee venom hyaluronidase (BVH) as a function 
of pH yielded nearly identical pH activity profiles in the colorimetric and turbidimetric assay 
showing maximum activity at pH 3.5. Considering that BVH and BTH belong to the same 
family of glycosyl hydrolases (EC 3.2.1.35) and show 37 % sequence similarity, it is 
surprising that BVH does not show the inverted pH profiles which were obtained with BTH 
under identical conditions.  
The colorimetrically and turbidimetrically obtained pH profile of BVH was confirmed by 
viscosimetry (maximum activity at pH 3.8). In the viscosimetric assay of BVH the kinetics of 
viscosity reduction was independent of the pH of the incubation mixture (linear curves were 
obtained when plotting 1/ln ηr versus reaction time within the range of pH 3.8 to pH 5.8), thus 
indicating that the pH-related differences in the kinetics of viscosity reduction, which were  
observed in the viscosimetric assay of Neopermease®, are most probably not due to different 
rheological properties of the incubation mixture at various pH but reflect pH-dependent 
differences in the mechanism of HA degradation by BTH.  
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6 pH-dependent differences in the mechanism of hyaluronate 
degradation by bovine testicular hyaluronidase  
6.1 Introduction 
Since several different methods are used for the determination of enzymatic activity of bovine 
testicular hyaluronidase (BTH), the data reported in the literature are inconsistent in part or 
even contradictory: optimum activity of BTH was found at acidic pH (pH 3.5 - 4.0) (Bonner 
and Cantey, 1966; Muckenschnabel et al., 1998a; Seaton et al., 2000) as well as at weakly 
acidic pH (pH 5.0 - 6.0) (Dorfman and Ott, 1948; Allalouf et al., 1975; Highsmith et al., 
1975) and at neutral pH (Tung et al., 1994; Csoka et al., 1998).  
Comparative analysis of the two BTH preparations Neopermease® and Hylase® “Dessau” 
with respect to their activity in two frequently used hyaluronidase assays - the colorimetric 
assay and the turbidimetric assay - revealed that the two BTH preparations are characterised 
by nearly identical complex pH activity profiles. However, the pH profiles obtained by the 
different methods were almost inverted showing maximum activity at pH 3.6 (colorimetric 
assay) and at pH 6.0 (turbidimetric assay), respectively (cf. chapter 5, figures 5-10 and 5-13). 
For Neopermease® the turbidimetrically obtained pH profile was confirmed by the 
viscosimetric determination of hyaluronidase activity. In addition, comparison of the viscosity 
reduction curves (plots of viscosity reduction induced by hyaluronidase versus reaction time) 
at varying pH showed that the kinetics of viscosity reduction by Neopermease® depended on 
the pH of the incubation medium, thus indicating pH-related differences in the mechanism of 
HA degradation by BTH (cf. chapter 5, figures 5-16, 5-17 and  5-18). 
In addition to hydrolysis, BTH catalyses the reverse reaction, i.e. the transglycosylation  
(cf. chapter 1, Fig. 4-1). It has been reported that the optimal pH for the transglycosylation 
reaction is about pH 7.0, whereas hydrolysis is favoured at pH < 5.0. Furthermore, highest 
transglycosylase activity was found in the absence of NaCl, whereas transglycosylation was 
nearly completely inhibited at concentrations of NaCl higher than 0.5 M (Saitoh et al., 1995).  
It can be assumed that the discrepancy between the pH activity profiles obtained for BTH in 
the different assays results from the fundamentally different principles of the colorimetric 
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assay on the one hand and the turbidimetric and the viscosimetric assay on the other hand. 
The turbidimetric and the viscosimetric assay are physicochemical methods in which the 
activity of hyaluronidase is quantified according the reduction of the size of high molecular 
mass HA molecules by measuring the changes in the physicochemical properties of HA 
solutions (reduction of turbidity (precipitation) with quartery ammonium salts or reduction of 
viscosity, respectively). While hydrolysis of high molecular mass HA is sensitively detected 
by the physicochemical methods, hydrolysis and transglycoslation reactions on HA fragments 
of low molecular mass are not measured in these assays. In the colorimetric assay the activity 
of hyaluronidase is quantified by the determination of N-acetyl-D-glucosamine (NAG) at the 
reducing ends of HA fragments generated by HA hydrolysis and transglycoslation. In contrast 
to the physicochemical methods, the colorimetric method detects hydrolysis of high and low 
molecular mass HA molecules in equal measure. However, the results of the activity 
measurements are affected by the transglycosylase activity of BTH, which, in contrast to 
hydrolysis, does not lead to the formation of new reducing NAG end groups. 
Taking the different principles of the assays into account, the discrepancy in the pH activity 
profiles obtained for BTH by the different methods might on one hand be explained by the pH 
related transglycosylase activity of BTH, which is detected in colorimetric assay but not by 
the physicochemical methods. On the other hand the discrepancy might result from different 
affinities of the enzyme to high and low molecular mass HA, depending on the pH.  
To find out, if the phenomenon that the pH profile of BTH depends on the type of assay 
indeed results from pH-related differences in the mechanism of HA degradation by BTH, in 
the present study the composition of the oligosaccharide mixtures produced by the action of 
Neopermease® at varying pH was analysed by CE and anion exchange HPLC. 
6.2 Materials and methods 
6.2.1 Chemicals 
Neopermease® and the pure stabiliser (cf. chapter 3) were gifts from Sanabo (Vienna, Austria) 
whereas bee venom hyaluronidase (BVH, cf. chapter 5) was kindly provided by Dr. Zora 
Markovic-Housley, University of Basel (Switzerland). Hyaluronic acid (HA) from 
Streptococcus zooepidemicus was purchased from Aqua Biochem GmbH (Dessau, Germany). 
HA from rooster comb, HA from human umbilical cord and bovine serum albumin (BSA) 
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were purchased from Serva (Heidelberg, Germany). HA from bovine trachea was from Sigma 
(Deisenhofen, Germany). Cetyltrimethylammonium bromide (CTAB) was from Roth 
(Karlsruhe, Germany). 2,5-dihydroxybenzoic acid (DHB) and dextrin 15 were kindly 
provided by GSG Mess- und Analysengeräte GmbH (Bruchsal, Germany). Deuteriumoxide 
(D2O, isotopic enrichment 99.98 %) was purchased from Deutero GmbH (Kastellaun, 
Germany). All other chemicals were of analytical grade and were obtained from Merck 
(Darmstadt, Germany). Water was purified by a Milli-Q system (Millipore, Eschborn, 
Germany). 
6.2.2 Measurement of hyaluronidase activity 
6.2.2.1 Colorimetric method 
The colorimetric determination of the activity of Neopermease® was based on the method of 
Reissig et al. (1955) and performed as described in the material and methods section of 
chapter 3. The composition of the buffer solutions and the various incubation mixtures used is 
given in the following:  
citrate-phosphate buffer 1: solution A: 0.2 M Na2HPO4/0.1M NaCl, solution B: 0.1 M citric 
acid/0.1 M NaCl; solutions A and B were mixed in appropriate portions to adjust the required 
pH;  
citrate-phosphate buffer 2: solution A: 0.2 M Na2HPO4/0.05 M NaCl, solution B: 0.1 M citric 
acid/0.05 M NaCl; solutions A and B were mixed in appropriate portions to adjust the 
required pH;  
citrate-phosphate buffer 3: 1.003 g of NaCl were added to 100 ml of citrate-phosphate buffer 
2 of pH 3.6; 
incubation mixture 6-I: 100 µl of substrate (5 mg HA from S. zooepidemicus per ml of water), 
200 µl of citrate-phosphate buffer 1, 50 µl of BSA (0.2 mg BSA per ml of water: solution 1), 
50 µl of water;  
incubation mixture 6-II: 100 µl of substrate (1 mg HA from S. zooepidemicus per ml of 
water), 200 µl of citrate-phosphate buffer 1, 50 µl of BSA (solution 1), 50 µl of water;  
incubation mixture 6-III: 50 µl of substrate (5 mg HA from S. zooepidemicus per ml of water), 
200 µl of citrate-phosphate buffer 2, 50 µl of BSA (solution 1), 100 µl of water;  
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incubation mixture 6-IV: 50 µl of substrate (5 mg HA from S. zooepidemicus per ml of 
water), 200 µl of citrate-phosphate buffer 3, 50 µl of BSA (solution 1), 100 µl of water;  
incubation mixture 6-V: 50 µl of substrate (5 mg HA from S. zooepidemicus per ml of water), 
200 µl of citrate-phosphate buffer 1, 50 µl of BSA (solution 1), 100 µl of water. 
6.2.2.2 Turbidimetric method 
The turbidimetric determination of the activity of Neopermease® was based on the method of 
Di Ferrante (1956) and performed as described in the material and methods section of   
chapter 5. The following incubation mixtures were used: 
incubation mixture 6-VI: 100 µl of substrate (1 mg HA from S. zooepidemicus per ml of 
water), 200 µl of citrate-phosphate buffer 2, 50 µl of BSA (solution 1), 50 µl of water;  
incubation mixture 6-VII: 100 µl of substrate (1 mg HA from S. zooepidemicus per ml of 
water), 200 µl of citrate-phosphate buffer 3, 50 µl of BSA (solution 1), 50 µl of water. 
6.2.3 Incubation mixtures of constant ionic strength (I) 
For the determination of the effect of pH on the activity of Neopermease® under conditions of 
constant ionic strength the difference in the ionic strength of incubation mixture 6-III (cf. 
6.2.2.1, colorimetric method) at different pH (pH 3.6 and 6.0) was calculated, and 
compensated by the addition of NaCl.  
The ionic strengths of the incubation mixtures were calculated taking into account the ionic 
species present in citrate-phosphate buffer 2 (cf. 6.2.2.1) of the respective pH (citric acid: 
pKa1 = 3.06; pKa2 = 4.74; pKa3 = 5.4; phosphoric acid: pKa1 = 2.12; pKa2 = 7.21; pKa3 = 
12.32) and the substrate hyaluronate containing negatively charged carboxylic groups (pKa = 
3.18) with associated sodium ions. The concentration of the polymeric hyaluronate was 
expressed as the concentration of the disaccharide units (1.38 mM). The contribution of BSA 
was neglected due to the very low concentration (0.67 µM). Ionic strength was calculated 
with the Maple software based on the law of mass action and using the electroneutrality 
condition and the mass balance condition. 
The calculation revealed ionic strengths of 0.080 M (pH 3.6) and 0.156 M (pH 6.0), 
respectively. Compensation of the calculated difference was achieved by the use of citrate-
phosphate buffer 3, containing 0.22 M NaCl (cf. 6.2.2.1), instead of citrate-phosphate buffer 
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2, containing 0.05 M NaCl, for preparation of the incubation mixture at pH 3.6 (= incubation 
mixture 6-IV, cf. 6.2.2.1). 
Since hyaluronate was found to make only a minor contribution to the ionic strength of the 
incubation mixture 6-III (1.5 % at pH 3.6; 0.89 % at pH 6), also in case of incubation mixture 
6-VI (cf. 6.2.2.2, turbidimetric method), which differs from incubation mixture 6-III only with 
respect to a 2.5 times lower hyaluronate concetration (0.552 mM), the ionic strength of pH 3.6 
was made up to that of pH 6.0 by the use of citrate-phosphate buffer 3 (= incubation mixture 
6-VII). 
In the aforementioned calculations the single ion activity coefficients were not taken into 
account, since according to the present state of the theory in case of complex electrolyte 
systems an explicit calculation of the single ion activity coefficients is impossible (Wittmann, 
H.-J.; personal communication). 
6.2.4 Analysis of oligosaccharide mixtures produced by the digestion of 
hyaluronate with hyaluronidase  
6.2.4.1 Separation of hyaluronate oligosaccharides by anion exchange HPLC  
6.2.4.1.1 Digestion of hyaluronate  
The incubation mixture (incubation mixture 6-VIII) consisted of 100 µl of citrate-phosphate 
buffer 1 (pH 3.5, 5.0, 5.8 and 6.0; cf. 6.2.2.1), 150 µl of substrate (5 mg HA from S. 
zooepidemicus per ml of water), 50 µl of BSA (solution 1, cf. 6.2.2.1) and 100 µl of water. 
400 µl of incubation mixture 6-VIII were incubated with 50 µl of enzyme (Neopermease®: 
100 units#, bee venom hyaluronidase: 171.45 ng, each dissolved in BSA (solution 1)) at  
37 °C. Incubation was carried out for 1 h, 16.5 h and 62 h, respectively. With Neopermease® 
additionally a 7-d incubation was performed. In this case enzyme was added in two portions 
(each 25 µl, containing 100 units#) at the beginning and after 4 d of incubation and incubation 
was carried out at 30 °C. The enzyme reactions were stopped by heating at 100 °C for 15 min. 
For the subsequent analysis by HPLC protein was removed from the mixtures by 
ultrafiltration using the Nanosep® centrifugal device with a molecular weight cutoff of 10 kDa 
(Nanosep® 10 K, Pall Life Sciences, New York, USA). In addition, reference mixtures 
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consisting of incubation mixture 6-VIII + 50 µl of BSA (solution 1) instead of enzyme were 
prepared at various pH and treated in the same way as described for the digestion mixtures. 
6.2.4.1.2 Instrumentation 
The HPLC analysis was performed with a TSP (tsp Thermo Separation Products GmbH, 
Egelsbach, Germany) liquid chromatograph consisting of a SN 4000 controller, a P 4000 
pump, an SCM 400 degasser, an AS 3000 autosampler and a Spectra Focus UV-VIS detector. 
The chromatograms were recorded with the TSP software on a microcomputer running on 
OS2/Warp. The separation of the oligosaccharides was carried out on two different stationary 
phases: (1) Luna 3µ NH2 (150 mm x 3.0 mm i.d.) column equipped with a security guard 
cartridge (NH2, 4 mm x 2.0 mm i.d.) and (2) Sphereclone 5µ NH2 (250 mm x 4.6 mm i.d.) 
column equipped with a security guard cartridge (NH2, 4 mm x 3.0 mm i.d.). In both cases the 
column and the security guard cartridge were from Phenomenex (Aschaffenburg, Germany). 
6.2.4.1.3 HPLC conditions 
The separation of the hyaluronate oligosaccharides was based on the method described by 
Tawada et al. (2002), i.e. oligosaccharides were eluted by application of a linear phosphate 
gradient (16 – 800 mM NaH2PO4) under constant flow at 40 °C. The flow rate was 0.5 ml/min 
for stationary phase 1 (Luna-NH2) and 1.0 ml/min in case of stationary phase 2 (Spereclone-
NH2). Solvent A was Milli-Q water, solvent B consisted of 800 mM NaH2PO4, dissolved in 
Milli-Q water, and was filtrated (GH Polypro membrane disc filter, 0.45 µm, Pall Life 
Sciences, Dreieich, Germany) prior to use. A linear gradient was applied which consisted of  
2 to 100 % of solvent B over 70 min for stationary phase 1. In case of stationary phase 2 the 
percentage of solvent B was linearly increased from 2 to 33 % within the first 40 min and then 
up to 100 % within the following 15 min. In between the different runs the columns were re-
equilibrated with 16 mM NaH2PO4 (2 % of solvent B) for 60 min. Detection was carried out 
at 205 nm. Peaks were collected manually, pooled according to their retention times and 
lyophilised. 
6.2.4.2 Desalting of the oligosaccharide fractions by size exclusion chromatography  
Size exclusion chromatography was performed on a Superdex Peptide column (10 mm x 300 
mm, Amersham Biosciences, Freiburg, Germany) with a Pharmacia LKB Pump P-500, a 
Waters 2410 refractive index detector (Waters GmbH, Milford, USA), a Servogor 210 
recorder (Metrawatt GmbH, Nürnberg, Germany) and a Pharmacia Biotech valve V-7, 
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equipped with a 200 µl loop. For desalting the lyophilised oligosaccharide fractions were 
redissolved in Milli-Q water and filtrated. 200 µl of each sample were applied onto the 
column, equilibrated with mobile phase for at least 2 h. The mobile phase consisted of 0.1 M 
NH4OAc, dissolved in Milli-Q water, and was filtrated (GH Polypro membrane disc filter, 
0.45 µm, Pall Life Sciences, Dreieich, Germany) and degassed by ultrasound prior to use. 
Chromatography was carried out at room temperature at a flow rate of 30 ml per h, and the 
eluent was monitored by refractive index detection.  Fractions containing the oligosaccharide 
were manually collected, lyophylised and stored at -20 °C until analysis by mass 
spectroscopy. 
6.2.4.3 ESI-MS 
HA oligosaccharides were analysed by ESI-MS on a ThermoQuest Finnigan TSQ 7000 
spectrometer (Thermo Electron GmbH, Dreieich, Germany). The desalted and lyophilised 
oligosaccharide samples were dissolved in a 1:10 mixture of water and MeOH containing  
10 mM NH4OAc and manually injected into the ion source. Analysis was carried out in the 
negative ion mode with a spray voltage of 3 kV. The temperature of the heated capillary was 
200 °C.  
6.2.4.4  MALDI-TOF MS 
6.2.4.4.1 Characterisation of the oligosaccharide fractions from anion exchange HPLC 
MALDI-TOF MS was carried out on a GSG/future linear MALDI-TOF mass spectrometer 
(GSG Mess- und Analysengeräte GmbH, Bruchsal, Germany). For sample preparation the 
GSG/SPA sample preparation system was used. The desalted and lyophilised oligosaccharide 
samples were dissolved in methanol/water (50:50). 2 µl of oligosaccharide solution were 
mixed with 6 µl of matrix solution (10 mg of 2,5-dihydroxybenzoic acid (DHB) dissolved in 
1 ml of methanol/ water (50:50)). 1 µl of the mixture was applied onto one of the mesas on 
the sample target and allowed to dry. Spectra were recorded in the positive ion mode over the 
m/z range from 0 to 3000 Da. For each mesa a number of mass spectra were acquired and 
summed (50-100, depending on the signal intensity of the single spectra). The laser energy 
required to give a detectable signal varied from 5 to 7 µJ and was modified during the 
measurement to attain optimal signal intensity. The calibration of the spectrometer was 
performed over the m/z range from 0 to 3000 Da with a dextrin 15 standard (1 mg dissolved 
in methanol/water (50:50)) and the DHB matrix solution described above using a ratio 
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(standard:matrix) of  
1:3 (v/v).  
6.2.4.4.2 Effect of boiling on the stability of HA hexasaccharide 
6.2.4.4.2.1 Preparation of HA hexasaccharide 
HA hexasaccharide was kindly provided by Edith Hofinger. Briefly, 3.32 ml of 
Neopermease® (6640 units#, dissolved in BSA (solution 1, cf. 6.2.2.1)) were added to an 
incubation mixture consisting of 10 ml of substrate (5 mg HA from S. zooepidemicus per ml 
of water), 6.66 ml of acetate buffer (0.1 M NH4OAc/HOAc, pH 4.0), 3.32 ml of BSA 
(solution 1) and 6.66 ml of water. After an incubation period of 86 h at 37 °C the enzyme 
reaction was stopped by boiling for 10 min. Protein was removed from the incubation mixture 
by centrifugation (12000 g; 20 min) and the supernatant containing a mixture of HA 
oligosaccharides was lyophilised. The lyophilised oligosaccharides were redissolved in H2O 
(10 mg/ml) and  separated by size exclusion chromatography on a Superdex Peptide column 
(10 mm x 300 mm, Amersham Biosciences, Freiburg, Germany) at a flow rate of 0.5 ml/min 
using 0.1 M NH4OAc as mobile phase. The sample volume was 200 µl. Elution was 
monitored by UV detection at 210 nm, and fractions containing HA hexasaccharide were 
manually collected and then lyophilised. 
6.2.4.4.2.2 MALDI-TOF MS 
Lyophilised HA hexasaccharide was dissolved in millipore water at a concentration of     
11.78 mg/ml (hexasaccharide solution A). 100 µl of solution A were boiled for 15 min 
(hexasaccharide solution A*). For MALDI-TOF MS analysis solutions A and A*, respectively, 
were diluted by a factor of 110 with methanol/water (50:50). MALDI-TOF MS was carried 
out as described in section 6.2.4.4.1. 
Additonally, the effect of boiling on HA hexasaccharide was investigated under the 
conditions prevalent in the incubation mixtures analysed by anion exchange HPLC. 100 µl of 
hexasaccharide solution A were mixed with 100 µl of BSA (solution 1, cf. 6.2.2.1), 200 µl of 
water and 100 µl of citrate-phosphate buffer 1 (pH 3.6 or pH 6.0, cf. 6.2.2.1) yielding the 
hexasaccharide solutions B (pH 3.6) and C (pH 6.0). 200 µl of solutions B and C were boiled 
for 15 min yielding hexasaccharide solutions B* and C*, respectively. Protein was removed 
from solutions B, C, B* and C* by ultrafiltration using the Nanosep® 10 K centrifugal device       
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(cf. 6.2.4.1.1). For MALDI-TOF MS analysis the ultrafiltrated samples were diluted by a 
factor of 4 with methanol/water (50:50). MALDI-TOF MS was carried out as described in 
section 6.2.4.4.1. 
6.2.4.5 Separation of hyaluronate oligosaccharides by capillary electrophoresis (CE) 
6.2.4.5.1 Digestion of hyaluronate 
150 µl of Neopermease® (300 units#, dissolved in BSA (solution 1, cf. 6.2.2.1)) were 
incubated with 1200 µl of incubation mixture 6-IX, consisting of 600 µl of acetate buffer  
(pH 3.65 and pH 5.8; solution A: 0.1 M acetic acid, solution B: 0.1 M NaOAc, solutions A 
and B were mixed in appropriate portions to adjust the required pH), 450 µl of substrate (5 mg 
HA from S. zooepidemicus per ml of water) and 150 µl of BSA (solution 1) at 37 °C. Three 
samples (samples a, b and c) were prepared at each pH. After an incubation time of 28 h in 
case of samples a and b the enzyme reactions were stopped by boiling the mixtures for  
15 min (a) or 2 h (b), respectively, before protein was removed from the mixtures by 
ultrafiltration using the Nanosep® 10 K centrifugal device (cf. 6.2.4.1.1), whereas in case of 
samples c the boiling procedure was omitted. In addition, reference mixtures consisting of 
incubation mixture 6-IX + 150 µl of BSA (solution 1) instead of Neopermease® were 
prepared. Two samples (samples b and c) were prepared at pH 3.65 and pH 5.8, respectively, 
and treated in the same way as described for the digestion mixtures. A 1 ml volume of each 
ultrafiltrated sample was then lyophilised and redissolved in 1 ml of CE sample buffer  
(cf. 6.2.4.5.2) for subsequent CE analysis. 
6.2.4.5.2  CE conditions 
CE analysis was carried out in the normal mode on a Biofocus 3000 capillary electrophoresis 
system (Biorad, München, Germany) equipped with an uncoated fused silica capillary (75 cm 
x 50 µm; Chrompack). Operating buffer: 50 mM Na2HPO4, 20 mM Na2B4O7, pH 9; sample 
buffer: operating buffer 1:10 diluted with Milli-Q water. The sample was injected by pressure 
(20 psi · s) and analysis was performed at a capillary temperature of 15 °C applying a run 
voltage of 15 kV. The detector wavelength was 195 nm. Between the single analyses the 
capillary was washed with 0.1 M NaOH (200 s), Milli-Q water (200 s) and finally with the 
operating buffer (300 s).  
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6.2.4.6 Analysis of hyaluronate oligosaccharides by NMR spectroscopy 
6.2.4.6.1 Digestion of hyaluronate 
6.2.4.6.1.1 Exhaustive digestion 
Hyaluronate was digested with Neopermease® at pH 3.8 and pH 6.0 for subsequent 
characterisation of the produced oligosaccharide mixtures by NMR spectroscopy. The 
incubation mixture (incubation mixture 6-X) consisted of 6 ml of citrate-phosphate buffer 1  
(pH 3.8 and 6.0; cf. 6.2.2.1), 4.5 ml of substrate (6 mg HA from S. zooepidemicus per ml of 
water), 1.5 ml of BSA (0.4 mg BSA per ml of water) and 150 µl of water. 12.15 ml of 
incubation mixture 6-X were incubated with l.35 ml of Neopermease® (135 000 units#; 1 vial 
of Neopermease® was dissolved in 2 ml of water) at 37 °C. In addition reference mixtures 
were prepared by incubation with 1.35 ml of the pure stabiliser of Neopermease® (1 vial of 
the stabiliser was dissolved in 2 ml of water). After an incubation time of 30 h both the 
digestion and the reference mixtures were frozen with liquid N2 and lyophilised. The 
lyophilised digestion mixtures were redissolved in 1 ml of D2O and 15 µl of internal standard 
solution (50 mg of TSP (3-(trimethylsilyl)-propionic acid-2,2,3,3-d4 sodium salt) per ml of 
D2O) were added. Since considerable turbidity was observed at pH 3.8, the mixture was 1:1 
diluted with D2O. To obtain solutions free of turbidity, both digestion mixtures were 
centrifuged and the supernatants used for NMR analysis. The lyophilised reference mixtures 
were dissolved in 4 ml of D2O. For NMR analysis 250 µl of the solution were diluted with 
750 µl of D2O and 15 µl of internal standard solution were added.  
6.2.4.6.1.2 Incubation conditions for monitoring the digestion by NMR spectroscopy 
The degradation of hyaluronate by the action of Neopermease® was investigated at pH 3.8 
and pH 6.0 by monitoring the changes in the digestion mixture by 1H NMR spectroscopy. For 
the digestion at pH 6.0 incubation conditions, which had been elaborated in preliminary 
studies by viscosimetry (cf. chapter 5), were applied. The incubation mixture (mixture 6-XI) 
was prepared as follows: 10 mg of substrate (HA from S. zooepidemicus) were dissolved in 6 
ml of 0.133 M phosphate buffer (pH 6) containing 0.1 M NaCl and 0.044 mg/ml BSA (140.93 
mg NaH2PO4, 22.73 mg Na2HPO4, 0.44 mg BSA and 5.84 mg NaCl per 10 ml of D2O). To  
1 ml of incubation mixture 6-X 10 µl of internal standard solution (TSP, cf. 6.2.4.6.1.1) were 
added and a reference spectrum of the undigested incubation mixture was recorded. At  
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t = 0 min 50 µl of Neopermease® (2.7 units#, dissolved in BSA (0.2 mg of BSA per ml of 
D2O)) were added to the mixture directly into the NMR tube, and after thorough mixing 
spectra were recorded at increasing reaction times (t = 0-16 h, at intervals of 10 min within 
the first two hours, and 60 min, respectively). Since under the described conditions (2.55 
units#/ml, t = 16 h) no changes were detected in the digestion mixture, additional experiments 
were performed using higher concentrations of enzyme and longer reaction times (13.3 
units#/ml, t = 187 h; 26.67 units#/ml, t = 60 h). 
The incubation mixture for digestion at pH 3.8 (incubation mixture 6-XII) was prepared as 
follows: 16.7 mg of substrate (HA from S. zooepidemicus) were dissolved in 10 ml of 0.1 M 
formate buffer (pH 3.8) containing 0.1 M NaCl and 0.044 mg/ml BSA (68.01 mg of sodium 
formate and 58.4 mg of NaCl were dissolved in 9.9 ml of D2O. To this solution 100 µl of 
BSA (4.44 mg per ml of D2O) were added. The pH was adjusted by addition of 28 µl of 
formic acid.) 1.5 ml of incubation mixture 6-XII was mixed with 10 µl of internal standard 
solution (TSP, cf. 6.2.4.6.1.1). The digestion was started at t = 0 min by the addition of 100 µl 
of Neopermease® (20 units#, dissolved in BSA (0.2 mg of BSA per ml of D2O)). After 
thorough mixing 1 ml of the digestion mixture was transferred into a NMR tube and spectra 
were recorded at increasing reaction times (t = 17 min, 4 h, 7 h). Since no changes were 
detected in the digestion mixture additional enzyme (20 units#) was added into the NMR tube 
at t = 7.5 h and another spectrum recorded at t = 23 h. In a next step digestion was promoted 
by adding even more enzyme (40 units# at t = 23.5 h; 80 units# at t = 96 h; 100 units# at            
t = 120 h) and increasing the incubation temperature from 21 °C to 30 °C (at t = 23.5 h) and to 
37 °C (at t = 96 h). A final spectrum was recorded at t = 145 h.  
6.2.4.6.2 NMR spectroscopy 
In case of the exhaustively digested incubation mixtures (cf. 6.2.4.6.1.1) measurements were 
performed on an Avance 600 spectrometer operating at 600.13 MHz for 1H (Bruker Biospin 
GmbH, Rheinstetten, Germany). All spectra were recorded at 300 K and the intense water 
signal was suppressed by the application of presaturation on the water resonance frequency. 
Chemical shifts were referenced to internal TSP. The peak assignment of the 1H spectra was 
made via the plots obtained from 2D experiments, i.e. double quantum filter correlation 
spectroscopy (DQF COSY), rotating frame nuclear Overhauser effect spectroscopy (ROESY), 
heteronuclear multiple quantum coherence (HMQC) and heteronuclear multiple bond 
correlation (HMBC). 
                                                 
# as declared by the supplier 
pH-dependent differences in hyaluronate degradation by BTH 
 150
The kinetic experiments, i.e. the monitoring of hyaluronate digestion by Neopermease® (cf. 
6.2.4.6.1.2) by 1H NMR spectroscopy, were carried out on a Bruker Avance 400 
spectrometer, operating at 400.13 MHz for 1H, at 294 K. 
6.3 Results and discussion 
6.3.1 Effect of substrate concentration on the pH activity profile of Neopermease®  
In the course of the comparative studies on hyaluronidases from different sources (bovine 
testes, bee venom, S. agalactiae) with respect to their apparent activity in different 
hyaluronidase assays (cf. chapter 5), it turned out that in case of the investigated bovine 
enzyme preparations (Neopermease®, Hylase® “Dessau”) the effect of pH on the apparent 
activity depended on the type of assay. Almost inverted pH activity profiles were obtained by 
the colorimetric and the turbidimetric method, respectively (cf. chapter 5, Fig. 5-10). From 
previous investigations it was known that changes in the composition of the incubation 
mixture with respect to the type of buffer, NaCl concentration and BSA concentration, cause a 
shift of the pH optimum of BTH (Gorham et al., 1975; Gacesa et al., 1981; Oettl, 2000). 
Therefore, in the preceding chapter the turbidimetric determination of the pH activity profile 
was performed under identical incubation conditions as used for the colorimetric assay, 
except for the substrate (hyaluronic acid, HA) concentration, which was chosen by a factor of 
2.5 lower in the turbidimetric assay to guarantee a linear relationship between HA 
concentration and the induced turbidity (cf. chapter 5, Fig. 6).  
Hyaluronic acid has, depending on the pH of the medium, a polyanionic character due to the 
carboxylic groups on the glucuronic acid residues, the pKa of which is 3-4, again depending 
on the type and concentration of the ions in the medium (Hascall and Laurent, 1997). To rule 
out the possibility that, due to the effect of the ionic strength of the incubation mixture, the 
different HA concentrations account for the observed inversion of the pH activity profile of 
BTH, additional pH profiles of BTH (Neopermease®) were determined by the colorimetric 
method using a) the substrate concentration of the turbidimetric assay (0.22 mg/ml) and b) a 
substrate concentration of 1.11 mg/ml, which was twice as high compared to the standard 
conditions of the colorimetric assay.  
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The results, which are depicted in Fig. 6-1, clearly show that varying substrate concentrations 
did not affect the pH profile of Neopermease® in the colorimetric assay. Therefore, it can be 
ruled out that the discrepancy between the turbidimetrically and colorimetrically determined 
pH activity curves originates from different HA concentrations in the incubation mixtures. 
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Fig. 6-1: Effect of pH on the activity of Neopermease® determined by the colorimetric method at 
different substrate concentrations. 50 µl of enzyme solution (25 units#) were incubated with incubation 
mixture 6-I (—●—; 0.22 mg/ml of HA) for 3 h and with incubation mixture 6-II (—□—; 1.11 mg/ml 
of HA) for 30 min, respectively, at 37 °C. pH activity profile of Neopermease® as obtained by the 
turbidimetric method (—○—; cf. chapter 5, Fig. 5-10). 
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6.3.2 Activity of Neopermease® in incubation mixtures of constant ionic strength 
The determination of the pH activity profiles in the preceding experiments was performed 
using Mc Ilvaine’s citric acid-phosphate buffer (McIlvaine, 1921). Since the buffer system 
covers a broad range from pH 2.2 to 8.0 it allowed for the determination of the pH activity 
profiles without changing the buffer system. However, the ionic strength of McIlvaine’s 
buffer varies depending on pH resulting in a difference in the ionic strength of the incubation 
mixtures at pH 3.6 and pH 6.0 by a factor of approximately 1.8. 
The ionic strength of the standard incubation mixture of the colorimetric assay (mixture 6-V, 
cf. 6.2.2.1) was calculated by two methods: a) taking into account the activity coefficients 
estimated according to the extended Debye-Hückel equation (pH 3.6: I = 0.105 M; pH 6.0:     
I = 0.195 M) and b) without consideration of the activity coefficients (pH 3.6: I = 0.102 M;    
pH 6.0: I = 0.178 M). Comparison of the results showed that at pH 3.6 almost identical values 
of I were obtained by both methods, whereas at pH 6.0 the calculated value of I was about   
10 % higher when taking the activity coefficients into account compared to the value obtained 
by the calculation disregarding the activity coefficients. 
To ensure that the activity maxima obtained for BTH in the different assays really reflect the 
effect of pH and are not caused by differences in the ionic strength of the incubation mixtures, 
enzyme activity was determined at pH 3.6 and pH 6.0 in mixtures of constant ionic strength, 
which were prepared by raising the ionic strength of the pH 3.6-mixture to that of the  
pH 6.0-mixture by the addition of NaCl. Since the standard incubation mixture (mixture 6-V) 
already contains a relatively high concentration of NaCl (44 mM), it was decided to use an 
incubation mixture with a lower concentration of NaCl (22 mM; mixture 6-III) for the 
correction of I. For this mixture (incubation mixture 6-III) the values of I, calculated without 
consideration of the activity coefficients, are 0.080 M (pH 3.6) and 0.156 M (pH 6.0), 
respectively (cf. 6.2.3).  
Indeed, the activity as measured by the colorimetric method after the incubation of 
Neopermease® (10 and 20 units#, respectively) in the mixture which was corrected for ionic 
strength was 25 % (20 units#) - 30 % (10 units#) lower compared to the value obtained with 
the uncorrected mixture at pH 3.6 under otherwise identical conditions (Fig. 6-2). However, 
although the difference between the activity at pH 3.6 and pH 6.0 was found to be less 
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pronounced than observed without correction for ionic strength, Neopermease® still showed 
higher activity at pH 3.6 compared to pH 6.0. 
 
Fig. 6-2: Effect of pH on the activity of Neopermease® in the colorimetric assay using incubation 
mixtures of constant ionic strength. 50 µl of enzyme solution (10 and 20 units#, respectively) were 
incubated with incubation mixture 6-III (pH 6.0, I = 0.156 M) and incubation mixture 6-IV (pH 3.6,  
I = 0.156 M) for 1 h at 37 °C. For comparison the activity obtained at pH 3.6 without correction for 
ionic strength is shown (I = 0.08 M, incubation mixture 6-III, pH 3.6). 
Interestingly, the difference in the activities at pH 3.6 and pH 6.0 was less pronounced in case 
of incubation with 10 units# than in case of incubation with 20 units# of Neopermease®. This 
finding may be explained by the transglycosylase activity of Neopermease®, which is 
favoured at pH 6.0 (Saitoh et al., 1995) and may occur to a higher extent in the incubation 
mixture containing 20 units# of enzyme due to the fact that in this mixture a higher amount of 
low MW substrate being susceptible to the transglycosylation reaction is produced within the 
given incubation time (1h). 
The effect of pH on the activity of Neopermease® in incubation mixtures of constant ionic 
strength measured by the turbidimetric method is presented in figure 6-3. Like in the 
colorimetric assay a significant decrease (34 %) in activity was observed in the incubation 
mixture which was corrected for ionic strength compared to the uncorrected mixture at pH 
3.6. The difference between the activity at pH 3.6 and the activity maximum of the 
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turbidimetric assay at pH 6.0 was thus even more pronounced when using incubation mixtures 
of constant ionic strength.  
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Fig. 6-3: Effect of pH on the activity of Neopermease® in the turbidimetric assay using incubation 
mixtures of constant ionic strength. 50 µl of enzyme solution (1.5 units#) were incubated with 
incubation mixture 6-VI (pH 6.0, I = 0.156 M) and incubation mixture 6-VII (pH 3.6, I = 0.156 M) for 
1 h at 37 °C. For comparison the activity obtained at pH 3.6 without correction for ionic strength is 
shown (I = 0.08 M, incubation mixture 6-VI, pH 3.6). 
Taken together, the results of the colorimetric and the turbidimetric assay demonstrate that the 
correction for the ionic strength of the incubation mixtures at pH 3.6 and 6.0 did not alter the 
activity optima of Neopermease® in the respective assay but resulted in a quantitative change, 
insofar, as the activity optimum of the colorimetric assay at pH 3.6 was found to be less 
pronounced, while the activity optimum of the turbidimetric assay at pH 6.0 was found to be 
even more pronounced compared to the measurements in McIlvaine’s buffer without 
correction for ionic strength.  
This means that the activity maxima obtained for BTH in our preceding investigations 
qualitatively reflect the effect of pH on enzyme activity, although the effect of pH was 
superimposed by an effect caused by the different ionic strength in the incubation mixtures. 
                                                 
# as declared by the supplier 
pH-dependent differences in hyaluronate degradation by BTH 
 155
6.3.3 Anion exchange HPLC of hyaluronate depolymerisation mixtures  
6.3.3.1 Digestion of hyaluronate with Neopermease® 
From preceding experiments it was assumed that the discrepancies in the apparent activity of 
BTH, which were observed, when assaying the enzyme with the colorimetric and the 
turbidimetric method, might be ascribed to the pH related transglycosylase activity of BTH. 
To test this hypothesis, the composition of the oligosaccharide mixtures produced by the 
action of Neopermease® at various pH (using incubation mixtures analogous to those of the 
activity assays) was analysed by anion exchange HPLC according to the procedure described 
by Tawada et al. (2002). Using a linear phosphate gradient the even numbered negatively 
charged HA oligosaccharides were eluted from the column in the order of increasing chain 
length as shown by MALDI-MS (cf. 6.3.4). Figures 6-4 and 6-5 show the separation of the 
mixtures obtained after incubation at pH 3.6 (Fig. 6-4) and pH 6.0 (Fig. 6-5) for 1 h (B) and 
16.5 h (C), respectively.  
Comparison of the 1 h digests clearly shows that HA degradation at pH 3.6 yielded a 
considerably higher amount of low molecular HA oligosaccharides (peaks 2, 3, 4) than 
incubation at pH 6.0. This observation is in agreement with the results of the colorimetric 
assay, in which a higher amount of reducing NAG end groups was detected after incubation at 
pH 3.6 compared to pH 6.0. On the other hand the peaks which were detected in the  
pH 6.0-1 h digestion mixture at retention times up to 30 min, i.e. corresponding to HA 
fragments with a molecular mass up to 6 kDa (15 disaccharide units), indicate that that the 
high molecular HA was degraded to a mixture of HA fragments being too short to precipitate 
with CTAB. This provides an explanation for the high apparent activity of Neopermease® at 
pH 6.0 in the turbidimetric assay.  
Analysis of the 16.5 h digestion mixtures revealed an increase in the low molecular weight 
oligosaccharides associated with a decrease in the oligosaccharides of higher molecular 
weight compared to the 1 h digests, both at pH 3.6 and pH 6.0. The digest at pH 3.6  
(Fig. 6-4C) contained a mixture of only four different oligosaccharides with the tetra 2 - and 
the hexasaccharide 3 as the main digestion products accompanied by a small amount of the 
octasaccharide 4 and the disaccharide 1. 
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Fig. 6-4: Anion exchange HPLC chromatograms of hyaluronate (HA) oligosaccharides produced by 
the digestion of HA with Neopermease® at pH 3.6 for 1 h (B) and 16.5 h (C), respectively. A: without 
enzyme. Separation was performed on stationary phase 1 (Luna-NH2) as described in the materials and 
methods section (cf. 6.2.4.1). The injection volume was 10 µl. 1 = HA disaccharide: βGlcUA1-
3βGlcNAc; 2 = HA tetrasaccharide: (βGlcUA1-3βGlcNAc1-4)2; 3 = HA hexasaccharide: (βGlcUA1-
3βGlcNAc1-4)3; 4 = HA octasaccharide: (βGlcUA1-3βGlcNAc1-4)4. Peaks 2-4 were collected and 
assigned to the respective HA oligosaccharides by mass spectrometry (cf. 6.3.4). Peak 1 was identified 
by comparison with the chromatogram of unsaturated HA disaccharide (?4,5GlcUA1-3βGlcNAc) 
obtained after exhaustive digestion of HA by bacterial hyaluronate lyase (cf. chapter 7). 
pH-dependent differences in hyaluronate degradation by BTH 
 157
1
2
3
4
3 42
retention time [min]
0 10 20 30 40
ab
so
rb
an
ce
 [V
]
0,0
0,1
0,2
0,3
0,4
A: without enzyme
B: 1 h digest
C: 16.5 h digest
 
Fig. 6-5: Anion exchange HPLC chromatograms of hyaluronate (HA) oligosaccharides produced by 
the digestion of HA with Neopermease® at pH 6.0 for 1h (B) and 16.5 h (C), respectively. A: without 
enzyme. For HPLC conditions and peak assignment confer to figure 6-4 (1 = HA disaccharide; 2 = 
HA tetrasaccharide; 3 = HA hexasaccharide; 4 = HA octasaccharide). 
In contrast to the tetra-, hexa- and octasaccharide, which were collected and characterised by 
MALDI-MS, peak 1 was identified by comparison with the chromatogram of an exhaustive 
digest of HA with hyaluronate lyase from Streptococcus agalactiae, which is known to yield 
unsaturated HA disaccharides as the final product (cf. chapter 7). Compared to the digest at 
pH 3.6 the oligosaccharide mixture obtained after an incubation period of 16.5 h at pH 6.0 
was much more heterogeneous (Fig. 6-5C). In addition to the peaks corresponding to 
oligosaccharides of higher molecular mass additional small peaks were detected at retention 
times between those of the even numbered oligosaccharides, and were not present in the 
chromatograms of digestion mixtures at pH 3.6.  
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So far it has not been reported in the literature that BTH catalyses the formation of odd 
numbered oligosaccharides during the hydrolysis of HA. However, the question arose, if the 
observed intermediate peaks resulted from odd numbered HA oligosaccharides, since the 
elution profiles of the digestion mixtures at pH 6.0 resembled those reported by Nebinger et 
al. (1983), who investigated the separation of even- and odd-numbered HA oligosaccharides 
by anion exchange HPLC. Mahoney et al. (2001) separated a product mixture obtained after 
digestion of HA with hyaluronidase from ovine testes and found a small amount of odd- 
numbered oligosaccharides, the formation of which they ascribed to the presence of a 
contaminating hydrolase in the ovine testicular hyluronidase preparation used. Unfortunately 
due to a limited column life span it was not possible to collect enough material for 
characterisation of the intermediate peaks eluted from the Luna-NH2 stationary phase, which 
was used for the separations depicted in figures 6-4 and 6-5. However, the identification of 
the intermediate peaks as odd-numbered HA oligosaccharides having glucuronic acid at the 
reducing end was successful after separation of pH 6.0-digestion mixtures on a different 
stationary phase (Sphereclone-NH2), which showed a slightly altered selectivity (cf. Fig. 6-9). 
The peak eluted in the void volume might thus be ascribed to the elution of free uncharged 
NAG. Investigations concerning the formation of the odd-numbered oligosaccharides, which 
might be formed during the 15 min boiling procedure performed to stop the enzymatic 
reaction, are subject of another section in this chapter (cf. 6.3.5). 
The chromatograms in figure 6-6 show the separation of the oligosaccharide mixtures 
obtained after exhaustive digestion (7 d) of HA with Neopermease® at varying pH (pH 3.6; 
5.0; 6.0). At all pH values the tetrasaccharide 2 was the main product. However, while at pH 
3.6 the substrate was degraded to the tetrasaccharide, hexasaccharide and a considerable 
amount of disaccharide, at pH 6.0 the digestion mixture still contained the octasaccharide and 
trace amounts of oligosaccharides of higher molecular mass. In addition, odd-numbered 
oligosaccharides and the presumptive free NAG (eluted in the void volume) were detected in 
the digest at pH 6.0 and to a lower extent also in the digest at pH 5.0. Analysis of the changes 
in the product spectrum from pH 3.6 over pH 5.0 to pH 6.0 revealed decreasing amounts of 
disaccharide associated with increasing amounts of hexasaccharide with increasing pH, 
whereas a maximum concentration of tetrasaccharide was found at pH 5.0.  
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Fig. 6-6: Effect of pH on the exhaustive digestion of hyaluronate (HA) by Neopermease®. Anion 
exchange HPLC chromatograms of the produced HA oligosaccharides. For HPLC conditions and peak 
assignment see figure 6-4 (1 = HA disaccharide; 2 = HA tetrasaccharide; 3 = HA hexasaccharide;  
4 = HA octasaccharide). 
These results most probably reflect the pH related transglycosylase activity of Neopermease® 
taking place under the weak acidic conditions at pH 6.0 but not at lower pH values and are 
thus in agreement with the results reported by Saitoh et al. (1995). This consistency could not 
be anticipated because of the different composition of the incubation buffer used in our 
experiments compared with that used by Saitoh and coworkers, concerning ionic strength and 
the presence of BSA.  
In summary, the analysis of the product mixtures obtained after time dependent HA digestion 
with Neopermease® at varying pH values demonstrates that the pH of the incubation medium 
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does not only affect the rate of hydrolysis but also the incidence of the transglycosylation 
reaction and, thus, the composition of the resulting mixture of oligosaccharides. The 
observation that the amount of low molecular mass oligosaccharides was rather low at pH 6.0 
after 1 h of incubation suggests that the transglycosylation reaction, involving low molecular 
mass oligosaccharides, makes only a minor contribution to the product spectrum at this stage 
of the reaction.  
The observed discrepancies in the apparent pH optima of BTH in the colorimetric assay  
(pH 3.6) on the one hand and in the turbidimetric (pH 6.0) and the viscosimetric assay (pH 
6.0) on the other hand are thus presumably not caused by the transglycosylation reaction. 
However, the different pH optima may be explained as follows: although HA chains with a 
molecular mass > 10 kDa were not detected by anion exchange HPLC as they were removed 
from the digestion mixtures by ultrafiltration prior to analysis, it is most probable that at pH 
3.6 oligosaccharides are preferentially generated in the presence of high molecular mass HA, 
resulting in the low activity detected in the turbidimetric and the viscosimetric assay at pH 
3.6. Provided that, in contrast to the hydrolysis at pH 3.6, at pH 6.0, the enzyme does not 
prefer small HA fragments, i.e. all types of molecules of the polydisperse substrate are 
processed to the same extent, the higher activity of BTH in the turbidimetric and the 
viscosimetric assay can be explained, regardless of the higher rate of NAG exposure at the 
reducing end (the activity criterion in the colorimetric assay) at pH 3.6. 
6.3.3.2 Digestion of hyaluronate with bee venom hyaluronidase (BVH) 
By analogy with the oligosaccharide mixtures obtained by the degradation of HA with 
Neopermease®, the digestion products resulting from incubation of HA with bee venom 
hyaluronidase (BVH) at varying pH were also separated by anion exchange HPLC to reveal 
possible differences in the degradation of HA by the two hyaluronidases, including the 
production of odd-numbered oligosaccharides. 
Figure 6-7A shows the chromatogram of a 16.5 h digest at pH 3.6 containing a mixture of di-, 
tetra-, hexa- and octasaccharides, which was in good agreement with the product mixture 
obtained with the bovine enzyme under the same conditions (Fig. 6-4C). By contrast at pH 6.0 
after an incubation time of 16.5 h the substrate was degraded to a considerably lesser extent 
by the bee venom hyaluronidase (Fig. 6-7B) than by the bovine enzyme (Fig. 6-5C), when 
using the same enzyme concentrations as at pH 3.6. This result was expected because of the 
low activity of BVH in the colorimetric, turbidimetric and viscosimetric assay. However, after 
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incubation for 62 h at pH 5.8 the product mixture formed by the action of BVH (Fig. 6-7C) 
was similar to that obtained by the exhaustive digestion of HA with Neopermease® at pH 6.0 
(Fig. 6-6). The odd-numbered oligosaccharides and the peak eluted in the void volume, the 
presumptive NAG, were also detected, indicating that the formation of these odd-numbered 
products was not specific for the action of BTH.  
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Fig. 6-7: Anion exchange HPLC chromatograms of hyaluronate (HA) oligosaccharides produced by 
the digestion of HA with bee venom hyluronidase under various conditions. A: pH 3.6, 16.5 h; B: pH 
6.0, 16.5 h; C: pH 5.8; 62 h. For HPLC conditions and peak assignment see figure 6-4 (1 = HA 
disaccharide; 2 = HA tetrasaccharide; 3 = HA hexasaccharide; 4 = HA octasaccharide). 
Except for the presence of the intermediate peaks the chromatogram of the 62 h digest at pH 
5.8 was very similar to that of the 16.5 h digest at pH 3.6 (Fig. 6-7A and C). However, as 
shown for Neopermease®, it can be assumed that the octasaccharide is further degraded by 
BVH at pH 3.6, too, when the incubation time is increased. Unfortunately we were not able to 
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further investigate the obtained product mixtures by exhaustive digestion of HA with BVH at 
varying pH, since the stationary phase of the Luna-NH2 column turned out to be unstable 
when exposed to the aqueous mobile phase of high ionic strength necessary for the elution of 
the negatively charged analytes. Therefore it is still unclear if BVH also catalyses pH related 
transglycosylation as demonstrated for the bovine enzyme.  
6.3.3.3 Digestion of hyaluronate from different sources 
Although the hyaluronate present in various mammalian tissues and bacteria has a uniform 
chemical structure (cf. chapter 1), the preparations of hyaluronate isolated from various 
sources may differ with respect to their molecular mass and may be contaminated by other 
glycosaminoglycans, for example chondroitin sulphate. The degradation of HA by BTH is 
affected by both the molecular mass of the substrate molecules, which may differ in their 
susceptibility to degradation by BTH, and the presence of chondroitin sulphate, which is also 
substrate for BTH (Meyer, 1971) and may act as a competitive inhibitor.  
Therefore it was investigated, if the product mixtures obtained by the BTH digestion of HA 
from different sources showed differences in oligosaccharide composition. Considering the 
fact that no reports concerning the formation of odd-numbered oligosaccharides by the 
digestion of HA with BTH and BVH exist in the literature so far it was of particular interest to 
find out, if odd-numbered oligosaccharides, which were found in the incubation mixtures after 
digestion of HA from S. zooepidemicus at pH 6.0, might be produced exclusively with the 
bacterial HA as substrate. Figures 6-8 and 6-9 show the chromatograms of the oligosaccharide 
mixtures obtained by the digestion of four different HA preparations with Neopermease® at 
pH 3.6 and pH 6.0, respectively, using the same incubation buffer as in the preceding 
experiments. The slight difference of the elution pattern compared to the former 
chromatograms results from the use of a new, slightly more hydrophilic stationary phase 
(Sphereclone-NH2), which was, according to the supplier, supposed to be more stable against 
the required mobile phase.  
Comparison of the product spectra obtained by the digestion of the different HA preparations 
at pH 3.6 and pH 6.0 revealed no differences for HA from S. zooepidemicus, rooster comb 
and human umbilical cord, whereas in the mixtures with HA from bovine trachea within the 
limits of detection no oligosaccharides were identified. The reason for the low activity of 
Neopermease® towards HA from bovine trachea was not further investigated. However, 
solutions of HA from bovine trachea showed much lower viscosity compared to solutions of 
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the other HA preparations of the same concentration, indicating a lower molecular mass of the 
HA from bovine trachea. The low activity may thus be explained by a low affinity of 
Neopermease® to the low molecular mass substrate.   
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Fig. 6-8: Anion exchange HPLC chromatograms of hyaluronate (HA) oligosaccharides produced by 
the digestion of HA from various sources with Neopermease® at pH 3.6 for 16.5 h. Separation was 
performed on stationary phase 2 (Sphereclone-NH2) as described in the materials and methods section 
(cf. 6.2.4.1). The injection volume was 30 µl. 1 = HA disaccharide; 2 = HA tetrasaccharide; 3 = HA 
hexasaccharide; 4 = HA octasaccharide. Peaks 2-4 were collected and assigned to the respective HA 
oligosaccharides by mass spectrometry (cf. 6.3.4), whereas peak 1 was identified by comparison with 
the chromatogram of unsaturated HA disaccharide obtained after exhaustive digestion of HA by 
bacterial hyaluronate lyase (cf. chapter 7). 
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Fig. 6-9: Anion exchange HPLC chromatograms of hyaluronate (HA) oligosaccharides produced by 
the digestion of HA from various sources with Neopermease® at pH 6.0 for 16.5 h. For HPLC 
conditions and peak assignment see figure 6-8. 1 = HA disaccharide; 2 = HA tetrasaccharide; 3 = HA 
hexasaccharide; 4 = HA octasaccharide; 5 = HA trisaccharide: βGlcUA1-3βGlcNAc1-4GlcUA; 6 = 
HA pentasaccharide: βGlcUA1-3(βGlcNAc1-4βGlcUA1-3)2; 7 = HA heptasaccharide: βGlcUA1-
3(βGlcNAc1-4βGlcUA1-3)3. 
As mentioned in section 6.3.3.1 the peaks (2-7) eluted from the Sphereclone-NH2 column 
were collected from several runs, pooled and characterised by mass spectroscopy (cf. 6.3.4). 
The small intermediate peaks were identified as odd-numbered oligosaccharides of HA, with 
glucuronic acid (GlcUA) at the reducing end. Due to their higher charge to mass ratios the 
odd-numbered oligosaccharides eluted shortly after the respective even-numbered 
oligosaccharide containing an additional N-acetylglucosamine (GlcNAc) at the reducing end, 
i.e. the trisaccharide 5 eluted shortly after the tetrasaccharide 2. The observed retention 
behaviour is in accordance with the results reported in the literature for the separation of even- 
and odd-numbered HA oligosaccharides by chromatography on different anion exchange 
columns (Nebinger et al., 1983; Mahoney et al., 2001). 
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6.3.4 Characterisation of the anion exchange HPLC fractions by mass 
spectrometry 
The assignment of the fractions collected from anion exchange HPLC to the respective HA 
oligosaccharides was accomplished by mass spectrometry. Prior to the analysis by ESI-MS 
and MALDI-TOF MS, phosphate was removed from the chromatography fractions by size 
exclusion chromatography on a Superdex Peptide column (cf. 6.2.4.2). The calculated 
monoisopotic masses of the HA oligosaccharides are given in table 6-1. 
Table 6-1: Calculated monoisotopic masses of hyaluronate oligosaccharides: 
 
 Molecular formula Monoisotopic mass [Da] 
HA trisaccharide 
βGlcUA1-3βGlcNAc1-4GlcUA 
 
C20H31NO18 
 
573.15 
HA tetrasaccharide 
(βGlcUA1-3βGlcNAc1-4)2 
 
C28H44N2O23 
 
776.23 
HA pentasaccharide 
βGlcUA1-3(βGlcNAc1-4βGlcUA1-3)2 
 
C34H52N2O29 
 
952.27 
HA hexasaccharide 
(βGlcUA1-3βGlcNAc1-4)3 
 
C42H65N3O34 
 
1155.34 
HA heptasccharide 
βGlcUA1-3(βGlcNAc1-4βGlcUA1-3)3 
 
C48H73N3O40 
 
1331.38 
HA octasaccharide 
(βGlcUA1-3βGlcNAc1-4)4 
 
C56H86N4O45 
 
1534.46 
 
Fig. 6-10 presents the negative-ion ESI-MS spectra of the peaks 2 and 5 from anion exchange 
HPLC, which were identified as the HA tetrasaccharide and the trisaccharide having 
glucuronic acid (GlcUA) at the nonreducing and the reducing end, respectively. The spectrum 
of the tetrasaccharide fraction (peak 2 from anion exchange HPLC), which proved to be quite 
pure, showed the mono- and the dianion as the main peaks and an additional minor peak, 
corresponding to the dianion plus Na+. Also in the spectrum of the trisaccharide fraction (peak 
5 from anion exchange HPLC) the trisaccharide was unambiguously identified by the 
presence of the peaks corresponding to the mono- and dianion and the corresponding Na+-
adduct. However, a number of additional peaks was present, two of which were assigned to 
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the dianion and the Na+-adduct of a 655 Da molecule, which was not further characterised. 
The impurities observed in the ESI-MS spectrum of the trisaccharide fraction might be 
ascribed to stationary phase material, which was dissolved in the mobile phase buffer and 
coeluted with the respective peak during anion exchange HPLC.  
 
 
 
 
 
Fig. 6-10: Negative ion ESI-MS spectra of (A) HA tetrasaccharide: C28H44N2O23, calculated 
monoisotopic mass (M) = 776.23 Da (peak 2 from anion exchange HPLC) and (B) *HA trisaccharide: 
C20H31NO18, M = 573.15 Da (peak 5 from anion exchange HPLC). 
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In a recent publication Prebyl and coworkers (Prebyl et al., 2003) investigated the 
fragmentation pattern of HA oligosaccharides during ESI-MS. By comparison of ESI-MS 
spectra with those obtained by MALDI-MS of the respective oligosaccharide samples they 
observed, depending on the cone voltage applied, the generation of odd-numbered 
oligosaccharides during ESI-MS of samples containing exclusively even-numbered 
oligosaccharides. To ascertain that our ESI-MS spectra reflect the masses of the 
oligosaccharides originally present in the respective fractions and not the masses of 
fragmentation products that might form during the electrospray process, the anion exchange 
HPLC fractions were additionally investigated by MALDI-MS, which has been proven to be a 
suitable and reliable method for the characterisation of HA oligosaccharides in the work of 
Prebyl et al. (2003). 
The MALDI-MS spectra, which were recorded in the positive ion mode, for peaks 2-7 from 
anion exchange HPLC are depicted in Fig. 6-11 (even-numbered oligosaccharides) and  
Fig. 6-12 (odd-numbered oligosaccharides), respectively. Analysis of the spectra revealed the 
derivative [M+Na]+ of the respective oligosaccharides as the predominant species 
accompanied by a number of Na+- and K+-adducts as indicated in detail for the tetrasaccharide 
(Fig. 6-11A) and trisaccharide (Fig. 6-12A) fraction. All of the oligosaccharide fractions 
collected from anion exchange HPLC were thus unambiguously identified. The results proved 
the presence of odd-numbered oligosaccharides, having reducing and nonreducing terminal 
GlcUA residues in the pH 6.0 digests of HA with Neopermease®. Since the formation of odd-
numbered oligosaccharides is not in agreement with the mechanism of action reported in the 
literature for BTH, it was assumed that the odd-numbered degradation products might be 
generated by a process independent of hyaluronidase. One possibility would be the presence 
of contaminating hydrolytic enzymes in the hyaluronidase preparation, as suggested by 
Mahoney et al., who observed odd-numbered oligosaccharides after digestion of HA with a 
preparation of hyaluronidase from ovine testes (Mahoney et al., 2001). However, we found 
odd-numbered oligosaccharides in mixtures digested with various hyaluronidase preparations 
(BTH, BVH), and a contamination of the different preparations with the same kind of 
hydrolase seems rather unlikely. We therefore investigated the possibility that the formation 
of odd-numbered products might occur during the 15 min boiling procedure performed with 
the digestion mixtures to stop the enzyme reaction at the end of the incubation period.  
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Fig. 6-11: Positive ion MALDI-TOF mass spectra of (A) HA tetrasaccharide: C28H44N2O23, calculated 
monoisotopic mass (M) = 776.23 Da (peak 2 from anion exchange HPLC), Inset: magnified view of 
the m/z-range 750-900, (B) HA hexasaccharide: C42H65N3O34, M = 1155.34 Da (peak 3 from anion 
exchange HPLC) and (C) HA octasaccharide: C56H86N4O45, M = 1534.46 Da (peak 4 from anion 
exchange HPLC). 
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Fig. 6-12: Positive ion MALDI-TOF mass spectra of (A) HA trisaccharide: C20H31NO18, calculated 
monoisotopic mass (M) = 573.15 Da (peak 5 from anion exchange HPLC), Inset: magnified view of 
the m/z-range 570-690, (B) HA pentasaccharide: C34H52N2O29, M = 952.27 Da (peak 6 from anion 
exchange HPLC) and (C) HA heptasaccharide: C48H73N3O40, M = 1331.38 Da (peak 7 from anion 
exchange HPLC).  
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6.3.5 Investigations on the effect of boiling on hyaluronate oligosaccharides 
6.3.5.1 Capillary electrophoresis (CE) of hyaluronate depolymerisation mixtures 
Anion exchange HPLC of the oligosaccharide mixtures produced by the enzymatic digestion 
of hyaluronate and subsequent characterisation of the individual oligosaccharide fractions by 
mass spectrometry revealed the presence of odd-numbered oligosaccharides having reducing 
and nonreducing terminal GlcUA residues in the pH 6.0 digests of HA with Neopermease®. 
Since the formation of odd-numbered oligosaccharides is not in agreement with the 
mechanism of HA degradation reported in the literature for BTH, in the following 
experiments it was investigated if the formation of the odd-numbered products might result 
from the 15 min boiling procedure performed at the end of the incubation period to stop the 
enzyme reaction. For this purpose digestion mixtures obtained by incubation of HA with 
Neopoermease® and subsequent removal of protein by ultrafiltration were compared with 
digestion mixtures obtained by incubation of HA with Neopoermease® under identical 
conditions and subsequent boiling for 15 min or 2 h before ultrafiltration. As the application 
of anion exchange HPLC was impractical due to the instability of the stationary phase 
(cf. 6.3.3), the comparative analysis of the oligosaccharide mixtures was carried out by 
capillary electrophoresis. Based on the protocol of Grimshaw et al. (1994) the CE analysis 
was performed in the normal polarity mode using an alkaline running buffer (phosphate-
borate buffer, pH 9). Under these conditions the negatively charged HA oligosaccharides are 
separated showing increasing migration times with increasing chain length (Carney and 
Osborne, 1991; Grimshaw et al., 1994; Grimshaw, 1997).  
Figure 6-13 shows the electropherograms of the oligosaccharide mixtures obtained by 28 h 
digestion of HA with Neopoermease® at pH 3.65. The digest was boiled for 2 h at the end of 
the incubation period (Fig. 6-13B), whereas in case of the digest shown in figure 6-13A the 
boiling procedure was omitted. Comparison of the electropherograms depicted in Fig. 6-13 A 
and B reveals no difference in the oligosaccharide composition of the digestion mixtures, thus 
indicating that no odd-numbered oligosaccharides were produced during the 2 h boiling 
procedure at pH 3.65. This result was expected, since also by anion exchange HPLC analysis 
the formation of odd-numbered degradation products was not observed in digestion mixtures 
at pH 3.6, which had been boiled for 15 min to stop the enzyme reaction.  
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Fig. 6-13: Electropherograms of hyaluronate (HA) oligosaccharides produced by the digestion of HA 
with Neopermease® at pH 3.65 for 28 h. A: the digest was ultrafiltrated (MWCO 10 kDa) immediately 
after the incubation period; B: the digest was boiled for 2 h prior to ultrafiltration. CE analysis was 
performed as described in the materials and methods section (cf. 6.2.4.5). The detector wavelength 
was 195 nm.  
The electropherograms of the oligosaccharide mixtures obtained by 28 h digestion of HA with 
Neopermease® at pH 5.8 are presented in figure 6-14. As in case of the digestion mixtures at 
pH 3.65, also at pH 5.8 no additional peaks were detected in the digest which was boiled for  
2 h at the end of the incubation period (Fig. 6-14B), compared to the digest which was not 
boiled prior to analysis (Fig. 6-14A). This indicates that the boiling procedure does not result 
in the formation of additional oligosaccharides. This in turn suggests that the presence of the 
odd-numbered oligosaccharides, which have been found in the digestion mixtures at pH 6.0 
by anion exchange HPLC (cf. Fig. 6-9), is not caused by the 15 min boiling procedure. 
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Fig. 6-14: Electropherograms of hyaluronate (HA) oligosaccharides produced by the digestion of HA 
with Neopermease® at pH 5.8 for 28 h. A: the digest was ultrafiltrated (MWCO 10 kDa) immediately 
after the incubation period; B: the digest was boiled for 2 h prior to ultrafiltration. CE analysis was 
performed as described in the materials and methods section (cf. 6.2.4.5). The detector wavelength 
was 195 nm.  
Anion exchange HPLC analysis of the product mixtures obtained by digestion of HA with 
Neopoermease® revealed at pH 6.0 the presence of a peak eluted in the void volume that was 
not observed at pH 3.6 and was assumed to result from free NAG.  
CE analysis of the digestion mixtures revealed the presence of a peak eluted near the 
electroosmotic flow (migration time t approx. 23.8 min) that might be ascribed to free NAG 
and is more pronounced at pH 5.8 (Fig. 6-14 A, B) than at pH 3.65 (Fig. 6-13 A, B). 
Furthermore, comparison of figures 6-14A and 6-14B shows, that the peak is remarkably 
higher in the digest after the 2 h boiling procedure. 
To investigate if this peak indeed results from free NAG the digestion mixtures were spiked 
with NAG and analysed by CE. The resulting electropherograms are shown in figure 6-15 
(pH 3.65) and figure 6-16 (pH 5.8), respectively.  
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Fig. 6-15: A, B: Magnified view of the electropherograms A and B of figure 6-13; C: electro-
pherogram of the same sample as in B, spiked with N-acetylglucosamine (NAG) (10 µl of NAG  
(2 mg/ml, dissolved in operating buffer) were added to 90 µl of the sample); D: electropherogram of 
NAG (2 mg/ml, dissolved in running buffer). CE analysis was performed as described in the materials 
and methods section (cf. 6.2.4.5). The detector wavelength was 195 nm.  
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Fig. 6-16: A, B: Magnified view of the electropherograms A and B of figure 6-14; C: electro-
pherogram of the same sample as in B, spiked with N-acetylglucosamine (NAG) (10 µl of NAG  
(2 mg/ml, dissolved in operating buffer) were added to 90 µl of the sample); D: electropherogram of 
NAG (2 mg/ml, dissolved in running buffer). CE analysis was performed as described in the materials 
and methods section (cf. 6.2.4.5). The detector wavelength was 195 nm.  
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The electropherograms clearly show that NAG did not coelute with any substance originally 
present in the digestion mixtures, indicating that the main peak of the digestion mixture at  
pH 5.8 after 2 h boiling does not result from NAG.  
When heated under alkaline conditions (pH 9; 100 °C) NAG residues at the reducing ends of 
HA fragments are removed from the HA chains according to the Morgan-Elson reaction 
yielding chromogens I and II (anhydro-NAG) (cf. Fig. 6-17). 
 
 
Fig. 6-17: Mechanism of the Morgan-Elson reaction, adapted from Muckenschnabel et al. (1998b). 
It can be speculated that also under the weak acidic conditions in the digestion mixture at  
pH 5.8 even-numbered HA oligosaccharides having NAG at the reducing end are cleaved 
during the boiling procedure yielding odd-numbered HA oligosaccharides having GlcUA at 
the reducing end and anhydro-NAG. The main peak of the digestion mixture at pH 5.8 after 2 
h boiling may thus be assigned to anhydro-NAG. However, further investigations are 
necessary to test this hypothesis. 
6.3.5.2  MALDI-TOF mass spectrometry of HA hexasaccharide 
HA hexasaccharide was obtained by digestion of HA with Neopermease® and subsequent 
separation of the produced mixture of oligosaccharides by size exclusion chromatography. 
Samples of the pure HA hexasaccharide, dissolved in Milli-Q water, were boiled for 15 min 
and then analysed by MALDI-TOF mass spectrometry with respect to the presence of 
potential degradation products which may have formed during the boiling procedure.  
Figure 6-18 shows the MALDI-TOF mass spectrum of HA hexasaccharide after the 15 min 
boiling procedure (Fig. 6-18B) in comparison with the spectrum of an untreated 
hexasaccharide sample (Fig. 6-18A) and the spectrum of the matrix (Fig. 6-18C).  
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Fig. 6-18: Positive ion MALDI-TOF mass spectra of (A) HA hexasaccharide: C42H65N3O34, calculated 
monoisotopic mass (M) = 1155.34 Da (solution A, cf. 6.2.4.4.2.2), (B) HA hexasaccharide after 
boiling for 15 min (solution A*, cf. 6.2.4.4.2.2). C: Positive ion MALDI-TOF mass spectrum of the 
matrix (DHB, M = 154.03). 
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Comparison of the spectra shows that no additional peaks were detected in the sample 
subjected to the 15 min boiling procedure compared to the untreated sample, indicating that 
the HA hexasaccharide was not degraded during the boiling procedure. The small peak at  
m/z = 975 might result from the Na+-adduct [M+Na]+ of HA pentasaccharide having GlcUA 
at the reducing end (M = 952). However, this peak is also present in the spectrum of the 
untreated hexasaccharide sample suggesting that the corresponding molecule did not result 
from the boiling process. 
Anion exchange HPLC analysis revealed the presence of odd-numbered oligosaccharides in 
incubation mixtures at pH 6.0 but not at pH 3.6 (cf. 6.3.3). The effect of boiling on HA 
hexasaccharide was therefore additionally investigated at various pH under the conditions 
prevalent in the incubation mixtures, which had been analysed by anion exchange HPLC. 
Hexasaccharide was dissolved in citrate-phosphate buffer (pH 3.6 or pH 6.0), containing 
NaCl and BSA, and MALDI-TOF mass spectra were recorded of samples after a 15 min 
boiling process and of samples left at room temperature. Like in the aforementioned 
experiment, where hexasaccharide was dissolved in Milli-Q water (cf. Fig. 6-18), no 
difference was observed between the spectra of the boiled and the untreated samples of HA 
hexasaccharide, dissolved in citrate-phosphate buffer at pH 3.6 or pH 6.0 (results not shown).  
Taken together, the results of the investigations performed to study the effect of boiling on 
oligosaccharides of HA (CE analysis of mixtures of HA oligosaccharides and MALDI-TOF 
MS analysis of HA hexasaccharide) do not confirm the hypothesis of Prebyl et al. (2003), 
who proposed that the presence of odd-numbered oligosaccharides in product mixtures 
obtained by BTH digestion of HA can be ascribed to the boiling procedure performed to stop 
the enzyme reaction.  
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6.3.6 NMR spectroscopy 
An additional approach to investigate the differences in the product mixtures derived from the 
digestion of hyaluronate (HA) with Neopermease® at different pH was made by means of 
NMR spectroscopy. Figure 6-20 shows the 1H NMR spectra obtained for hyaluronate 
exhaustively digested with Neopermease® at pH 3.8 and pH 6.0 using incubation mixtures 
analogous to those of the activity measurements, i.e. citrate-phosphate buffer containing NaCl 
and BSA. For NMR spectroscopy, after exhaustive digestion, the mixtures were lyophilised 
and redissolved in D2O.  
The peak assignment of the 1H spectra via the plots of 2D experiments (DQF COSY, ROESY, 
HMQC and HMBC) revealed that in both cases, i.e. at pH 3.8 and pH 6.0, the main product 
was the HA tetrasaccharide (Fig. 6-19) occurring at a ratio of the anomers of α : β ≈ 1.6 : 1. 
The spectra of the digests depicted in figure 6-20 were found to be in very good agreement 
with the NMR data (chemical shift, coupling constants) reported for hyaluronate 
tetrasaccharide dissolved in D2O by Toffanin et al. (1993). The results are thus in agreement 
with those obtained by anion exchange HPLC with respect to the main degradation product 
(cf. Fig. 6-6). However, the additional presence of minor amounts of di- and hexasaccharides 
at a different ratio depending on pH, which was observed in anion exchange HPLC, was not 
detected by the NMR measurements. This may be ascribed to the relatively low sensitivity of 
NMR spectroscopy and to the fact that buffer components (citrate, phosphate) may have 
interfered with the recording of highly resolved NMR spectra. 
In addition to the characterisation of the exhaustively digested incubation mixtures described 
above, efforts were made to elucidate pH related kinetic differences in the degradation of HA 
with Neopermease® by monitoring the product formation at pH 3.8 and pH 6.0 by NMR 
spectroscopy, i.e. after the addition of enzyme to the incubation mixture 1H NMR spectra 
were recorded at increasing reaction times. 
For the experiment at pH 6.0 the incubation conditions which had been elaborated in 
preliminary studies by viscosimetry (cf. chapter 5), were applied. However, although under 
these conditions the relative viscosity of the substrate solution had been reduced by about  
80 % after 60 min and 90 % after 150 min (cf. chapter 5, Fig. 5-19), product formation was 
not observed in the 1H NMR spectra even after an incubation time of 16 h. When raising the 
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enzyme concentration by a factor of 5 (13.3 units#/ml), product formation was detected by the 
appearance of the peaks corresponding to free anomeric protons (δ = 5.16 ppm; 4.73 ppm), 
however only to a small extent, which was not further increased even after prolonged 
incubation (91h, 187 h). Analysis of the obtained spectra with respect to the length of the 
produced oligosaccharides was not possible due to the overlaying peaks resulting from high 
molecular mass HA (results not shown). By further elevation of the enzyme concentration 
(26.27 units#/ml) spectra similar to those of the exhaustive digests were obtained after 60 h. 
However, during the digestion process the overlaying peaks of high molecular mass HA 
interfered with the identification of the digestion products.  
Similar observations were made in the course of the investigation of HA degradation at  
pH 3.8, which is described in detail in the materials and methods section (6.2.4.6.1.2). The 
use of high concentrations of enzyme and raising the incubation temperature from 21 °C to 37 
°C yielded spectra similar to those of the exhaustive digests after prolonged incubation times 
(results not shown). Since, like in case of the experiments at pH 6.0, described above, during 
the digestion process the peak assignment of the degradation products was impossible due to 
interfering peaks of high molecular mass HA, NMR spectroscopy was found to be an 
unsuitable method to monitor the action of hyaluronidase on HA.  
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Fig. 6-19: Structure of hyaluronate tetrasaccharide 
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Fig. 6-20: 600-MHz 1H NMR spectra of the product mixtures obtained by the digestion of hyaluronate 
(HA) with Neopermease® at pH 3.8 and pH 6.0 as described in the materials and methods section (see 
6.2.4.6.1.1). The main component was HA tetrasaccharide (ratio of the anomers α : β ≈ 1.6 : 1). The 
peaks were assigned according to figure 6-19. A: H-1 signals (anomer region); B (see following page): 
signals of H-2,3,4,5,6. 
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6.4 Conclusion 
The colorimetric determination of the activity of Neopermease® as a function of pH yielded 
identical pH activity profiles (maximum at pH 3.6) at various substrate (HA) concentrations, 
including the substrate concentration of the turbidimetric assay. Therefore, it can be ruled out 
that the discrepancy between the colorimetrically and the turbidimetrically (maximum at  
pH 6.0) determined pH activity curves of Neopermease® reported in the preceding chapter  
(cf. chapter 5, Fig. 5-10) originates from different HA concentrations in the incubation 
mixture. 
In addition, it was demonstrated that the activity maxima obtained for BTH in the different 
assays indeed reflect the effect of pH and are not caused by differences in the ionic strength of 
the incubation mixtures at varying pH. Adjusting the ionic strength at pH 3.6 to that at pH 6.0 
by NaCl supplementation of the buffers resulted in a decrease in the activity of Neopermease® 
at pH 3.6 in both assays. However, also at constant ionic strength activity was still higher at 
pH 3.6 compared to pH 6.0 in the colorimetric assay, whereas in the turbidimetric assay 
highest activity was measured at pH 6.0. 
To investigate, if the different pH activity profiles of BTH obtained by the colorimetric and 
the turbidimetric assay can be ascribed to the pH related transglycosylase activity of BTH, the 
composition of the oligosaccharide mixtures produced by the action of Neopermease® at 
varying pH was analysed by anion exchange HPLC. Indeed, the product mixtures obtained 
after exhaustive digestion of HA at varying pH indicated transglycosylase activity of 
Neopermease® at pH 6.0 but not at pH 3.6. However, analysis of the product mixtures 
obtained after HA digestion for 1 h revealed that the amount of low molecular mass 
oligosaccharides was rather low at pH 6.0. This suggests that the transglycosylation reaction 
involving low molecular mass oligosaccharides makes only a minor contribution to the 
product spectrum at this stage of the reaction and does, thus, presumably not account for the 
different pH optima of BTH in the colorimetric and the turbidimetric assay. However, 
comparison of the 1 h digests at various pH suggests that the pH optima of BTH in the various 
assays may be explained as follows:  
HA degradation at pH 3.6 yielded a considerably higher amount of short oligosaccharides 
than incubation at pH 6.0. This explains the pH profile obtained in the colorimetric assay, 
where a higher amount of reducing NAG end groups is detected after incubation at pH 3.6 
compared to pH 6.0. Although at pH 6.0 after 1 h of incubation the formation of short 
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oligosaccharides was relatively low, the anion exchange HPLC analysis indicates that HA is 
degraded to HA fragments which are not precipitated in the turbidimetric assay. Assuming 
that at pH 3.6 oligosaccharides are preferentially generated in the presence of high molecular 
mass HA, whereas at pH 6.0 all types of molecules of the polydisperse substrate are processed 
to the same extent, the higher activity detected in the turbidimetric assay and also in the 
viscosimetric assay (cf. chapter 5) at pH 6.0 can be explained regardless of the higher rate of 
NAG formation detected in the colorimetric assay at pH 3.6.  
At pH 6.0 odd-numbered oligosaccharides having reducing and nonreducing terminal GlcUA 
residues were identified in the product mixtures obtained by the degradation of HA with 
Neopermease®. Since the formation of odd-numbered oligosaccharides is not in agreement 
with the mechanism of HA degradation reported in the literature for BTH it was investigated 
if the odd-numbered products might be formed during the 15 min boiling procedure 
performed at the end of the incubation period to stop the enzyme reaction, as proposed by 
Prebyl et al. (2003). However, this assumption could not be confirmed.  
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7 Investigations on hyaluronate degradation by hyaluronate lyase 
from Streptococcus agalactiae  
7.1 Introduction 
Streptococcus agalactiae is a human pathogenic bacterium, which is one of the major causes 
of meningitis and septicemia, often leading to death in neonates (Dillon et al., 1987; Baker 
and Edwards, 1988). A major virulence factor of S. agalactiae is hyaluronate lyase, which 
breaks down the biophysical barrier of the host connective tissue by degrading the hyaluronic 
acid of the extracellular matrix thereby facilitating the invasion and the spreading of the 
bacteria and the associated toxins (Li and Jedrzejas, 2001). In recent years the search for 
potent inhibitors of hyaluronate lyase, which could be useful tools in studying the role of 
hyaluronan and hyaluronidases in bacterial infections and may be promising agents with 
respect to the investigation of a novel auxiliary antibacterial therapy, was started (Salmen, 
2003; Botzki, 2004; Botzki et al., 2004). 
In the course of the characterisation of inhibitors of hyaluronate lyase from S. agalactiae with 
respect to their activity at different pH values it turned out that in many cases lower IC50 
values were obtained at physiological pH (pH 7.4) compared to pH 5.0, where the enzyme 
shows maximum activity (Salmen, 2003). Motivated by this observation the present study was 
carried out to find out, if the pH dependency of the inhibitory activity can be ascribed to a 
different affinity of the enzyme to the substrate depending on pH. The degradation of 
hyaluronan by S. agalactiae hyaluronate lyase was therefore investigated with respect to the 
effect of pH on the kinetic parameters Vmax and Km. 
As described in detail in chapter 1, hyaluronate lyase from S. agalactiae is supposed to 
degrade the polymeric substrate via a processive mode of action. In brief, the enzyme 
randomly binds to a hyaluronate molecule and cleaves it into two pieces by β-elimination. 
After this initial endolytic cleavage one of the two generated hyaluronan fragments is released 
from the enzyme and may serve as substrate for another enzymatic attack, whereas the other 
fragment remains a the binding site of the enzyme to be processively degraded to unsaturated 
disaccharides (Baker and Pritchard, 2000; Li and Jedrzejas, 2001).  
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In ordinary enzyme catalysed reactions the enzyme E binds to the substrate S, forming an 
enzyme substrate complex ES, and the substrate is converted in the following step into a 
product P, which is finally released from the enzyme, as shown by equation 7-1. In this case 
the kinetic parameters Vmax and Km can be derived from the experimentally determined initial 
rates of product formation v0 at various concentrations of substrate according to the Michaelis 
Menten equation (eq. 7-2). 
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Hyaluronate degradation by S. agalactiae hyaluronate lyase, involving an initial endolytic 
cleavage followed by rapid and processive release of unsaturated disaccharide, differs from 
the common mechanism underlying the Michaelis Menten equation, since the substrate 
remains at the enzyme during the processive release of unsaturated disaccharide products. To 
check the validity for the estimation of the kinetic parameters Vmax and Km of the Michaelis 
Menten formalism from a set of initial rates of product formation measured at various 
substrate concentrations it was demonstrated by theoretical considerations that hyaluronate 
degradation by S. agalactiae hyaluronate lyase obeys Michaelis Menten kinetics, regardless 
of the processive character of the exolytic cleavage of the substrate.  
In preliminary studies the product mixtures resulting from partial and exhaustive digestion of 
HA by hyaluronate lyase from S. agalactiae were analysed by anion exchange HPLC and 
NMR spectroscopy to confirm the aforementioned processive mode of action. 
 
ES E + PEPE + S (eq. 7-1) 
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7.2 Materials and methods 
7.2.1 Chemicals 
Stabilised hyaluronate lyase, i.e. 200 000 units# of lyophilised hyaluronidase (0.572 mg) from 
Streptococcus agalactiae, strain 4755, plus 2.2 mg BSA and 37 mg Tris-HCl per vial, was 
kindly provided by id-pharma GmbH (Jena, Germany). Hyaluronic acid (HA) from 
Streptococcus zooepidemicus was purchased from Aqua Biochem GmbH (Dessau, Germany). 
Bovine serum albumin (BSA) was from Serva (Heidelberg, Germany). Deuteriumoxide (D2O, 
isotopic enrichment 99.98 %) was purchased from Deutero GmbH (Kastellaun, Germany). All 
other chemicals were of analytical grade and were obtained from Merck (Darmstadt, 
Germany). Water was purified by a Milli-Q system (Millipore, Eschborn, Germany). 
7.2.2 Separation of hyaluronate oligosaccharides by anion exchange HPLC 
7.2.2.1 Digestion of hyaluronate  
For the subsequent analysis of the degradation products by anion exchange HPLC digestion 
of hyaluronate with S. agalactiae hyaluronate lyase was carried out under the same incubation 
conditions as used in case of the analogous experiments with hyaluronidases from bovine 
testes and bee venom, respectively, which are described in chapter 6. The incubation mixture 
(incubation mixture 7-I) consisted of 100 µl of citrate-phosphate buffer, pH 5.0 (solution A: 
0.2 M Na2HPO4/0.1M NaCl, solution B: 0.1 M citric acid/0.1 M NaCl; solutions A and B 
were mixed in appropriate portions to adjust the required pH), 150 µl of substrate (5 mg HA 
from S. zooepidemicus per ml of water), 50 µl of BSA (0.2 mg BSA per ml of water: solution 
1) and 100 µl of water. 400 µl of incubation mixture 7-I were incubated with 50 µl of enzyme 
(S. agalactiae hyaluronate lyase: 5 units#, dissolved in BSA (solution 1)) at 37 °C for 1 h and 
16.5 h, respectively. The enzyme reaction was stopped by heating at 100 °C for 15 min. 
Protein was removed from the mixtures by ultrafiltration (Nanosep® 10 K centrifugal device, 
Pall Life Sciences, New York, USA). In addition, a reference mixture, consisting of 
incubation mixture 7-I plus 50 µl of BSA (solution 1) instead of enzyme, was prepared and 
treated in the same way as described for the digestion mixture. 
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7.2.2.2 Instrumentation 
HPLC analysis was performed with the equipment specified in the materials and methods 
section of chapter 6 (see 6.2.4.1.2). As stationary phase the Luna 3µ NH2 (150 x 3.0 mm i.d.) 
column equipped with a security guard cartridge (NH2, 4 x 2.0 mm i.d.) was used 
(Phenomenex, Aschaffenburg, Germany).  
7.2.2.3 HPLC conditions 
The separation of the hyaluronate oligosaccharides was performed by the application of a 
linear phosphate gradient (16 - 800 mM NaH2PO4) at 40 °C according to the method 
described for the Luna-NH2 stationary phase in the materials and method section of chapter 6 
(see 6.2.4.1.3). Detection was carried out at 205 nm and 232 nm, respectively.  
7.2.3 Analysis of hyaluronate degradation products by NMR spectroscopy 
7.2.3.1 Digestion of hyaluronate 
7.2.3.1.1  Exhaustive digestion  
For the characterisation of the final degradation products by means of NMR spectroscopy HA 
was exhaustively digested with S. agalactiae hyaluronate lyase. The incubation mixture 
(incubation mixture 7-II) consisted of ammonium acetate buffer (0.2 M; pH 5.6), containing 
1.67 mg/ml of HA from S. zooepidemicus and 0.04 mg/ml of BSA. 30 ml of incubation 
mixture 7-II were incubated with 20 units# of hyaluronate lyase (dissolved in solution 1). 
After incubation for 5 days at room temperature the mixture was lyophilised. For NMR 
analysis 26.7 mg of the lyophilised sample were dissolved in 0.6 ml of D2O.  
7.2.3.1.2 Incubation conditions for monitoring the digestion by NMR spectroscopy 
To investigate product formation during HA degradation with S. agalactiae hyaluronate lyase 
the changes in the digestion mixture were monitored by NMR spectroscopy. The digestion 
was performed under the conditions, which had been investigated in preliminary studies by 
viscosimetry (see chapter 5). The incubation mixture (incubation mixture 7-III) was prepared 
as follows: 10 mg of substrate (HA from S. zooepidemicus) were dissolved in 6 ml of 0.133 M 
phosphate buffer (pH 6) containing 0.044 mg/ml BSA (140.93 mg NaH2PO4, 22.73 mg 
Na2HPO4 and 0.44 mg BSA per 10 ml of D2O). To 700 µl of incubation mixture 7-III 10 µl of 
                                                 
# according to the declaration of the supplier 
Hyaluronate degradation by hyaluronate lyase from S. agalactiae  
 191
internal standard solution (50 mg of TSP (3-(trimethylsilyl)-propionic acid-2,2,3,3-d4 sodium 
salt) per ml of D2O) were added, and a reference spectrum of the undigested incubation 
mixture was recorded. At t = 0 the enzyme (50 µl, 0.5 units#, dissolved in solution 1) was 
added to the mixture directly into the NMR tube and after thorough mixing spectra were 
recorded at increasing reaction times (t = 6 min - 7 h, at intervals of 10 min within the first  
3 hours and 60 min, respectively). Additional spectra were acquired at t = 24 h and t = 4 d. 
7.2.3.2 NMR spectroscopy 
Measurements were performed on a Bruker Avance 400 spectrometer, operating at 400.13 
MHz for 1H (Bruker Biospin GmbH, Rheinstetten, Germany). All spectra were recorded at 
294 K and the intense water signal was suppressed by the application of presaturation on the 
water resonance frequency. Chemical shifts were referenced to internal TSP. The peak 
assignment of the 1H spectrum of the exhaustive digest was made via the plots obtained from 
2D experiments, i.e. double quantum filter correlation spectroscopy (DQF COSY) and 
rotating frame nuclear overhouser effect spectroscopy (ROESY).  
7.2.4 Determination of hyaluronidase activity by UV spectroscopy 
The activity of S. agalactiae hyaluronate lyase was determined by quantifying the unsaturated 
degradation product 2-acetamido-2-deoxy-3-O-(ß-D-gluco-4-enepyranosyluronic acid)-D-
glucose (?DiHA) photometrically at 232 nm according to Greiling (1957). The incubation 
mixture (incubation mixture 7-IV) consisted of 400 µl of citrate-phosphate buffer (pH 5 and 
pH 7.4, respectively, see 7.2.2.1), 100 µl of BSA (solution 1, see 7.2.2.1) and    300 µl of 
substrate (varying concentrations of HA from S. zooepidemicus dissolved in H2O). HA 
solutions of varying concentrations in the range from 0.1 to 6 mg/ml were prepared by 
dilution of a stock solution (6 mg/ml). The measurements were performed as described in the 
materials and methods section of chapter 4 (see 4.2.2.2) with a Cary 100 spectrophotometer 
(Varian, Darmstadt, Germany). Instead of tandem cuvettes a set of matched cuvettes (Semi-
Micro Cells, Hellma®, No. 104-QS, Müllheim, Germany) with pathlength a l = 10 mm were 
used. The reference cuvette contained incubation mixture 7-IV and 100 µl of BSA (solution 
1). The amount of enzyme used is given in the results section in the context with the 
respective experiments. 
                                                 
# according to the declaration of the supplier 
Hyaluronate degradation by hyaluronate lyase from S. agalactiae  
 192
From the increase in absorbance (?A) at 232 nm per time (?t) the velocity of the enzymatic 
reaction was calculated according to the following equation:  
v [µmol · l-1 · min-1] = ?A / (?t  · ε  · l)    (eq. 7-3) 
where ε = 4550 l· mol-1· cm-1 (see 4.2.2.2). For the calculation of the specific activity of  
S. agalactiae hyaluronate lyase the amount of enzyme per vial, as indicated by the supplier, 
was used. 
7.3 Results and discussion 
7.3.1 Analysis of the products of hyaluronate digestion  
7.3.1.1 Anion exchange HPLC 
HA degradation by S. agalactiae hyaluronate lyase is reported in the literature to occur via a 
mechanism which involves an initial endolytic cleavage of a HA chain followed by rapid 
exolytic and processive release of unsaturated disaccharide (?DiHA) being the sole product 
(Pritchard et al., 1994; Baker and Pritchard, 2000; Li and Jedrzejas, 2001; Mello et al., 2002).  
To confirm that HA degradation by the S. agalactiae hyaluronate lyase preparation 
investigated in our laboratory is in agreement with the commonly assumed mechanism 
product mixtures resulting from partial and exhaustive digestion of HA were analysed by 
anion exchange HPLC by analogy to the analysis of the product mixtures obtained by HA 
digestion with hyaluronidases from bovine testes and bee venom, respectively (cf. to     
chapter 6). Separation of the exhaustively digested incubation mixture showed that HA was 
degraded to the disaccharide 1 as the only product (Fig. 7-1A). The disaccharide 1 was found 
to be the predominant product also after partial digestion. However, additional peaks 
corresponding to the tetra 2 - hexa 3 - and octasaccharide 4 were detected (Fig. 7-1B).  
Detection of the peaks at 232 nm (Fig. 7-2A) indicated that they correspond to the 
oligosaccharides having 4,5 - unsaturated glucuronic acid residues at their nonreducing ends 
resulting from the β-elimination catalysed by the bacterial hyaluronidases. Presuming a 
similar retention time for the saturated and unsaturated HA oligosaccharides the peaks in 
figures 7-1 and 7-2 were assigned according to the peaks in the chromatograms of the 
saturated oligosaccharides which have been identified by mass spectroscopy (cf. to chapter 6).  
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Fig. 7-1: Anion exchange HPLC chromatograms of hyaluronate (HA) oligosaccharides produced by 
the digestion of HA with S. agalactiae hyaluronate lyase at pH 5.0 for 16.5 h (A) and 1h (B), 
respectively. Separation was performed as described in the materials and method section. The 
injection volume was 10 µl and the detection wavelength was 205 nm. Inset: magnified view of lanes 
A and B; C: chromatogram of the reference mixture (see 7.2.2.1). 
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Fig. 7-2: Anion exchange HPLC of hyaluronate (HA) oligosaccharides produced by the digestion of 
HA with S. agalactiae hyaluronate lyase for 1h at pH 5.0. Separation was performed as described in 
the materials and method section. The injection volume was 10 µl. UV detection was carried out at 
232 nm (A) and 205 nm (B), respectively. Inset: magnified view of lanes A and B.  
By comparison of the peak areas detected at 232 nm (Fig. 7-2A) the relative amounts of the 
unsaturated oligosaccharides compared to ?DiHA in the incomplete digest were calculated 
as 56 % (tetrasaccharide), 13.7 % (hexasaccharide) and 6 % (octasaccharide), respectively.  
At first sight the presence of unsaturated oligosaccharides in addition to the disaccharide in 
the partial digest seems to disagree with a processive action pattern of S. agalactiae 
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hyaluronate lyase. According to this mechanism the digestion mixture is expected to contain 
only the processively released unsaturated disaccharides and HA chains of high molecular 
mass. However, the transient accumulation of unsaturated tetra- and hexasaccharides is 
consistent with the results of Baker and Pritchard (2000), who proposed the following 
mechanism for the degradation of hyaluronan by S. agalactiae hyaluronate lyase: after an 
initial random endolytic attack the enzyme remains at the substrate chain and processively 
releases unsaturated disaccharides until the chain is degraded to small oligosaccharides, which 
are released and finally cleaved endolytically and more slowly. 
Compared to the results of Baker and Pritchard (2000), who reported a maximum 
accumulation of unsaturated oligosaccharides of 2.5 % (relative to ?DiHA) in partially 
digested incubation mixtures, the amount of unsaturated oligosaccharides detected in the 1 h 
digest of our experiment was quite high (76 % relative to ?DiHA). This discrepancy may be 
explained by differences in the molecular mass and the polydispersity of the HA used as 
substrate and by a different ratio of enzyme to substrate in the incubation mixture. 
Considering that according to the described mechanism each initial endolytic cleavage leads 
to the release of a small unsaturated oligosaccharide, before this is finally cleaved into 
disaccharides, a higher ratio of enzyme to substrate, which is associated with an increased 
number of initial chain cleavages, would result in a higher transient accumulation of 
unsaturated oligosaccharides. However, this explanation remains speculative, since the 
digestion conditions used by Baker and Pritchard are not described in detail in their 
publication. In addition, unfortunately we were not able to further investigate the effect of 
varying enzyme concentrations on the accumulation of unsaturated oligosaccharides by anion 
exchange HPLC, since the stationary phase turned out to be unstable against the aqueous 
mobile phase of high ionic strength. The continuous decrease in column efficiency becomes 
obvious when comparing the chromatograms of Fig. 7-1B and Fig. 7-2B, which show the 
separation of the identical sample, applied onto a new column (Fig. 7-1) and reanalysed after 
about 100 working hours of the column (Fig. 7-2). 
The inset in Fig. 7-1 shows that in the 1 h digest in addition to the peaks of the even-
numbered oligosaccharides (1 – 4) small peaks (6; 7) were detected, which are not present in 
the reference mixture and the exhaustive digest. Taking the results of chapter 6 into account it 
is likely that the small peaks result from odd-numbered oligosaccharides, as shown for the 
intermediate peaks in the chromatograms of the oligosaccharide mixtures resulting from HA 
digestion with bovine testicular hyaluronidase (BTH). The presence of odd-numbered 
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oligosaccharides in oligosaccharide mixtures derived from HA by hyaluronate lyase treatment 
has been reported by Price et al. (1997), too, who identified the odd-numbered products as 
oligosaccharides having 4,5-unsaturated glucuronic acid at the nonreducing and glucuronic 
acid at the reducing end. This structure is in agreement with the odd-numbered 
oligosaccharides found in the BTH digests (saturated glucuronic acid at the nonreducing and 
the reducing end). However, due to the limited column life we were not able to collect enough 
material to characterise the intermediate peaks of the hyaluronate lyase digest.  
The absence of peaks 6 and 7 in the mixture which had been exhaustively digested to ?DiHA 
indicates that the odd-numbered products might have formed from an even-numbered 
oligosaccharide by the loss of one sugar unit presumably during the 15 min boiling procedure 
performed to stop the enzymatic reaction. Provided that the odd-numbered oligosaccharides 
contain glucuronic acid at the reducing end, as reported by Price et al. (1997), the peak eluted 
with the void volume of the column (5) could be assigned to free NAG. However, a 
compound is co-eluted, which is also detected at 232 nm (Fig. 7-2A), indicating that it 
contains a chromophore, like the 4,5-unsaturated glucuronic acid, the putative cleavage 
product of ?DiHA. Considering that glucuronic acid contains a negatively charged carboxyl 
group whereas NAG is uncharged under the conditions of the described anion exchange 
HPLC analyses (pH 4.6) it is unlikely that the two compounds are eluted at the same time. 
Thus, the identification of peak 5 and the correct assignment of peaks 6 and 7 require further 
investigation.  
7.3.1.2 NMR spectroscopy 
An additional approach to investigate product formation during HA degradation with S. 
agalactiae hyaluronate lyase was made by NMR spectroscopy. Figure 7-4 shows an 1H NMR 
spectrum of the product mixture obtained by HA digestion which has been allowed to proceed 
to completion. Assignment of the peaks via the plots of 2D spectra (DQF COSY, ROESY) 
revealed the 4,5-unsaturated hyaluronate disaccharide (?DiHA, see Fig. 7-3), occurring at a 
ratio of the anomers of α : β ≈ 2 : 1, as the sole product of exhaustive digestion (see table 7-1) 
and thus confirmed the results of anion exchange HPLC (see Fig. 7-1A). Similar 1H NMR 
spectra are also reported for HA after digestion with a hyaluronate lyase from S. intermedius 
(Homer et al., 1994). 
To further elucidate the mechanism of HA degradation by hyaluronate lyase from S. 
agalactiae with respect to the transient accumulation of unsaturated oligosaccharides in the 
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digestion mixture, as reported by Baker and Pritchard (2000), and as observed in the course of 
our investigations by anion exchange chromatography (see Fig. 7-1B), an attempt was made 
to monitor product formation by NMR spectroscopy. So after the addition of enzyme to the 
incubation mixture 1H NMR spectra were recorded at increasing reaction times. 
For this purpose incubation conditions which had been investigated in preliminary 
viscosimetric studies (cf. to chapter 5) were applied. After a reaction time of 16 min product 
formation was detected by the appearance of the signals characteristic for the 4-position 
olefinic proton of 4,5-unsaturated hyaluronate derived oligosaccharides (δ = 5.87 ppm) and 
the signals corresponding to the free anomeric protons (δ = 5.17 ppm; 4.77 ppm; results not 
shown). The observation that the signals corresponding to the free anomeric protons of the  
α-anomer occurred earlier than the respective signals of the β-anomer was surprising, since 
the anomeric configuration of the NAG residue is known to be retained during the cleavage of 
the β-1,4 glycosidic bond by the β-elimination process, which is catalysed by S. agalactiae 
hyaluronate lyase (Jedrzejas, 2000). However, it may be explained by a fast achievement of 
the mutarotation equilibrium (α : β ≈ 2 : 1). 
With increasing reaction time additional signals corresponding to 1H resonances of ?DiHA 
emerged due to a decrease of the signals resulting from high molecular mass HA. The final 
spectrum, which was recorded after a reaction time of 4 days, resembled the spectrum of the 
exhaustive digest which has been shown to contain ?DiHA as the sole product (Fig. 7-4). 
However, a transient accumulation of hyaluronate degradation products other than the 
?DiHA, as it had been found by anion exchange HPLC, was not observed in the 1H NMR 
spectra in the course of the reaction. The absence of signals corresponding to unsaturated HA 
oligosaccharides may be explained by the relatively low sensitivity of NMR spectroscopy. In 
view of the fact that the ratio of enzyme to substrate was relatively low in the NMR 
incubation mixture (0.4 units# per mg of HA) compared to the mixture which had been 
analysed by anion exchange chromatography (6.65 units# per mg of HA), it is conceivable 
that also the amount of transiently released unsaturated oligosaccharides was lower than that 
determined by anion exchange HPLC. According to the degradation mechanism discussed in 
the preceding section (7.3.1.1) a lower enzyme to substrate ratio is accompanied by a 
decreased number of initial chain cleavages and thus a decreased transient release of 
unsaturated oligosaccharides. Further investigations using varying enzyme concentrations 
would be necessary to support this hypothesis. However, due to the relatively low sensitivity 
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of the method and the fact that during the course of the digestion overlaying signals of high 
molecular HA would interfere with peak assignment of the produced HA oligosaccharides, no 
further studies were carried out by NMR spectroscopy.  
 
 
 
Fig. 7-3: Structure of the 4,5-unsaturated hyaluronate disaccharide (?DiHA). 
 
 
Table 7-1: Chemical shifts (δ in ppm) of the 1H resonances of ?DiHA in D2O. 
1H positiona δ in ppm  1H positiona δ in ppm 
a/a’ β - anomer  α - anomer  b/b’ β - anomer  α - anomer 
1  4.77  5.17  1  5.20 5.18 
2  3.80 – 3.84  4.02  2  3.77 
3  3.80 – 3.84  4.00  3  4.16 
4  3.52 3.55  4  5.87 
5  3.77 3.90    
6  ca. 3.7 – 3.9 ca. 3.8 – 3.9    
NHCOCH3 2.07    
a designated according to Fig. 7-3 
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7.3.2 Determination of the kinetic parameters Vmax  and Km 
7.3.2.1 Theoretical considerations 
For the determination of the kinetic parameters Vmax and Km the initial rates of product 
formation were determined at different substrate concentrations by measuring the increase in 
absorbance at 232 nm. To check if the experimental data can be interpreted according to the 
Michaelis Menten equation the mechanism of hyaluronate degradation by S. agalactiae 
hyaluronate lyase was expressed by the following set of equations: 
 
Equation 7-4 describes the binding of the enzyme E to high molecular mass hyaluronate S 
followed by the cleavage of the hyaluronate chain into a fragment S', which is released, and a 
fragment P0 which consists of n disaccharide units and remains at the binding site of the 
enzyme to be processively degraded to unsaturated disaccharides D. Equation 7-5 describes 
the formation of disaccharide, starting with a translocation step, in which the truncated 
hyaluronate chain in the enzyme substrate complex EP0 is moved by one disaccharide unit to 
yield the enzyme substrate complex EP0*, in which the substrate is placed in the right 
position, so that the following cleavage step results in the formation of an unsaturated 
disaccharide, which is released, and a hyaluronate fragment P1, which remains at the enzyme 
for the next round of catalysis (equation 7-6). Processive degradation of the enzyme bound 
substrate chain analogous to equations 7-5 and 7-6 occurs n-times until the whole chain is 
degraded. The final degradation product Pn is released from the enzyme, as indicated by 
equation 7-7. The enzyme is now available for the binding of new substrate (S or S', 
respectively). 
k1 
k-1 E + S ES EP
0 + S'
k2
k3 
k-3 EP
0 EP0*
k4
EP1 + D
k3 
k-3 EP
1 EP1*
k4
EP2 + D
k3 
k-3 EP
n-1 EPn-1*
k4
Pn + E + D
. 
. 
. 
(eq. 7-4) 
(eq. 7-5) 
(eq. 7-6) 
(eq. 7-7) 
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According to the mechanism described by equations 7-4 to 7-7 the changes in the 
concentrations of substrate (S; S'), product (D) and the different enzyme forms with time were 
derived: 
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Under steady state conditions the expressions for the rates of changing concentrations of the 
different enzyme forms become zero, yielding equations 7-17 to 7-20. 
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Expression of the different enzyme forms as a function of [ES] yields equations 7-21 to 7- 28. 
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(from eq. 7-17: substitution of [EP0*] according to eq. 7-18)  
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  (from eq. 7-19: substitution of [EPi*] according to eq. 7-20;  
  substitution of [EPi-1*] (= [EP0*]) according to eq. 7-22) 
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(from eq. 7-20: substitution of [EPi] according to eq. 7-23) 
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i = 2:  
43
43-22
kk
[ES])k(kk
][EP ⋅
+=  (eq. 7-25) 
  (from eq. 7-19: substitution of [EPi*] according to eq. 7-20;  
  substitution of [EPi-1*] (= [EP1*]) according to eq. 7-24) 
 
4
2*2
k
[ES]k][EP ⋅=  (eq. 7-26) 
(from eq. 7-20: substitution of [EPi] according to eq. 7-25) 
   
By analogy, the expressions for [EPi] and [EPi*] as a function of [ES] can be derived for i = 3        
to i = n-1, yielding the general expressions (eqs. 7-27 and 7-28). 
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With [EPi*] = [EP0*] (cf. eqs. 7-22 and 7-28) the rate equation for product formation  
(eq. 7-10) can be rewritten as follows: 
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The concentration of free enzyme E can be expressed as follows: 
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   (according to eqs. 7-27 and 7-28) 
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By combining eqs. 7-30 and 7-31, the concentration of the enzyme substrate complex can be 
expressed as a function of [ET] and [S]:   
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In the following, the terms 
1
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k
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3
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Multiplication of eq. 7-32 with (n ? k2) yields an expression for the rate of product formation 
as a function of [ET] and [S]:   
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Equation 7-33 is in agreement with the Michaelis Menten equation of the general form: 
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According to eq. 7-33, the kinetic parameters Vmax and Km of hyaluronate degradation by  
S. agalactiae hyaluronate lyase are given by the following expressions:  
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The term Km is used according to the simple operational definition of the Michaelis constant 
Km as the substrate concentration at which the reaction velocity is halfmaximal.  
 
The catalytic constant (turnover number) kcat is given by the following expression: 
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At substrate concentrations [S] <<< Km equation 7-2 reduces to a second order rate equation 
with the second order rate constant kcat/Km (specificity constant): 
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According to eqs. 7-35 and 7-36, for hyaluronate degradation by S. agalactiae hyaluronate 
lyase kcat/Km is given by the following expression: 
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The theoretical considerations concerning the mechanism of hyaluronate degradation by S. 
agalactiae hyaluronate lyase revealed that according to the Michaelis Menten theory the 
kinetic parameters Vmax and Km can be derived from the experimentally determined rates of 
product formation under steady state conditions (dD/dt = v0) at various concentrations of 
substrate. Since equation 7-33 was derived under the assumption of steady state conditions, its 
validity is warranted only in the steady state phase of the reaction. Concerning the duration of 
the steady state the investigated enzyme reaction shows an extraordinary property. In usual 
enzyme catalysed reactions, where a particular substrate is converted into a particular product, 
the reaction rate decreases as the substrate is consumed. The maintenance of the steady state 
is thus limited by the depletion of substrate. On the contrary, in case of the investigated 
degradation of hyaluronate the concentration of substrate remains constant, since the released 
cleavage product of the first step of the enzyme reaction (S', cf. equation 7-4) again serves as 
substrate for another enzymatic attack. 
]S'[[S]][Stotal +=  (eq. 7-39) 
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This constancy of the substrate concentration accounts for a prolonged maintenance of the 
steady state and thus of the linear part of the product versus time curve, even when low 
substrate concentrations are applied. As will be seen in the following chapter the prolonged 
linearity of the progress curve allows for the reliable determination of the steady state reaction 
rates (dD/dt = v0), which are used for the calculation of the kinetic parameters Vmax and Km. 
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7.3.2.2 Determination of v0 
The determination of the steady state rate (v0) of hyaluronate (HA) degradation by S. 
agalactiae hyaluronate lyase was carried out by monitoring the increase of the unsaturated 
degradation product (?DiHA) photometrically at 232 nm as described in the materials and 
methods section. 
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Fig. 7-5: Degradation of HA by S. agalactiae hyaluronate lyase, monitored at 232 nm (—). 100 µl of 
enzyme solution (2.5 units# and 0.83 units#, dissolved in BSA (solution 1)) were incubated with 800 µl 
of incubation mixture 7-IV (pH 5.0; c (HA): 0.67 mg/ml). The dashed lines indicate the slope of the 
linear part of the respective absorbance curve. Inset: magnified view of the initial part (t = 0-10 min) 
of figure 7-5; black curve: 100 µl of BSA (solution 1) were incubated with incubation mixture 7-IV. 
Figure 7-5 shows the kinetics of product formation obtained with two different concentrations 
of enzyme at a fixed concentration of substrate (0.67 mg/ml) under identical incubation 
conditions. For both enzyme concentrations a prolonged linear increase in absorbance is 
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observed which indicates a long-lasting maintenance of the steady state of the reaction. This 
is in agreement with the theoretical considerations outlined above. As expected, the rate of 
product formation (slope of the linear part of the curve) was found to be proportional to the 
enzyme concentration. The unexpected observation that the prolonged linear phase does not 
coincide with the initial phase of the respective progress curve (cf. inset of Fig. 7-5) was 
found to arise from the fact that at the initial stage of the reaction the increase in absorbance at 
232 nm due to the formation of ?DiHA is overlaid by an effect induced by BSA, contained 
in the enzyme solution as a stabiliser, causing a slight turbidity due to precipitation with HA 
(inset of Fig. 7-5, black line).  
Aiming at the determination of the kinetic parameters Vmax and Km a set of activity curves 
was recorded using various concentrations of substrate and the standard incubation mixture 
(see 7.2.4) at optimum pH for S. agalactiae hyaluronate lyase (pH 5). With 2.8 units#/ml an 
enzyme concentration was chosen, which ensured both access of the substrate and a 
measurable increase in absorbance at 232 nm also at low concentrations of the substrate. 
Assuming a molecular mass of 1.5 · 106 Da for hyaluronate (according to the declaration of 
the supplier) the lowest molar concentration of hyaluronate (0.133 mg/ml; 8.87 · 10-8 M), 
which was taken into account for the calculation of Vmax and Km, was by a factor of 1000 
higher compared to the enzyme (9.35 · 10-11 M).  
In figure 7-6 a selection of the recorded activity curves is presented. With decreasing 
concentrations of substrate an increase in the discrepancy between the slope of the initial part 
of the curve and the slope of the prolonged linear part is observed, since the rate of increase in 
absorbance at 232 nm due to product formation becomes relatively low compared to the 
unspecific effect of BSA.  
At first sight the observed bending of the activity curves seems to make the curves unusable 
for the determination of the kinetic constants of the enzyme reaction, since due to the 
interfering effect of BSA, it is impossible to determine the rate of product formation at the 
initial stage of the reaction at t = 0. However, figure 7-6 also shows that even at low 
hyaluronate concentrations the steady state (linear increase in product formation) is 
maintained during the recorded reaction time (10 and 15 min, respectively) - due to the 
extraordinary situation that in the course of the investigated enzyme reaction the 
concentration of substrate remains constant. The prolonged linearity allows for the reliable 
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determination of the steady state rate of product formation (v0), which is the required rate for 
deriving the kinetic parameters Vmax and Km according to the Michaelis Menten equation, by 
taking into account the slope of a later segment of the product formation curve (t > 5 min) and 
omitting the initial part, which is affected by the influence of BSA. 
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Fig. 7-6: Degradation of HA by S. agalactiae hyaluronate lyase, monitored at 232 nm (—). 100 µl of 
enzyme solution (2.5 units#, dissolved in BSA (solution 1)) were incubated with 800 µl of incubation 
mixture 7-IV (pH 5.0), containing various concentrations of HA. The dashed lines indicate the slope of 
the linear part of the respective absorbance curve. 
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7.3.2.3 Estimation of Vmax and Km  
hyaluronate [mg/ml]
0,0 0,5 1,0 1,5 2,0 2,5
v 0
 [µ
m
ol
· l-
1 ·
m
in
-1
]
0
2
4
6
8
10
Vmax: 10.2 µmol·l
-1·min-1
Km: 1.45 mg/ml
 
Fig. 7-7: Activity of S. agalactiae hyaluronate lyase as a function of the concentration of HA (at pH 
5.0). The rate of product formation was determined photometrically at 232 nm as indicated in figure  
7-6. The data (●) were fitted to the Michaelis Menten equation by nonlinear regression (R2 = 0.9993). 
The data for c(HA) < 0.1 mg/ml (●) were omitted from the fit due to a molar ratio of substrate to 
enzyme < 1000. 
To characterise the degradation of HA by S. agalactiae hyaluronate lyase with respect to Vmax 
and Km the kinetic parameters were estimated according to the Michaelis Menten equation 
(eq. 7-2) from a series of steady state reaction rates (v0) measured at various substrate 
concentrations as described in the preceding section. 
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⋅=     (eq. 7-2) 
In figure 7-7 v0 is plotted as a function of the substrate concentration. Fitting the data 
according to the Michaelis Menten equation by a nonlinear regression program (SigmaPlot) 
yielded values of 10.2 µmol · l-1 · min-1 for Vmax and 1.45 mg/ml for Km, respectively. The 
turnover number kcat was calculated according to eq. 7-36 yielding a value of 1.1·105 min-1. 
To ensure that the concentration of enzyme bound substrate [ES] can be disregarded 
compared to the concentration of free substrate [S], the data obtained with HA concentrations 
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< 0.1 mg/ml (molar ratio of substrate to enzyme < 1000) were excluded from the fitting 
process. 
The double reciprocal plot of the data according to equation 7-42 (obtained from eq. 7-2 by 
taking reciprocals of both sides) is presented in figure 7-8.  
[S]
1
V
K
V
1
v
1
max
m
max0
⋅+=    (eq. 7-42) 
As expected for a reaction that obeys Michaelis Menten kinetics the datapoints lie on a 
straight line with intercepts 1/Vmax on the 1/v0 axis and -1/Km on the 1/[S] axis. 
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Fig. 7-8: Double reciprocal (Lineweaver-Burk) plot of the data presented in figure 7-7 (●). The data 
were fitted to the reciprocal form of the Michaelis Menten equation (eq. 7-42) by unweighted linear 
regression (dashed line) and by weighted linear regression (solid line) using the weighting factor 
w(1/v0) = v04 as recommended by Cornish-Bowden (1995b, chapter 2). Inset: magnified view of the 
region of high substrate concentrations in figure 7-8. [S]: hyaluronate in mg/ml; v0 in µmol · l-1 · min-1; 
Fitting the data to eq. 7-42 by weighted linear regression using the weighting factor  
w(1/v0) = v04 as recommended by Cornish-Bowden (1995b, chapter 2) yielded values of  
10.2 µmol · l-1 · min-1 for Vmax and 1.44 mg/ml for Km, respectively, which are in very good 
agreement with the results estimated from the hyperbolic curve in figure 7-7. The line 
obtained by the weighted linear regression (Fig. 7-8, solid line) appears to the eye to fit rather 
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badly compared to the line obtained by unweighted linear regression (Fig. 7-8, dashed line). 
However, as discussed in detail by Cornish-Bowden (1995a; 1995b), the use of suitable 
weights provides results, which are more reliable compared to those obtained by unweighted 
linear regression, as it takes into account that for small values of v0 small errors in v0 lead to 
enormous errors in 1/v0, whereas for large values of v0 the same small errors in v0 lead to 
barely noticeable errors in 1/v0. Indeed, the values for Vmax (9.0 µmol · l-1 · min-1) and Km 
(1.19 mg/ml), which were estimated from the unweighted regression line, were found to 
deviate from the results of the hyperbolic plot (Fig. 7-7). 
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Fig. 7-9: Left: plot of the data presented in figure 7-7 (●) according to eq. 7-43 (Hanes plot). The data 
were fitted to eq. 7-43 by unweighted linear regression (dashed line) and by weighted linear regression 
(solid line) using the weighting factor w([S]/v0) = v04/[S]2 as recommended by Cornish-Bowden 
(1995b, chapter 2). Right: plot of the data presented in figure 7-7 (●) according to eq. 7-44 (Eadie-
Hofstee plot), fitted by linear regression (unweighted). 
Figure 7-9 shows two additional straight line plots of enzyme kinetic data according to the 
Michaelis Menten equation. In the Hanes plot [S]/v0 is plotted versus [S] according to eq.     
7-43 (obtained from eq. 7-42 by multiplying both sides by [S]) yielding a straight line with 
slope 1/Vmax and intercept -Km on the [S] axis.  
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m
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⋅+=    (eq. 7-43) 
As done in case of the Lineweaver Burk plot the datapoints of the Hanes plot were fitted to 
the underlying equation (eq. 7-43) according to the recommendations of Cornish-Bowden, i.e. 
by weighted linear regression using the weighting factor w([S]/v0) = v04/[S]2 (Cornish-
Bowden, 1995b, chapter 2). The obtained values for Vmax (10.2 µmol · min-1 · mg-1) and Km 
(1.44 mg/ml) were identical to those estimated from the double reciprocal plot. The 
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observation that in case of the Hanes plot there is only a minor deviation between the 
weighted (solid line) and the unweighted regression line (dashed line) shows that the errors in 
the quotient [S]/v0 provide a faithful reflection of those in v0 (Cornish-Bowden, 1995a). In 
this respect the Hanes plot provides an advantage over the double reciprocal plot, which, as 
aforementioned, gives a misleading impression of the experimental error. The kinetic 
parameters estimated from the unweighted regression line were Vmax = 9.9 µmol · l-1 · min-1 
and Km = 1.36 mg/ml, respectively.  
In the third straight line plot, the Eadie-Hofstee plot, v0 is plotted versus v0/[S] according to 
eq. 7-44 (obtained from eq. 7-42 by multiplying both sides by v0Vmax and rearranging) 
yielding a straight line with slope -Km and intercept Vmax on the v0 axis. 
[S]
v
KVv 0mmax0 ⋅−=     (eq. 7-44) 
Compared to the other straight line plots (in particular the double reciprocal plot) in the 
Eadie-Hofstee plot deviations of the datapoints from the straight line become more obvious, 
especially if there are systematic deviations. It is therefore a useful tool for the detection of 
potential deviations from Michaelis Menten behaviour (Cornish-Bowden, 1995a).The finding 
that in the Eadie-Hofstee plot of our experimental data (Fig. 7-9, right plot) no remarkable 
deviation from the straight line is observed supports the validity of the theoretically derived 
assumption that the investigated hyaluronate degradation by S. agalactiae hyaluronate lyase 
obeys Michaelis Menten kinetics.The Eadie-Hofstee plot also clearly shows that the highest 
v0 determined in our kinetic experiments is much lower than Vmax, which indicates that 
additional experiments covering a higher range of substrate concentrations should be 
performed. However, in our case the increase in the substrate concentration was limited to 2 
mg/ml by the high viscosity of hyaluronate solutions. 
Our results are not in agreement with those reported by Rodig et al. (2000), who also 
investigated the degradation of HA by a purified S. agalactiae hyaluronate lyase and 
determined a Km value of 8 · 10-4 mg/ml, i.e. a value by a factor of about 1800 lower 
compared to the value estimated by us. In addition, Rodig and coworkers observed decreasing 
initial velocities with increasing concentrations of substrate (substrate inhibition) at 
concentrations of HA exceeding 0.1 mg/ml, whereas in the course of our investigations no 
deviation from Michaelis Menten kinetics was observed up to HA concentration of 2 mg/ml. 
These discrepancies are surprising, particularly, since in both cases HA from S. 
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zooepidemicus, obtained from Aqua Biochem GmbH, was used as substrate. However, the 
enzyme concentration used by Rodig et al. was by a factor of 167 higher compared to the 
concentration applied in our experiments, as far as can be seen from the experimental part of 
their publication. Therefore, it is questionable if their experimental data allow for a reliable 
estimation of Km, since the precondition that substrate is present in much higher concentration 
compared to the enzyme is not warranted. Other factors that might account for the 
discrepancy in the determined Km values are the differences in the incubation conditions used 
by Rodig et al. (0.1 M NaOAc, pH 6) and in our experiments (citrate-phosphate buffer, pH 5, 
containing NaCl and BSA). However, it seems unlikely that the 1800 times lower Km 
determined by Rodig et al. can be ascribed to the effect of pH, considering that in the course 
of our experiments an increase in Km was observed, when increasing the pH from pH 5 to pH 
7.4 under otherwise identical conditions (see below). 
 
In the course of the characterisation of inhibitors of S. agalactiae hyaluronate lyase with 
respect to their inhibitory potency at different pH it turned out that in many cases lower IC50 
values were obtained at physiological pH (pH 7.4) compared to pH 5, where the enzyme 
showed maximum activity (Salmen, 2003). To investigate if the observed pH dependency of 
the inhibitory potency can be ascribed to the effect pH on the affinity of the substrate to the 
enzyme, the attempt was made to determine Km also at pH 7.4.  
By analogy with the method applied for the determination of Vmax and Km at pH 5 the rate of 
product formation v0 was measured photometrically at 232 nm at various concentrations of 
substrate. However, due to the lower activity of S. agalactiae hyaluronate lyase at pH 7.4 the 
enzyme concentration in the incubation mixture was increased to obtain a readily measurable 
increase in absorbance at 232 nm within a reaction time of 10 min. The results of this first 
approach to determine the kinetic parameters at physiological pH are presented in figure 7-10. 
As described in the context with the results of pH 5 (Fig. 7-7) the data obtained with HA 
concentrations providing a molar ratio of substrate to enzyme > 1000 were fitted to the 
Michaelis Menten equation (eq. 7-2) by a nonlinear regression program (SigmaPlot).  
The obtained values for Vmax and Km were 18.7 µmol· l-1 · min-1 and 10.5 mg/ml, respectively. 
However, figure 7-10 clearly demonstrates that the existing dataset, which contains only four 
datapoints within the relevant range of substrate concentrations, does not allow for a reliable 
estimation of Vmax and Km. Due to the increased concentration of enzyme the lower limit of 
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the substrate concentrations yielding a molar ratio of substrate to enzyme > 1000 was 0.2 
mg/ml, resulting in a limited range of substrate concentrations differing only by a factor of 10 
(0.2 – 2mg/ml). Thus it seems questionable if the simple repetition of the experiment using 
additional substrate concentrations within the relevant range would allow for a reliable 
determination of the kinetic parameters. The results are expected to be unsatisfactory, 
particularly, since the data presented in Fig. 7-10 already indicate that the applicable substrate 
concentrations cover only the steep increasing initial part of the hyperbolic curve.  
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Fig. 7-10: Activity of S. agalactiae hyaluronate lyase as a function of the concentration of HA (at pH 
7.4). The rate of product formation was determined photometrically at 232 nm as indicated in figure  
7-6, using 5 units# of enzyme and incubation mixture 7-IV (pH 7.4). The data (●) were fitted to the 
Michaelis Menten equation by nonlinear regression (R2 = 0.9970). The data for c(HA) < 0.2 mg/ml (●) 
were omitted from the fit due to a molar ratio of substrate to enzyme < 1000. Inset: extended view of 
the fitted hyperbola of figure 7-10. 
The results of the first approach to determine Km at pH 7.4 thus showed that further efforts 
must be made to obtain data, which allow for a reliable estimation. The problem with such 
experiments is the fact that the range of substrate concentrations is limited due to the high 
viscosity of hyaluronate solutions at concentrations exceeding 2 mg/ml. However, although 
an exact determination of Km at pH 7.4 was impossible, the present data indicate that the Km 
is higher at pH 7.4 compared to the value obtained at pH 5.0 (1.44 mg/ml), suggesting that the 
higher activity of inhibitors at pH 7.4 may be explained by the lower affinity of the enzyme to 
the substrate at physiological pH. 
                                                 
# according to the declaration of the supplier 
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7.4 Conclusion 
The mixtures of products resulting from partial and exhaustive digestion of HA by 
hyaluronate lyase from S. agalactiae were analysed by anion exchange HPLC and NMR 
spectroscopy. Showing the unsaturated disaccharide as the only product after exhaustive 
digestion and as the main product after partial digestion, the mixtures proved to be in 
agreement with the mechanism reported in the literature for the degradation of HA by 
hyaluronate lyase from S. agalactiae. Theoretical analysis of this mechanism, involving an 
initial endolytic cleavage followed by rapid and processive release of unsaturated 
disaccharide, revealed that the kinetics of HA degradation by S. agalactiae hyaluronate lyase 
can be described according to the Michaelis Menten equation.  
At the optimum pH for S. agalactiae hyaluronate lyase (pH 5.0) estimation of the kinetic 
parameters according to the Michaelis Menten formalism from a series of steady state reaction 
rates, measured at various substrate concentrations, yielded a Km value of 1.45 mg/ml and a 
turnover number (kcat) of 1.1·105 min-1. In addition, no deviation from Michaelis Menten 
behaviour was observed when plotting the experimental data in a Lineweaver-Burk, Hanes 
and Eadie-Hofstee diagram.  
The determination of Km at physiological pH turned out to be problematic, since it would 
have required a further elevation of the substrate concentration, which was impractical due to 
the high viscosity of high molecular mass HA at concentrations exceeding 2 mg/ml. However, 
the data obtained at substrate concentrations ≤ 2 mg/ml already indicated a lower affinity of 
the enzyme to the substrate at pH 7.4 compared to pH 5.0, which might explain the higher 
activity of inhibitors of the enzyme at pH 7.4 compared to pH 5.0, as it was observed by 
Salmen (2003).  
For the investigations presented in this chapter high molecular mass HA from S. 
zooepidemicus was used as substrate. In addition to the high viscosity, this substrate implies 
the problem of being polydisperse, which makes an exact determination of Km impossible. At 
present, efforts are made to prepare low molecular mass HA of defined chain length 
(hyaluronate hexasaccharide), which may be used as substrate for the exact determination of 
Km in continuative studies. 
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8 Summary 
Pharmaceutical preparations of bovine testicular hyaluronidase (BTH) have been 
therapeutically applied in the fields of orthopaedia, ophthalmology and internal medicine for 
many years (Baumgartner and Moritz, 1988; Menzel and Farr, 1998). In the context with the 
risk of BSE, companies stopped the production of BTH preparations resulting in a shortage of 
this drug, which is the only highly effective antidote in the treatment of extravasations of 
vinca alkaloids. In this case hyaluronidase prevents local tissue necrosis by improving the 
absorption of the paravasate (Bertelli et al., 1994; Albanell and Baselga, 2000).  
To find a substitute for the poorly characterised BTH preparations, in the first part of this 
thesis two preparations of bovine testicular hyaluronidase (Neopermease®; Hylase® “Dessau”) 
and a hyaluronate lyase from Streptococcus agalactiae were compared with respect to purity 
(composition) and enzyme activity. As revealed by SDS-PAGE and size exclusion 
chromatography the BTH preparations were complex mixtures of proteins with enzymatic 
activity residing in different fractions. Although identical enzymatically active proteins were 
not detected, Neopermease® and Hylase® “Dessau” proved to be hyaluronidase preparations 
with nearly the same enzymatic properties. In the Morgan-Elson assay both preparations were 
characterised by almost identical though complex pH profiles showing activity over a broad 
range (pH 3 - 8) with maximum activity at pH 3.6. For Neopermease® it was shown that the 
complex effect of pH on the activity of the whole preparation can be explained as the sum of 
the pH profiles of several proteins, differing in specific activity. The bacterial enzyme 
preparation was separated into two main proteins [100 kDa (pI = 8.9) and 85 kDa (pI = 9.2)], 
which were enzymatically active in SDS substrate-PAGE. By measuring product formation 
both in the Morgan-Elson assay and by UV difference spectroscopy enzyme activity of 
hyaluronate lyase from S. agalactiae was detected in the range from pH 4.5 to pH 8, showing 
a maximum at pH 5.0. When comparing the preparations with respect to their specific 
activities, the bacterial hyaluronidase preparation was 410-times more active than 
Neopermease® and 5100-times more active than Hylase® “Dessau”, respectively. These 
results suggested that hyaluronate lyase from S. agalactiae, as it was found to meet the 
requirements for a pharmaceutical preparation with respect to purity and specific activity, 
might be an alternative for BTH. 
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Therefore it was investigated if the bacterial enzyme may serve as an appropriate substitute 
for BTH as a spreading factor and activity enhancer in cancer chemotherapy in preclinical in 
vitro and in vivo studies. In contrast to the combination therapy with BTH (Spruß et al., 1995; 
Muckenschnabel et al., 1996; Gürtler, 2001), the co-administration of hyaluronate lyase from 
S. agalactiae did neither enhance the efficacy of regional chemotherapy of human malignant 
melanoma, implanted in nude mice, nor improve the intratumoral accumulation of 
peritumorally (s.c.) injected chemotherapeutics. The bacterial enzyme was administered at 
concentrations yielding in the Morgan-Elson assay 150 to 300 times higher activiy compared 
to the activity applied in the corresponding experiments with BTH (Neopermease®). It was 
assumed that the apparent discrepancy between the activities determined in the colorimetric 
assay, which detects product formation (release of reducing N-acetylglucosamine (NAG)), 
and the observed spreading effect, which depends on viscosity reduction of the extracellular 
matrix, may be explained by the different mechanisms of HA degradation by the bacterial and 
the bovine enzyme: while in case of the endolytic action of BTH every cleavage step (release 
of reducing NAG) may be conducive to viscosity reduction, the processive release of 
disaccharides catalysed by the bacterial enzyme is supposed to reduce the viscosity rather 
ineffectively, regardless of the higher rate of product formation. 
To test this hypothesis, in subsequent studies Neopermease® and hyaluronate lyase from S. 
agalactiae were compared with respect to their activity in a turbidimetric and viscosimetric 
assay. According to Humphrey and Jaques (1953) the results obtained in these assays, which 
are physicochemical methods quantifying the activity of hyaluronidase according to the 
reduction of the size of high molecular mass HA, are supposed to be well correlated with the 
pharmacological activity of the enzymes when applied as a spreading factor. Indeed, it turned 
out that in the turbidimetric and the viscosimetric assay the activity of the bacterial enzyme 
was relatively low compared to its high activity in the colorimetric assay, which may partly 
explain the observation that the hyaluronate lyase did not show the desired spreading effect 
when applied to enhance the intratumoral accumulation of melphalan. However, this 
explanation is compromised by the fact that the activity administered in the in vivo 
experiments with the bacterial hyaluronate lyase was, compared to the activity applied in the 
corresponding experiments with Neopermease®, still by a factor of 19.3 higher, when 
extrapolated from the results of the turbidimetric and viscosimetric assay. 
The turbidimetrically determined pH activity profile of hyaluronate lyase from S. agalactiae 
showed a maximum at pH 5.0 and was in good agreement with the results of the colorimetric 
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assay. By contrast, in case of BTH the pH profile, obtained in the turbidimetric assay showing 
maximum activity at pH 6.0, was almost inverted compared to the pH profile obtained by the 
colorimetric method (activity optimum at pH 3.6). Comparison of the isolated enzymatically 
active proteins contained in Neopermease® with respect to their activity in both assays 
revealed that the main 58 kDa fraction showed the highest specific activity in both assays and 
gave the inverse profiles typical for the whole preparation. In addition, the turbidimetrically 
obtained pH profile of Neopermease® was confirmed by viscosimetry. 
Anion exchange HPLC analysis of the oligosaccharide mixtures produced by HA digestion 
with Neopermease® at various pH values suggests that the pH optima of BTH in the different 
assays may be explained as follows: after an incubation time of 1 h (incubation time used for 
the determination of the pH activity profiles) HA degradation at pH 3.6 yielded a 
considerably higher amount of short oligosaccharides than incubation at pH 6.0, which 
explains the pH profile of the colorimetric assay. Although at pH 6.0 the formation of short 
oligosaccharides was relatively low after 1 h of incubation, anion exchange HPLC analysis 
indicates that HA is degraded to HA fragments, which are not precipitated in the turbidimetric 
assay. Assuming that at pH 3.6 oligosaccharides are preferentially generated in the presence 
of high molecular mass HA, whereas at pH 6.0 all types of molecules of the polydisperse 
substrate are processed to the same extent, the higher activity detected in the turbidimetric and 
the viscosimetric assay at pH 6.0 can be explained regardless of the higher rate of NAG 
formation detected in the colorimetric assay at pH 3.6.  
Since in the present work HA chains with molecular masses > 10 kDa were not detected by 
anion exchange HPLC as they were removed from the digestion mixtures by ultrafiltration 
prior to analysis it was not proven that at pH 3.6 oligosaccharides were formed in the 
presence of high molecular mass HA. To confirm the hypothesis that BTH shows different 
affinities to high and low molecular mass HA, depending on pH, additional investigations are 
required. Size exclusion chromatography analysis of the digestion mixtures, obtained at 
various pH as a function of the incubation time, may provide valuable information on the 
time-dependent changes of the composition of the product mixtures. By this method HA 
fragments of high molecular mass and undegraded substrate are also taken into account. In 
addition, it seems worthwhile to investigate in continuative studies if in the colorimetric and 
the turbidimetric assay the pH profile of BTH varies with incubation time. Viscosimetric 
measurements revealed that the activity optimum of BTH shifted from pH 5.0 after an 
incubation time of 8 min to pH 6.0 after an incubation time of 60 min. 
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The investigations on hyaluronan degradation by hyaluronate lyase from S. agalactiae with 
respect to the effect of pH on the kinetic parameters Vmax and Km suggest that the enzyme 
shows lower affinity to the substrate at pH 7.4 than at pH 5.0. This may explain the higher 
activity observed for a number of inhibitors of the enzyme at pH 7.4 compared to pH 5.0 
(Salmen, 2003). However, an exact determination of Km as a function of pH has to be done in 
future experiments using HA of defined chain length as substrate. 
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9 Appendix 
9.1 List of abbreviations 
2D   two-dimensional 
?DiHA 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)- 
D-glucose 
[η]   intrinsic viscosity 
ηr   relative viscosity 
BSA   bovine serum albumin 
BTH    bovine testicular hyaluronidase 
BVH   bee venom hyaluronidase 
CD   circular dichroism 
CE   capillary electrophoresis 
CTAB   cetyltrimethylammonium bromide 
DHB   2,5-dihydroxybenzoic acid 
DQF COSY   double quantum filter correlation spectroscopy 
ECM   extracellular matrix 
ESI-MS  electrospray ionization mass spectrometry 
GAG   glycosaminoglycan 
GBS   group B streptococcal 
GlcNAc  N-acetyl-D-glucosamine 
GlcUA  glucuronic acid 
HA   hyaluronic acid 
HMBC  heteronuclear multiple bond correlation 
HMQC   heteronuclear multiple quantum coherence 
HPLC   high performance liquid chromatography 
i.d.   inner diameter 
i.p.   intraperitoneal 
I   ionic strength 
IC50 concentration of an inhibitor required to give  
50 % inhibition of enzyme activity 
IEF   isoelectric focussing 
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IgG   immunoglobulin G 
I.S. internal standard 
kcat catalytic constant; turnover number 
Km Michaelis constant; concentration of a substrate at which  
reaction rate is halfmaximal    
L-PAM  melphalan, L-Phenylalanine mustard 
MALDI-TOF MS matrix-assisted laser desorption-ionization time-of-flight  
mass spectrometry  
MW   molecular weight 
MWCO  molecular weight cutoff 
NAG   N-acetyl-D-glucosamine 
NMR   nuclear magnetic resonance 
pI   isoelectric point 
PAGE   polyacrylamide gel electrophoresis 
PAS   periodic acid-Schiff 
ROESY   rotating frame nuclear Overhauser effect spectroscopy 
s.c.   subcutaneous 
SDS   sodium dodecyl sulphate 
SEC   size exclusion chromatography 
TSP   3-(trimethylsilyl)-propionic acid-2,2,3,3-d4 sodium salt 
Tris    tris(hydroxymethyl)aminomethane  
TRU   turbidity reducing unit 
USP   United States Pharmacopeia 
UV   ultra violet 
v0   steady state reaction rate 
Vmax   maximum velocity 
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